[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_422cda1f-2109-4031-81e3-7d6a19c6493f":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:422cda1f-2109-4031-81e3-7d6a19c6493f,\"}":804},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":669,"manageAffiliations":686,"indexDatabases":706,"url":747,"thumbnailPath":26,"statistic":748,"gsStatistic":26,"type":175,"analyzePriority":26},"422cda1f-2109-4031-81e3-7d6a19c6493f","2024-04-11T05:32:37.553+00:00","2025-11-21T10:00:49.577+00:00",[],"Radiation-Oncology",{"issn":665,"title":667},{"VOID":666},"1748-717X",{"EN":668},"Radiation Oncology",[670,678],{"id":671,"createTime":672,"updateTime":673,"relativeEntities":674,"label":675,"description":677,"parentId":26,"standard":26,"scholarHubFieldId":26},"e8fbc4e0-9522-4354-a98f-7f288efdcb2a","2023-05-29T10:24:07.493+00:00","2023-11-21T08:07:05.805+00:00",[],{"EN":676},"Radiology, Nuclear Medicine and Imaging",{},{"id":679,"createTime":680,"updateTime":681,"relativeEntities":682,"label":683,"description":685,"parentId":26,"standard":26,"scholarHubFieldId":26},"d9687dc3-fd83-46ff-aef4-1925044c24eb","2023-05-29T10:24:05.052+00:00","2023-11-21T05:08:37.643+00:00",[],{"EN":684},"Oncology",{},[687,696],{"id":688,"createTime":689,"updateTime":690,"relativeEntities":691,"slug":692,"properties":693,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":52,"url":26,"parentIds":695,"statistic":26},"67883518-0c98-470e-b6b0-160ab49bb03d","2023-05-29T12:06:59.969+00:00","2024-02-19T18:45:45.100+00:00",[],"BMC",{"title":694},{"EN":692},[],{"id":697,"createTime":698,"updateTime":699,"relativeEntities":700,"slug":701,"properties":702,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":116,"url":26,"parentIds":705,"statistic":26},"c5894808-4e99-4047-bbce-594f58821845","2023-05-29T10:24:08.212+00:00","2025-11-21T10:07:05.787+00:00",[],"BioMed-Central-Ltd-",{"title":703},{"EN":704},"BioMed Central Ltd.",[],[707,727],{"id":708,"indexDatabase":709,"url":723,"indexYears":26,"academicFieldIds":724,"indexDatabaseRanking":26},"1fd7f1d7-2fe6-40fe-a825-b70310eb4b8e",{"id":710,"createTime":711,"updateTime":712,"relativeEntities":713,"label":714,"description":716,"key":719,"publicationTags":720,"standard":26},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":715,"VI":715},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":717,"EN":718},"Cơ sở dữ liệu SCIE","SCIE database","scie",[721,722],"SCIE","ISI","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002Fnull",[725,726],"80b08079-ffdc-4da1-b3fe-7d13758975d8","248e54de-c562-4c06-8a10-d7f8a37c06fe",{"id":728,"indexDatabase":729,"url":741,"indexYears":742,"academicFieldIds":743,"indexDatabaseRanking":746},"f9351f79-37ba-40e0-a1ab-93a20b91c4fb",{"id":730,"createTime":731,"updateTime":732,"relativeEntities":733,"label":734,"description":736,"key":738,"publicationTags":739,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":735,"VI":735},"Scopus - Elsevier",{"EN":735,"VI":737},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[740],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F5800179603","2005-2025",[744,745],"462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","a2541f09-5a54-41e7-820b-effbd7bac237","SCOPUS__Q1","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F13014",{"impactFactor":36,"impactFactorByYear":749,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":756,"totalCitation":768,"totalCitationByYear":769,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":786,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},0.79,0.57,0.42,0.74,271,2266,{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},75,150,200,201,96,125,166,167,165,141,112,10313,{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},186,463,328,534,657,922,1231,1056,972,750,306,468,746,602,308,4.55,{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},5.64,13.23,10.25,10.08,8.76,7.62,8.21,5.28,4.84,4.24,3.19,3.74,4.49,3.93,3.65,2.03,0.52,{"meta":805,"data":807},{"total":806},"2274",[808,1257,2573,3000,3236,3573,4046,4308,4743,5164],{"id":809,"createTime":810,"updateTime":811,"relativeEntities":812,"slug":813,"properties":814,"entityType":829,"verifyStatus":25,"verifyTime":811,"verifyNote":830,"syncStatus":28,"languages":831,"translateLanguages":26,"viewCount":36,"primaryUrl":832,"fullTextUrl":26,"authors":833,"publicationType":918,"publisherRelationship":919,"citationCount":952,"citationInfo":953,"publishDate":955,"publishYear":956,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":957,"isForceReanalyzing":1256},"3cd75e3e-320a-45cf-9c5a-60a5acdf5983","2024-04-16T17:08:52.200+00:00","2025-01-16T07:01:28.058+00:00",[],"Wound-healing-after-radiation-therapy-Review-of-the-literature",{"mag":815,"keywords":817,"pmc":818,"openalex":820,"abstract":822,"title":823,"pm":825,"doi":827},{"VOID":816},"2147938868",{},{"VOID":819},"3504517",{"VOID":821},"W2147938868",{},{"EN":824},"Wound healing after radiation therapy: Review of the literature",{"VOID":826},"23006548",{"VOID":828},"10.1186\u002F1748-717x-7-162","PUBLICATION","Auto Verify",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-7-162",[834,855,870,885,903],{"id":835,"sortIndex":36,"researcher":26,"roles":836,"affiliations":837,"properties":848},"2a8f8bca-2033-45e7-82f5-d727a08739c6",[],[838],{"id":839,"sortIndex":36,"affiliation":840,"properties":26},"9ddab95d-c2e3-4d01-8881-580558b83e5a",{"id":841,"createTime":842,"updateTime":842,"relativeEntities":843,"slug":844,"properties":845,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"edda6e75-f727-4e1d-8946-8002c3171f17","2024-04-16T17:08:52.213+00:00",[],"Department-of-Otorhinolaryngology-Division-of-Facial-Plastic-Surgery-University-of-Regensburg-Regensburg-Germany",{"title":846},{"EN":847},"Department of Otorhinolaryngology, Division of Facial Plastic Surgery, University of Regensburg, Regensburg, Germany",{"openalex":849,"orcid":851,"title":853},{"VOID":850},"A5085001535",{"VOID":852},"https:\u002F\u002Forcid.org\u002F0000-0001-6198-2966",{"EN":854},"Frank Haubner",{"id":856,"sortIndex":111,"researcher":26,"roles":857,"affiliations":858,"properties":865},"be517384-53c5-48af-8f19-810125a8aa45",[],[859],{"id":860,"sortIndex":36,"affiliation":861,"properties":26},"b240b8f8-7882-43b9-ac8c-8cd4c2989328",{"id":841,"createTime":842,"updateTime":842,"relativeEntities":862,"slug":844,"properties":863,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":864},{"EN":847},{"openalex":866,"title":868},{"VOID":867},"A5082578081",{"EN":869},"Holger G. Gassner",{"id":871,"sortIndex":115,"researcher":26,"roles":872,"affiliations":873,"properties":880},"73a0e7dd-ed21-42f7-93d1-3af04eefa6a6",[],[874],{"id":875,"sortIndex":36,"affiliation":876,"properties":26},"8b08b14f-2f73-4f7e-9dd3-afc97e9a4995",{"id":841,"createTime":842,"updateTime":842,"relativeEntities":877,"slug":844,"properties":878,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":879},{"EN":847},{"openalex":881,"title":883},{"VOID":882},"A5028693430",{"EN":884},"Elisabeth Ohmann",{"id":886,"sortIndex":114,"researcher":26,"roles":887,"affiliations":888,"properties":898},"1bd1592d-6b5a-48a2-bce5-c022bb5dc7dc",[],[889],{"id":890,"sortIndex":36,"affiliation":891,"properties":26},"c5d1ed30-5f92-47f6-af68-d3492d4a10fa",{"id":892,"createTime":893,"updateTime":893,"relativeEntities":894,"slug":26,"properties":895,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9e62cadd-d5e4-414c-b7ef-c698044a9b03","2024-01-16T01:24:42.699+00:00",[],{"title":896},{"VI":897},"Department of Radiotherapy, University of Regensburg, Regensburg, Germany",{"openalex":899,"title":901},{"VOID":900},"A5043058332",{"EN":902},"Fabian Pohl",{"id":904,"sortIndex":59,"researcher":26,"roles":905,"affiliations":906,"properties":913},"5b60f998-aa2b-4628-8b04-750255b58a75",[],[907],{"id":908,"sortIndex":36,"affiliation":909,"properties":26},"85fdd84c-d0e1-4395-996b-16f95da43f5a",{"id":841,"createTime":842,"updateTime":842,"relativeEntities":910,"slug":844,"properties":911,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":912},{"EN":847},{"openalex":914,"title":916},{"VOID":915},"A5040542634",{"EN":917},"Jürgen Strutz","ARTICLE",{"url":26,"publisher":920,"properties":947},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":921,"slug":663,"properties":922,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":925,"manageAffiliations":926,"indexDatabases":927,"url":747,"thumbnailPath":26,"statistic":942,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":923,"title":924},{"VOID":666},{"EN":668},[],[],[928,935],{"id":708,"indexDatabase":929,"url":723,"indexYears":26,"academicFieldIds":934,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":930,"label":931,"description":932,"key":719,"publicationTags":933,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":936,"url":741,"indexYears":742,"academicFieldIds":941,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":937,"label":938,"description":939,"key":738,"publicationTags":940,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":943,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":944,"totalCitation":768,"totalCitationByYear":945,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":946,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"volume":948,"issue":950},{"VOID":949},"7",{"VOID":951},"1",300,{"total":952,"publishYear":26,"statisticByYear":954},{"2013":111,"2014":116,"2015":124,"2016":238,"2017":285,"2018":240,"2019":240,"2020":79,"2021":244,"2022":286,"2023":168,"2024":59},"2012-12-01",2012,[958,962,966,969,973,977,981,985,988,992,996,1000,1004,1007,1010,1013,1017,1021,1025,1029,1033,1037,1041,1044,1047,1051,1055,1059,1063,1067,1070,1074,1078,1082,1085,1089,1093,1097,1100,1104,1108,1112,1116,1120,1124,1128,1132,1136,1140,1144,1148,1152,1156,1160,1164,1168,1172,1176,1180,1184,1188,1191,1195,1199,1202,1206,1210,1213,1216,1220,1223,1226,1230,1234,1238,1242,1245,1249,1252],{"id":26,"text":959,"url":26,"identifiers":960},"Marks JE, Freeman RB, Lee F, Ogura JH: Pharyngeal wall cancer: an analysis of treatment results complications and patterns of failure. Int J Radiat Oncol Biol Phys 1978, 4: 587-593. 10.1016\u002F0360-3016(78)90179-7",{"doi":961},"10.1016\u002F0360-3016(78)90179-7",{"id":26,"text":963,"url":26,"identifiers":964},"Tang Y, Shen Q, Wang Y, Lu K, Peng Y: A randomized prospective study of rehabilitation therapy in the treatment of radiation-induced dysphagia and trismus. Strahlenther Onkol 2011, 187: 39-44. 10.1007\u002Fs00066-010-2151-0",{"doi":965},"10.1007\u002Fs00066-010-2151-0",{"id":26,"text":967,"url":26,"identifiers":968},"Melan'in VD, Rybak RF, Senkevich VM: Prophylaxis of the postop complications in combined treatment of patients with laryngeal cancer. Vestn Otorinolaringol 1998, 46: 8.",{},{"id":26,"text":970,"url":26,"identifiers":971},"Girod DA, McCulloch TM, Tsue TT, Weymuller EA Jr: Risk factors for complications in clean-contaminated head and neck surgical procedures. Head Neck 1995, 17: 7-13. 10.1002\u002Fhed.2880170103",{"doi":972},"10.1002\u002Fhed.2880170103",{"id":26,"text":974,"url":26,"identifiers":975},"Lee S, Thiele C: Factors associated with free flap complications after head and neck reconstruction and the molecular basis of fibrotic tissue rearrangement in preirradiated soft tissue. J Oral Maxillofac Surg 2010, 68: 2169-2178. 10.1016\u002Fj.joms.2009.08.026",{"doi":976},"10.1016\u002Fj.joms.2009.08.026",{"id":26,"text":978,"url":26,"identifiers":979},"Hom DB, Adams G, Koreis M, Maisel R: Choosing the optimal wound dressing for irradiated soft tissue wounds. Otolaryngol Head Neck Surg 1999, 121: 591-598. 10.1016\u002FS0194-5998(99)70062-8",{"doi":980},"10.1016\u002FS0194-5998(99)70062-8",{"id":26,"text":982,"url":26,"identifiers":983},"Lambert PM, Patel M, Gutman E, Campana HA: Dermal grafts to bony defects in irradiated and nonirradiated tissues. Arch Otolaryngol 1984, 110: 657-659. 10.1001\u002Farchotol.1984.00800360029006",{"doi":984},"10.1001\u002Farchotol.1984.00800360029006",{"id":26,"text":986,"url":26,"identifiers":987},"Hunt TK KD, Thakral KK: Cellular control of repair. In Soft and hard tissue repair: biological and clinical aspects. Edited by: Hunt TK Heppenstall RB, Pines E, Rovee D. Praeger, New York 1984:3-19.",{},{"id":26,"text":989,"url":26,"identifiers":990},"Beaudry VG, Ihrie RA, Jacobs SB, et al.: Loss of the desmosomal component perp impairs wound healing in vivo. Dermatol Res Pract 2010, 2010: 759731.",{"doi":991},"10.1155\u002F2010\u002F759731",{"id":26,"text":993,"url":26,"identifiers":994},"Scheithauer M, Riechelmann H: Review part I: basic mechanisms of cutaneous woundhealing. Laryngorhinootologie 2003, 82: 31-35. 10.1055\u002Fs-2003-36908",{"doi":995},"10.1055\u002Fs-2003-36908",{"id":26,"text":997,"url":26,"identifiers":998},"Scheithauer M, Riechelmann H: Review part II: disorders in cutaneous woundhealing. Laryngorhinootologie 2003, 82: 36-39. 10.1055\u002Fs-2003-36909",{"doi":999},"10.1055\u002Fs-2003-36909",{"id":26,"text":1001,"url":26,"identifiers":1002},"Dormand EL, Banwell PE, Goodacre TE: Radiotherapy and wound healing. Int Wound J 2005, 2: 112-127. 10.1111\u002Fj.1742-4801.2005.00079.x",{"doi":1003},"10.1111\u002Fj.1742-4801.2005.00079.x",{"id":26,"text":1005,"url":26,"identifiers":1006},"Albers-Schonberg: Beitrag zur therapeutischen Verwendung der Roentgenstrahlen in der Behandlung des Lupus. Fortschritte a d Geb d Roentgen 1897, 1: 72-75.",{},{"id":26,"text":1008,"url":26,"identifiers":1009},"Hom DHV, Lee C: Irradiatid Skin and Its Postsurgical Management. In Essential Tissue Healing of the Face and the Neck Edited by: Hom H, Gosain F. 2009, 224-238.",{},{"id":26,"text":1011,"url":26,"identifiers":1012},"Herskind C, Bamberg M, Rodemann HP: The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 1998,174(Suppl 3):12-15.",{},{"id":26,"text":1014,"url":26,"identifiers":1015},"Shi HP, Most D, Efron DT, Tantry U, Fischel MH, Barbul A: The role of iNOS in wound healing. Surgery 2001, 130: 225-229. 10.1067\u002Fmsy.2001.115837",{"doi":1016},"10.1067\u002Fmsy.2001.115837",{"id":26,"text":1018,"url":26,"identifiers":1019},"Schaffer M, Weimer W, Wider S, et al.: Differential expression of inflammatory mediators in radiation-impaired wound healing. J Surg Res 2002, 107: 93-100.",{"doi":1020},"10.1016\u002FS0022-4804(02)96494-2",{"id":26,"text":1022,"url":26,"identifiers":1023},"Illsley MC, Peacock JH, McAnulty RJ, Yarnold JR: Increased collagen production in fibroblasts cultured from irradiated skin and effect of TGF beta(1)- clinical study. Br J Cancer 2000, 83: 650-654. 10.1054\u002Fbjoc.2000.1321",{"doi":1024},"10.1054\u002Fbjoc.2000.1321",{"id":26,"text":1026,"url":26,"identifiers":1027},"Gu Q, Wang D, Gao Y, et al.: Expression of MMP1 in surgical and radiation-impaired wound healing and its effects on the healing process. J Environ Pathol Toxicol Oncol 2002, 21: 71-78.",{"doi":1028},"10.1615\u002FJEnvironPatholToxicolOncol.v21.i1.70",{"id":26,"text":1030,"url":26,"identifiers":1031},"Goessler UR, Bugert P, Kassner S, et al.: In vitro analysis of radiation-induced dermal wounds. Otolaryngol Head Neck Surg 2010, 142: 845-850. 10.1016\u002Fj.otohns.2010.01.033",{"doi":1032},"10.1016\u002Fj.otohns.2010.01.033",{"id":26,"text":1034,"url":26,"identifiers":1035},"Medrado AP, Soares AP, Santos ET, Reis SR, Andrade ZA: Influence of laser photobiomodulation upon connective tissue remodeling during wound healing. J Photochem Photobiol B 2008, 92: 144-152. 10.1016\u002Fj.jphotobiol.2008.05.008",{"doi":1036},"10.1016\u002Fj.jphotobiol.2008.05.008",{"id":26,"text":1038,"url":26,"identifiers":1039},"Johnson LB, Jorgensen LN, Adawi D, et al.: The effect of preoperative radiotherapy on systemic collagen deposition and postoperative infective complications in rectal cancer patients. Dis Colon Rectum 2005, 48: 1573-1580. 10.1007\u002Fs10350-005-0066-0",{"doi":1040},"10.1007\u002Fs10350-005-0066-0",{"id":26,"text":1042,"url":26,"identifiers":1043},"Harris A, Komray RR: Cost-effective management of pharyngocutaneous fistulas following laryngectomy. Ostomy Wound Manage 1993, 39: 36–7-40–2. 4",{},{"id":26,"text":1045,"url":26,"identifiers":1046},"Jacobson AS, Buchbinder D, Hu K: Urken ML. Paradigm shifts in the management of osteoradionecrosis of the mandible, Oral Oncol; 2010.",{},{"id":26,"text":1048,"url":26,"identifiers":1049},"Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL: Complete Restoration of Refractory Mandibular Osteoradionecrosis by Prolonged Treatment with a Pentoxifylline-Tocopherol-Clodronate Combination (PENTOCLO): A Phase II Trial. Int J Radiat Oncol Biol Phys 2010,80(3):832-839.",{"doi":1050},"10.1016\u002Fj.ijrobp.2010.03.029",{"id":26,"text":1052,"url":26,"identifiers":1053},"Freiberger JJ, Yoo DS, de Lisle Dear G, et al.: Multimodality surgical and hyperbaric management of mandibular osteoradionecrosis. Int J Radiat Oncol Biol Phys 2009, 75: 717-724. 10.1016\u002Fj.ijrobp.2008.11.025",{"doi":1054},"10.1016\u002Fj.ijrobp.2008.11.025",{"id":26,"text":1056,"url":26,"identifiers":1057},"Peleg M, Lopez EA: The treatment of osteoradionecrosis of the mandible: the case for hyperbaric oxygen and bone graft reconstruction. J Oral Maxillofac Surg 2006, 64: 956-960. 10.1016\u002Fj.joms.2006.02.017",{"doi":1058},"10.1016\u002Fj.joms.2006.02.017",{"id":26,"text":1060,"url":26,"identifiers":1061},"Tai YJ, Birely BC, Im MJ, Hoopes JE, Manson PN: The use of hyperbaric oxygen for preservation of free flaps. Ann Plast Surg 1992, 28: 284-287. 10.1097\u002F00000637-199203000-00016",{"doi":1062},"10.1097\u002F00000637-199203000-00016",{"id":26,"text":1064,"url":26,"identifiers":1065},"Mayer R, Hamilton-Farrell MR, van der Kleij AJ, et al.: Hyperbaric oxygen and radiotherapy. Strahlenther Onkol 2005, 181: 113-123. 10.1007\u002Fs00066-005-1277-y",{"doi":1066},"10.1007\u002Fs00066-005-1277-y",{"id":26,"text":1068,"url":26,"identifiers":1069},"Narozny W, Sicko Z, Stankiewicz C, Przewozny T, Kot J, Kuczkowski J: An application of hyperbaric oxygen therapy in otolaryngological oncology. Otolaryngol Pol 2003, 57: 799-807.",{},{"id":26,"text":1071,"url":26,"identifiers":1072},"Grundmann T, Jaehne M, Fritze G: The value of hyperbaric oxygen therapy (HBO) in treatment of problem wounds in the area of plastic-reconstructive head and neck surgery. Laryngorhinootologie 2000, 79: 304-310. 10.1055\u002Fs-2000-8802",{"doi":1073},"10.1055\u002Fs-2000-8802",{"id":26,"text":1075,"url":26,"identifiers":1076},"Neovius EB, Lind MG, Lind FG: Hyperbaric oxygen therapy for wound complications after surgery in the irradiated head and neck: a review of the literature and a report of 15 consecutive patients. Head Neck 1997, 19: 315-322. 10.1002\u002F(SICI)1097-0347(199707)19:4\u003C315::AID-HED10>3.0.CO;2-8",{"doi":1077},"10.1002\u002F(SICI)1097-0347(199707)19:4\u003C315::AID-HED10>3.0.CO;2-8",{"id":26,"text":1079,"url":26,"identifiers":1080},"Mathes SJ, Alexander J: Radiation injury. Surg Oncol Clin N Am 1996, 5: 809-824.",{"doi":1081},"10.1016\u002FS1055-3207(18)30354-5",{"id":26,"text":1083,"url":26,"identifiers":1084},"Kendall AC, Whatmore JL, Harries LW, Winyard PG, Smerdon GR: Eggleton P. Changes in inflammatory gene expression induced by hyperbaric oxygen treatment in human endothelial cells under chronic wound conditions, Exp Cell Res; 2011.",{},{"id":26,"text":1086,"url":26,"identifiers":1087},"Thom SR: Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011,127(Suppl 1):131S-141S.",{"doi":1088},"10.1097\u002FPRS.0b013e3181fbe2bf",{"id":26,"text":1090,"url":26,"identifiers":1091},"Friedman HI, Fitzmaurice M, Lefaivre JF, Vecchiolla T, Clarke D: An evidence-based appraisal of the use of hyperbaric oxygen on flaps and grafts. Plast Reconstr Surg 2006, 117: 175S-90S. discussion 91S-92S 10.1097\u002F01.prs.0000222555.84962.86",{"doi":1092},"10.1097\u002F01.prs.0000222555.84962.86",{"id":26,"text":1094,"url":26,"identifiers":1095},"Lu G, Ling K, Zhao P, et al.: A novel in situ-formed hydrogel wound dressing by the photocross-linking of a chitosan derivative. Wound Repair Regen 2010, 18: 70-79. 10.1111\u002Fj.1524-475X.2009.00557.x",{"doi":1096},"10.1111\u002Fj.1524-475X.2009.00557.x",{"id":26,"text":1098,"url":26,"identifiers":1099},"Brown CD, Zitelli JA: Choice of wound dressing and ointments. In Essential Tissue Healing of the Face and the Neck. Edited by: Hebda , Hom , Friedman , Gosain . BC Decker, Shelton, CT; 2009:409-433.",{},{"id":26,"text":1101,"url":26,"identifiers":1102},"Legeza VI, Galenko-Yaroshevskii VP, Zinov'ev EV, et al.: Effects of new wound dressings on healing of thermal burns of the skin in acute radiation disease. Bull Exp Biol Med 2004, 138: 311-315.",{"doi":1103},"10.1007\u002Fs10517-005-0029-4",{"id":26,"text":1105,"url":26,"identifiers":1106},"Kwan Delta KH, Liu Delta X, Yeung KW, Ho CM, To MK, Wong KK: Modulation of collagen alignment by silver nanoparticles results in better mechanical properties in wound healing. Nanomedicine 2011,7(4):497-504. 10.1016\u002Fj.nano.2011.01.003",{"doi":1107},"10.1016\u002Fj.nano.2011.01.003",{"id":26,"text":1109,"url":26,"identifiers":1110},"Leon-Villapalos J, Eldardiri M, Dziewulski P: The use of human deceased donor skin allograft in burn care. Cell Tissue Bank 2010, 11: 99-104. 10.1007\u002Fs10561-009-9152-1",{"doi":1111},"10.1007\u002Fs10561-009-9152-1",{"id":26,"text":1113,"url":26,"identifiers":1114},"Ferguson PC, Boynton EL, Wunder JS, et al.: Intradermal injection of autologous dermal fibroblasts improves wound healing in irradiated skin. J Surg Res 1999, 85: 331-338. 10.1006\u002Fjsre.1999.5664",{"doi":1115},"10.1006\u002Fjsre.1999.5664",{"id":26,"text":1117,"url":26,"identifiers":1118},"Gorodetsky R, McBride WH, Withers HR, Miller GG: Effect of fibroblast implants on wound healing of irradiated skin: assay of wound strength and quantitative immunohistology of collagen. Radiat Res 1991, 125: 181-186. 10.2307\u002F3577886",{"doi":1119},"10.2307\u002F3577886",{"id":26,"text":1121,"url":26,"identifiers":1122},"Chunmeng S, Tianmin C, Yongping S, et al.: Effects of dermal multipotent cell transplantation on skin wound healing. J Surg Res 2004, 121: 13-9. 10.1016\u002Fj.jss.2004.04.008",{"doi":1123},"10.1016\u002Fj.jss.2004.04.008",{"id":26,"text":1125,"url":26,"identifiers":1126},"Rigotti G, Marchi A, Galie M, et al.: Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg 2007, 119: 1409-1422. discussion 23–4 10.1097\u002F01.prs.0000256047.47909.71",{"doi":1127},"10.1097\u002F01.prs.0000256047.47909.71",{"id":26,"text":1129,"url":26,"identifiers":1130},"Akita S, Akino K, Hirano A, Ohtsuru A, Yamashita S: Noncultured autologous adipose-derived stem cells therapy for chronic radiation injury. Stem Cells Int 2010, 2010: 532704.",{"doi":1131},"10.4061\u002F2010\u002F532704",{"id":26,"text":1133,"url":26,"identifiers":1134},"Hadad I, Johnstone BH, Brabham JG, et al.: Development of a porcine delayed wound-healing model and its use in testing a novel cell-based therapy. Int J Radiat Oncol Biol Phys 2010, 78: 888-896. 10.1016\u002Fj.ijrobp.2010.05.002",{"doi":1135},"10.1016\u002Fj.ijrobp.2010.05.002",{"id":26,"text":1137,"url":26,"identifiers":1138},"Hom DB, Unger GM, Pernell KJ, Manivel JC: Improving surgical wound healing with basic fibroblast growth factor after radiation. Laryngoscope 2005, 115: 412-422. 10.1097\u002F01.mlg.0000157852.01402.12",{"doi":1139},"10.1097\u002F01.mlg.0000157852.01402.12",{"id":26,"text":1141,"url":26,"identifiers":1142},"Forcheron F, Agay D, Scherthan H, et al.: Autologous adipocyte derived stem cells favour healing in a minipig model of cutaneous radiation syndrome. PLoS One 2012, 7: e31694. 10.1371\u002Fjournal.pone.0031694",{"doi":1143},"10.1371\u002Fjournal.pone.0031694",{"id":26,"text":1145,"url":26,"identifiers":1146},"Kim WS, Park BS, Sung JH: The wound-healing and antioxidant effects of adipose-derived stem cells. Expert Opin Biol Ther 2009, 9: 879-987. 10.1517\u002F14712590903039684",{"doi":1147},"10.1517\u002F14712590903039684",{"id":26,"text":1149,"url":26,"identifiers":1150},"Kim WS, Park BS, Park SH, Kim HK, Sung JH: Antiwrinkle effect of adipose-derived stem cell: activation of dermal fibroblast by secretory factors. J Dermatol Sci 2009, 53: 96-102. 10.1016\u002Fj.jdermsci.2008.08.007",{"doi":1151},"10.1016\u002Fj.jdermsci.2008.08.007",{"id":26,"text":1153,"url":26,"identifiers":1154},"Kim JH, Jung M, Kim HS, Kim YM, Choi EH: Adipose-derived stem cells as a new therapeutic modality for ageing skin. Exp Dermatol 2011, 20: 383-387. 10.1111\u002Fj.1600-0625.2010.01221.x",{"doi":1155},"10.1111\u002Fj.1600-0625.2010.01221.x",{"id":26,"text":1157,"url":26,"identifiers":1158},"Lee SH, Jin SY, Song JS, Seo KK, Cho KH: Paracrine effects of adipose-derived stem cells on keratinocytes and dermal fibroblasts. Ann Dermatol 2012, 24: 136-143. 10.5021\u002Fad.2012.24.2.136",{"doi":1159},"10.5021\u002Fad.2012.24.2.136",{"id":26,"text":1161,"url":26,"identifiers":1162},"Khanna S, Roy S, Bagchi D, Bagchi M, Sen CK: Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med 2001, 31: 38-42. 10.1016\u002FS0891-5849(01)00544-5",{"doi":1163},"10.1016\u002FS0891-5849(01)00544-5",{"id":26,"text":1165,"url":26,"identifiers":1166},"Chung YL, Wang AJ, Yao LF: Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 2004, 3: 317-325. 10.4161\u002Fcbt.3.3.698",{"doi":1167},"10.4161\u002Fcbt.3.3.698",{"id":26,"text":1169,"url":26,"identifiers":1170},"Jagetia GC, Rajanikant GK, Rao SK: Evaluation of the effect of ascorbic acid treatment on wound healing in mice exposed to different doses of fractionated gamma radiation. Radiat Res 2003, 159: 371-380. 10.1667\u002F0033-7587(2003)159[0371:EOTEOA]2.0.CO;2",{"doi":1171},"10.1667\u002F0033-7587(2003)159[0371:EOTEOA]2.0.CO;2",{"id":26,"text":1173,"url":26,"identifiers":1174},"Pollard JD, Quan S, Kang T, Koch RJ: Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg 2005, 7: 27-31. 10.1001\u002Farchfaci.7.1.27",{"doi":1175},"10.1001\u002Farchfaci.7.1.27",{"id":26,"text":1177,"url":26,"identifiers":1178},"Cromack DT, Porras-Reyes BH, Wee SS, et al.: Acceleration of soft tissue repair by a thrombin-derived oligopeptide. J Surg Res 1992, 53: 117-122. 10.1016\u002F0022-4804(92)90022-R",{"doi":1179},"10.1016\u002F0022-4804(92)90022-R",{"id":26,"text":1181,"url":26,"identifiers":1182},"Bourke SL, Al-Khalili M, Briggs T, Michniak BB, Kohn J, Poole-Warren LA: A photo-crosslinked poly(vinyl alcohol) hydrogel growth factor release vehicle for wound healing applications. AAPS PharmSci 2003, 5: E33.",{"doi":1183},"10.1208\u002Fps050433",{"id":26,"text":1185,"url":26,"identifiers":1186},"Sugiyama K, Ishii G, Ochiai A, Esumi H: Improvement of the breaking strength of wound by combined treatment with recombinant human G-CSF, recombinant human M-CSF, and a TGF-beta1 receptor kinase inhibitor in rat skin. Cancer Sci 2008, 99: 1021-1028. 10.1111\u002Fj.1349-7006.2008.00761.x",{"doi":1187},"10.1111\u002Fj.1349-7006.2008.00761.x",{"id":26,"text":1189,"url":26,"identifiers":1190},"Masucci G: New clinical applications of granulocyte-macrophage colony-stimulating factor. Med Oncol 1996, 13: 149-154.",{},{"id":26,"text":1192,"url":26,"identifiers":1193},"Garnick MB, Stoudemire JB: Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF). Int J Cell Cloning 1990,8(Suppl 1):356-371. discussion 71–3",{"doi":1194},"10.1002\u002Fstem.5530080733",{"id":26,"text":1196,"url":26,"identifiers":1197},"Vegesna V, McBride WH, Taylor JM, Withers HR: The effect of interleukin-1 beta or transforming growth factor-beta on radiation-impaired murine skin wound healing. J Surg Res 1995, 59: 699-704. 10.1006\u002Fjsre.1995.1226",{"doi":1198},"10.1006\u002Fjsre.1995.1226",{"id":26,"text":1200,"url":26,"identifiers":1201},"Amento EP, Beck LS: TGF-beta and wound healing. Ciba Found Symp 1991, 157: 115-123. discussion 23–9",{},{"id":26,"text":1203,"url":26,"identifiers":1204},"Lonergan DM, Mikulec AA, Hanasono MM, Kita M, Koch RJ: Growth factor profile of irradiated human dermal fibroblasts using a serum-free method. Plast Reconstr Surg 2003, 111: 1960-1968. 10.1097\u002F01.PRS.0000055065.41599.75",{"doi":1205},"10.1097\u002F01.PRS.0000055065.41599.75",{"id":26,"text":1207,"url":26,"identifiers":1208},"Schultze-Mosgau S, Wehrhan F, Amann K, Radespiel-Troger M, Rodel F, Grabenbauer GG: In Vivo TGF-beta 3 expression during wound healing in irradiated tissue. An experimental study. Strahlenther Onkol 2003, 179: 410-416.",{"doi":1209},"10.1007\u002Fs00066-003-1049-5",{"id":26,"text":1211,"url":26,"identifiers":1212},"Cromack DT, Porras-Reyes B, Purdy JA, Pierce GF, Mustoe TA: Acceleration of tissue repair by transforming growth factor beta 1: identification of in vivo mechanism of action with radiotherapy-induced specific healing deficits. Surgery 1993, 113: 36-42.",{},{"id":26,"text":1214,"url":26,"identifiers":1215},"Philipp K, Riedel F, Germann G, Hormann K, Sauerbier M: TGF-beta antisense oligonucleotides reduce mRNA expression of matrix metalloproteinases in cultured wound-healing-related cells. Int J Mol Med 2005, 15: 299-303.",{},{"id":26,"text":1217,"url":26,"identifiers":1218},"Cordeiro MF, Mead A, Ali RR, et al.: Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 2003, 10: 59-71. 10.1038\u002Fsj.gt.3301865",{"doi":1219},"10.1038\u002Fsj.gt.3301865",{"id":26,"text":1221,"url":26,"identifiers":1222},"Riedel K, Koellensperger E, Ryssel H, et al.: Abrogation of TGF-beta by antisense oligonucleotides modulates expression of VEGF and increases angiogenic potential in isolated fibroblasts from radiated skin. Int J Mol Med 2008, 22: 473-480.",{},{"id":26,"text":1224,"url":26,"identifiers":1225},"Riedel K, Kremer T, Ryssel H, et al.: TGF-beta antisense oligonucleotides modulate expression of matrix metalloproteinases in isolated fibroblasts from radiated skin. In Vivo 2008, 22: 1-7.",{},{"id":26,"text":1227,"url":26,"identifiers":1228},"Mustoe TA, Purdy J, Gramates P, Deuel TF, Thomason A, Pierce GF: Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB. Am J Surg 1989, 158: 345-350. 10.1016\u002F0002-9610(89)90131-1",{"doi":1229},"10.1016\u002F0002-9610(89)90131-1",{"id":26,"text":1231,"url":26,"identifiers":1232},"Hom DB, Linzie BM, Huang TC: The healing effects of autologous platelet gel on acute human skin wounds. Arch Facial Plast Surg 2007, 9: 174-183. 10.1001\u002Farchfaci.9.3.174",{"doi":1233},"10.1001\u002Farchfaci.9.3.174",{"id":26,"text":1235,"url":26,"identifiers":1236},"Hom DB, Manivel JC: Promoting healing with recombinant human platelet-derived growth factor–BB in a previously irradiated problem wound. Laryngoscope 2003, 113: 1566-1571. 10.1097\u002F00005537-200309000-00029",{"doi":1237},"10.1097\u002F00005537-200309000-00029",{"id":26,"text":1239,"url":26,"identifiers":1240},"Kilic D, Sayan H, Gonul B, Egehan I: The effect of granulocyte macrophage-colony stimulating factor on glutathione and lipid peroxidation in a rat model. Eur J Surg Oncol 2000, 26: 701-4. 10.1053\u002Fejso.2000.0984",{"doi":1241},"10.1053\u002Fejso.2000.0984",{"id":26,"text":1243,"url":26,"identifiers":1244},"Glaspy JA, Golde DW: Clinical applications of the myeloid growth factors. Semin Hematol 1989, 26: 14-7.",{},{"id":26,"text":1246,"url":26,"identifiers":1247},"Ryu SH, Kim YH, Lee SW, Hong JP: The preventive effect of recombinant human growth factor (rhEGF) on the recurrence of radiodermatitis. J Radiat Res (Tokyo) 2010, 51: 511-517. 10.1269\u002Fjrr.10010",{"doi":1248},"10.1269\u002Fjrr.10010",{"id":26,"text":1250,"url":26,"identifiers":1251},"Riedel F, Philipp K, Sadick H, Goessler U, Hormann K, Verse T: Immunohistochemical analysis of radiation-induced non-healing dermal wounds of the head and neck. In Vivo 2005, 19: 343-350.",{},{"id":26,"text":1253,"url":26,"identifiers":1254},"Avanzi GC, Gallicchio M, Saglio G: Hematopoietic growth factors in autologous transplantation. Biotherapy 1998, 10: 299-308. 10.1007\u002FBF02678550",{"doi":1255},"10.1007\u002FBF02678550",false,{"id":1258,"createTime":1259,"updateTime":1260,"relativeEntities":1261,"slug":1262,"properties":1263,"entityType":829,"verifyStatus":25,"verifyTime":1278,"verifyNote":830,"syncStatus":28,"languages":1279,"translateLanguages":26,"viewCount":36,"primaryUrl":1280,"fullTextUrl":26,"authors":1281,"publicationType":918,"publisherRelationship":1429,"citationCount":1461,"citationInfo":1462,"publishDate":1465,"publishYear":1466,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1467,"isForceReanalyzing":1256},"b07460a6-9859-452d-90c8-c935b2616bd9","2024-04-22T14:06:39.745+00:00","2024-12-28T01:25:58.534+00:00",[],"Pancreatic-ductal-adenocarcinoma-biological-hallmarks-current-status-and-future-perspectives-of-combined-modality-treatment-approaches",{"mag":1264,"keywords":1266,"pmc":1267,"openalex":1269,"abstract":1271,"title":1272,"pm":1274,"doi":1276},{"VOID":1265},"2968934833",{},{"VOID":1268},"6688256",{"VOID":1270},"W2968934833",{},{"EN":1273},"Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches",{"VOID":1275},"31395068",{"VOID":1277},"10.1186\u002Fs13014-019-1345-6","2024-12-28T01:25:58.533+00:00",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13014-019-1345-6",[1282,1302,1324,1345,1363,1380,1397,1414],{"id":1283,"sortIndex":36,"researcher":26,"roles":1284,"affiliations":1285,"properties":1295},"fb6fd730-1eb4-43ec-abb4-0d2364989e24",[],[1286],{"id":1287,"sortIndex":36,"affiliation":1288,"properties":26},"10532271-2dc7-4861-b799-b9aae870b661",{"id":1289,"createTime":1290,"updateTime":1290,"relativeEntities":1291,"slug":26,"properties":1292,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"8bd2b375-cce9-44f6-9332-1c3ca09c3616","2024-01-09T05:50:03.780+00:00",[],{"title":1293},{"VI":1294},"Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany",{"openalex":1296,"orcid":1298,"title":1300},{"VOID":1297},"A5044172388",{"VOID":1299},"https:\u002F\u002Forcid.org\u002F0000-0002-4608-7151",{"EN":1301},"Michael Orth",{"id":1303,"sortIndex":158,"researcher":26,"roles":1304,"affiliations":1305,"properties":1317},"c1cd3b61-7bc5-4da6-acb4-8d9e2a4f1cc4",[],[1306],{"id":1307,"sortIndex":36,"affiliation":1308,"properties":26},"b2bf3da1-4cd2-4395-b130-f0ac655fcdc6",{"id":1309,"createTime":1310,"updateTime":1311,"relativeEntities":1312,"slug":1313,"properties":1314,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d623366a-7ccc-458a-acfc-ceffdbb93ff0","2024-04-22T14:06:39.795+00:00","2024-09-26T01:30:14.688+00:00",[],"German-Cancer-Consortium-DKTK-LMU-Munich-81377-Munich-Germany",{"title":1315},{"EN":1316},"German Cancer Consortium (DKTK), LMU Munich, 81377, Munich, Germany",{"openalex":1318,"orcid":1320,"title":1322},{"VOID":1319},"A5016924764",{"VOID":1321},"https:\u002F\u002Forcid.org\u002F0000-0002-8141-0452",{"EN":1323},"Kirsten Lauber",{"id":1325,"sortIndex":59,"researcher":26,"roles":1326,"affiliations":1327,"properties":1338},"23b28985-7f6c-4cfa-bf48-466228755eea",[],[1328],{"id":1329,"sortIndex":36,"affiliation":1330,"properties":26},"6e7ca592-1ef2-46b2-9da5-ffb38a67ba71",{"id":1331,"createTime":1332,"updateTime":1332,"relativeEntities":1333,"slug":1334,"properties":1335,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"848388f6-b6f4-4dc2-b654-0a36f8411d7f","2024-04-09T22:20:59.440+00:00",[],"Department-of-Internal-Medicine-II-University-Hospital-LMU-Munich-Munich-Germany",{"title":1336},{"EN":1337},"Department of Internal Medicine II, University Hospital, LMU Munich, Munich, Germany",{"openalex":1339,"orcid":1341,"title":1343},{"VOID":1340},"A5008677072",{"VOID":1342},"https:\u002F\u002Forcid.org\u002F0000-0002-3666-6459",{"EN":1344},"Julia Mayerle",{"id":1346,"sortIndex":135,"researcher":26,"roles":1347,"affiliations":1348,"properties":1358},"cf3d72e5-a283-4319-81a1-be2705a27cd4",[],[1349],{"id":1350,"sortIndex":36,"affiliation":1351,"properties":26},"f9c95f4d-8269-472b-b8bf-eb394bc7cbe7",{"id":1352,"createTime":1353,"updateTime":1353,"relativeEntities":1354,"slug":26,"properties":1355,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b6de06b3-9b08-4b27-b5a2-c14c833458b8","2024-01-04T05:54:38.441+00:00",[],{"title":1356},{"VI":1357},"Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany",{"openalex":1359,"title":1361},{"VOID":1360},"A5025405527",{"EN":1362},"M. Schnurr",{"id":1364,"sortIndex":115,"researcher":26,"roles":1365,"affiliations":1366,"properties":1373},"c4d5840d-9836-4479-804b-3e5b93c5a7f1",[],[1367],{"id":1368,"sortIndex":36,"affiliation":1369,"properties":26},"486e7651-2e64-4973-a1d1-a8a4958aef13",{"id":1289,"createTime":1290,"updateTime":1290,"relativeEntities":1370,"slug":26,"properties":1371,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1372},{"VI":1294},{"openalex":1374,"orcid":1376,"title":1378},{"VOID":1375},"A5039829623",{"VOID":1377},"https:\u002F\u002Forcid.org\u002F0000-0001-5172-9174",{"EN":1379},"Philipp Metzger",{"id":1381,"sortIndex":162,"researcher":26,"roles":1382,"affiliations":1383,"properties":1390},"2da978f6-a898-4109-8d5b-1eb6b829470f",[],[1384],{"id":1385,"sortIndex":36,"affiliation":1386,"properties":26},"08a35094-a633-4e3b-be92-256bbb984970",{"id":1289,"createTime":1290,"updateTime":1290,"relativeEntities":1387,"slug":26,"properties":1388,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1389},{"VI":1294},{"openalex":1391,"orcid":1393,"title":1395},{"VOID":1392},"A5038323479",{"VOID":1394},"https:\u002F\u002Forcid.org\u002F0000-0002-1287-7825",{"EN":1396},"Claus Belka",{"id":1398,"sortIndex":111,"researcher":26,"roles":1399,"affiliations":1400,"properties":1407},"e5062dc8-7861-45ef-ac3a-2f41c2dcad62",[],[1401],{"id":1402,"sortIndex":36,"affiliation":1403,"properties":26},"008a5622-194e-4ddc-a816-02fa64f69bac",{"id":1309,"createTime":1310,"updateTime":1311,"relativeEntities":1404,"slug":1313,"properties":1405,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1406},{"EN":1316},{"openalex":1408,"orcid":1410,"title":1412},{"VOID":1409},"A5084866392",{"VOID":1411},"https:\u002F\u002Forcid.org\u002F0000-0003-1840-4508",{"EN":1413},"Günter Schneider",{"id":1415,"sortIndex":114,"researcher":26,"roles":1416,"affiliations":1417,"properties":1424},"73c5147d-84cc-4c67-b236-b7fcafd6fc94",[],[1418],{"id":1419,"sortIndex":36,"affiliation":1420,"properties":26},"8b5fb581-a96f-436f-9d19-44390a181930",{"id":1289,"createTime":1290,"updateTime":1290,"relativeEntities":1421,"slug":26,"properties":1422,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1423},{"VI":1294},{"openalex":1425,"title":1427},{"VOID":1426},"A5008555900",{"EN":1428},"S. Gerum",{"url":26,"publisher":1430,"properties":1457},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1431,"slug":663,"properties":1432,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1435,"manageAffiliations":1436,"indexDatabases":1437,"url":747,"thumbnailPath":26,"statistic":1452,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1433,"title":1434},{"VOID":666},{"EN":668},[],[],[1438,1445],{"id":708,"indexDatabase":1439,"url":723,"indexYears":26,"academicFieldIds":1444,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":1440,"label":1441,"description":1442,"key":719,"publicationTags":1443,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":1446,"url":741,"indexYears":742,"academicFieldIds":1451,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":1447,"label":1448,"description":1449,"key":738,"publicationTags":1450,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":1453,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":1454,"totalCitation":768,"totalCitationByYear":1455,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":1456,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"volume":1458,"issue":1460},{"VOID":1459},"14",{"VOID":951},285,{"total":1461,"publishYear":26,"statisticByYear":1463},{"2019":115,"2020":48,"2021":44,"2022":1464,"2023":568,"2024":238},82,"2019-12-01",2019,[1468,1472,1476,1480,1484,1488,1492,1496,1500,1503,1506,1510,1514,1518,1522,1526,1530,1534,1538,1542,1546,1550,1554,1558,1562,1566,1570,1574,1578,1582,1586,1590,1594,1598,1602,1606,1610,1614,1618,1622,1626,1630,1634,1638,1642,1646,1650,1654,1658,1662,1666,1670,1674,1678,1682,1686,1689,1693,1697,1701,1705,1709,1713,1717,1721,1725,1729,1733,1737,1741,1745,1749,1753,1757,1761,1765,1769,1773,1777,1781,1785,1789,1793,1797,1801,1805,1809,1813,1817,1821,1825,1829,1833,1837,1841,1845,1849,1853,1857,1861,1864,1868,1872,1876,1880,1884,1888,1892,1896,1900,1904,1908,1912,1916,1920,1924,1928,1932,1936,1939,1943,1947,1951,1955,1959,1963,1967,1971,1975,1979,1983,1987,1991,1995,1999,2003,2007,2011,2015,2019,2023,2027,2031,2035,2039,2043,2047,2051,2055,2059,2063,2067,2071,2075,2079,2083,2087,2091,2095,2099,2103,2107,2111,2115,2119,2123,2127,2131,2135,2139,2143,2147,2151,2155,2159,2163,2167,2171,2175,2179,2183,2187,2191,2195,2198,2202,2206,2210,2214,2218,2222,2226,2230,2234,2238,2242,2246,2250,2254,2258,2262,2266,2270,2274,2278,2282,2286,2290,2294,2298,2302,2305,2309,2313,2317,2321,2325,2329,2333,2337,2341,2345,2349,2353,2357,2361,2365,2369,2373,2377,2381,2385,2389,2393,2397,2401,2405,2409,2413,2417,2421,2425,2429,2433,2437,2441,2445,2449,2453,2457,2461,2465,2469,2473,2477,2481,2485,2489,2493,2497,2501,2505,2509,2513,2517,2521,2525,2529,2533,2537,2541,2545,2549,2553,2557,2561,2565,2569],{"id":26,"text":1469,"url":26,"identifiers":1470},"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.",{"doi":1471},"10.1038\u002Fnrdp.2016.22",{"id":26,"text":1473,"url":26,"identifiers":1474},"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.",{"doi":1475},"10.3322\u002Fcaac.21442",{"id":26,"text":1477,"url":26,"identifiers":1478},"Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, Westphalen CB, Strauch K. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649–56.",{"doi":1479},"10.1002\u002Fcam4.767",{"id":26,"text":1481,"url":26,"identifiers":1482},"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.",{"doi":1483},"10.1158\u002F0008-5472.CAN-14-0155",{"id":26,"text":1485,"url":26,"identifiers":1486},"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.",{"doi":1487},"10.1056\u002FNEJMoa021423",{"id":26,"text":1489,"url":26,"identifiers":1490},"Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23(1):48–62.",{"doi":1491},"10.1016\u002Fj.cmet.2015.12.015",{"id":26,"text":1493,"url":26,"identifiers":1494},"Rahn S, Zimmermann V, Viol F, Knaack H, Stemmer K, Peters L, Lenk L, Ungefroren H, Saur D, Schafer H, et al. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. Cancer Lett. 2018;415:129–50.",{"doi":1495},"10.1016\u002Fj.canlet.2017.12.004",{"id":26,"text":1497,"url":26,"identifiers":1498},"Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91(14):1194–210.",{"doi":1499},"10.1093\u002Fjnci\u002F91.14.1194",{"id":26,"text":1501,"url":26,"identifiers":1502},"Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48(11):3282–7.",{},{"id":26,"text":1504,"url":26,"identifiers":1505},"Blot WJ. Alcohol and cancer. Cancer Res. 1992;52(7 Suppl):2119s–23s.",{},{"id":26,"text":1507,"url":26,"identifiers":1508},"Gapstur SM, Jacobs EJ, Deka A, McCullough ML, Patel AV, Thun MJ. Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Intern Med. 2011;171(5):444–51.",{"doi":1509},"10.1001\u002Farchinternmed.2010.536",{"id":26,"text":1511,"url":26,"identifiers":1512},"Pelucchi C, Galeone C, Polesel J, Manzari M, Zucchetto A, Talamini R, Franceschi S, Negri E, La Vecchia C. Smoking and body mass index and survival in pancreatic cancer patients. Pancreas. 2014;43(1):47–52.",{"doi":1513},"10.1097\u002FMPA.0b013e3182a7c74b",{"id":26,"text":1515,"url":26,"identifiers":1516},"Olson SH, Chou JF, Ludwig E, O'Reilly E, Allen PJ, Jarnagin WR, Bayuga S, Simon J, Gonen M, Reisacher WR, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer. 2010;127(10):2412–9.",{"doi":1517},"10.1002\u002Fijc.25240",{"id":26,"text":1519,"url":26,"identifiers":1520},"Delitto D, Zhang D, Han S, Black BS, Knowlton AE, Vlada AC, Sarosi GA, Behrns KE, Thomas RM, Lu X, et al. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Clin Cancer Res. 2016;22(7):1787–99.",{"doi":1521},"10.1158\u002F1078-0432.CCR-15-1256",{"id":26,"text":1523,"url":26,"identifiers":1524},"Zhang S, Wang C, Huang H, Jiang Q, Zhao D, Tian Y, Ma J, Yuan W, Sun Y, Che X, et al. Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients. Sci Rep. 2017;7(1):9572.",{"doi":1525},"10.1038\u002Fs41598-017-08794-1",{"id":26,"text":1527,"url":26,"identifiers":1528},"Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42(3):224–8.",{"doi":1529},"10.1038\u002Fng.522",{"id":26,"text":1531,"url":26,"identifiers":1532},"Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8(42):73240–57.",{"doi":1533},"10.18632\u002Foncotarget.17291",{"id":26,"text":1535,"url":26,"identifiers":1536},"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319(23):2401–9.",{"doi":1537},"10.1001\u002Fjama.2018.6228",{"id":26,"text":1539,"url":26,"identifiers":1540},"Gillen S, Schuster T. Meyer Zum Buschenfelde C, Friess H, Kleeff J: Preoperative\u002Fneoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.",{"doi":1541},"10.1371\u002Fjournal.pmed.1000267",{"id":26,"text":1543,"url":26,"identifiers":1544},"Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10(6):323–33.",{"doi":1545},"10.1038\u002Fnrclinonc.2013.66",{"id":26,"text":1547,"url":26,"identifiers":1548},"Manji GA, Olive KP, Saenger YM, Oberstein P. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clin Cancer Res. 2017;23(7):1670–8.",{"doi":1549},"10.1158\u002F1078-0432.CCR-16-2319",{"id":26,"text":1551,"url":26,"identifiers":1552},"Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 2015;7(2):68–84.",{"doi":1553},"10.1177\u002F1758834014564775",{"id":26,"text":1555,"url":26,"identifiers":1556},"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.",{"doi":1557},"10.1056\u002FNEJMoa1011923",{"id":26,"text":1559,"url":26,"identifiers":1560},"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.",{"doi":1561},"10.1056\u002FNEJMoa1304369",{"id":26,"text":1563,"url":26,"identifiers":1564},"Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Boige V, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\u002FACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23–9.",{"doi":1565},"10.1200\u002FJCO.2012.44.4869",{"id":26,"text":1567,"url":26,"identifiers":1568},"Hall WA, Goodman KA. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiat Oncol. 2019;14(1):114.",{"doi":1569},"10.1186\u002Fs13014-019-1277-1",{"id":26,"text":1571,"url":26,"identifiers":1572},"Roeder F. Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol. 2016;8(2):186–97.",{"doi":1573},"10.4251\u002Fwjgo.v8.i2.186",{"id":26,"text":1575,"url":26,"identifiers":1576},"Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol. 2010;5:64.",{"doi":1577},"10.1186\u002F1748-717X-5-64",{"id":26,"text":1579,"url":26,"identifiers":1580},"Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26.",{"doi":1581},"10.1016\u002FS1470-2045(13)70021-4",{"id":26,"text":1583,"url":26,"identifiers":1584},"Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018;4(7):963–9.",{"doi":1585},"10.1001\u002Fjamaoncol.2018.0329",{"id":26,"text":1587,"url":26,"identifiers":1588},"Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol. 2019;14(1):95.",{"doi":1589},"10.1186\u002Fs13014-019-1309-x",{"id":26,"text":1591,"url":26,"identifiers":1592},"Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Radiat Oncol. 2019;14(1):71.",{"doi":1593},"10.1186\u002Fs13014-019-1275-3",{"id":26,"text":1595,"url":26,"identifiers":1596},"Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015;111(8):1028–34.",{"doi":1597},"10.1002\u002Fjso.23921",{"id":26,"text":1599,"url":26,"identifiers":1600},"Buwenge M, Macchia G, Arcelli A, Frakulli R, Fuccio L, Guerri S, Grassi E, Cammelli S, Cellini F, Morganti AG. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. J Pain Res. 2018;11:2169–78.",{"doi":1601},"10.2147\u002FJPR.S167994",{"id":26,"text":1603,"url":26,"identifiers":1604},"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.",{"doi":1605},"10.1056\u002FNEJMoa1200694",{"id":26,"text":1607,"url":26,"identifiers":1608},"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.",{"doi":1609},"10.1056\u002FNEJMoa1507643",{"id":26,"text":1611,"url":26,"identifiers":1612},"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.",{"doi":1613},"10.1200\u002FJCO.2013.53.0105",{"id":26,"text":1615,"url":26,"identifiers":1616},"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270–1.",{"doi":1617},"10.1056\u002FNEJMc1509660",{"id":26,"text":1619,"url":26,"identifiers":1620},"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–33.",{"doi":1621},"10.1097\u002FCJI.0b013e3181eec14c",{"id":26,"text":1623,"url":26,"identifiers":1624},"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.",{"doi":1625},"10.1126\u002Fscience.aan6733",{"id":26,"text":1627,"url":26,"identifiers":1628},"Lemery S, Keegan P, Pazdur R. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med. 2017;377(15):1409–12.",{"doi":1629},"10.1056\u002FNEJMp1709968",{"id":26,"text":1631,"url":26,"identifiers":1632},"Dougan SK. The Pancreatic Cancer Microenvironment. Cancer J. 2017;23(6):321–5.",{"doi":1633},"10.1097\u002FPPO.0000000000000288",{"id":26,"text":1635,"url":26,"identifiers":1636},"Puri S, Folias AE, Hebrok M. Plasticity and dedifferentiation within the pancreas: development, homeostasis, and disease. Cell Stem Cell. 2015;16(1):18–31.",{"doi":1637},"10.1016\u002Fj.stem.2014.11.001",{"id":26,"text":1639,"url":26,"identifiers":1640},"Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP, Pan FC, Akiyama H, Wright CV, Jensen K, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(6):737–50.",{"doi":1641},"10.1016\u002Fj.ccr.2012.10.025",{"id":26,"text":1643,"url":26,"identifiers":1644},"Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 2009;16(5):379–89.",{"doi":1645},"10.1016\u002Fj.ccr.2009.09.027",{"id":26,"text":1647,"url":26,"identifiers":1648},"Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142(4):730–3 e739.",{"doi":1649},"10.1053\u002Fj.gastro.2011.12.042",{"id":26,"text":1651,"url":26,"identifiers":1652},"Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683–95.",{"doi":1653},"10.1038\u002Fnrc2899",{"id":26,"text":1655,"url":26,"identifiers":1656},"Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.",{"doi":1657},"10.1038\u002Fncomms7744",{"id":26,"text":1659,"url":26,"identifiers":1660},"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.",{"doi":1661},"10.1038\u002Fnature14169",{"id":26,"text":1663,"url":26,"identifiers":1664},"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.",{"doi":1665},"10.1038\u002Fnature16965",{"id":26,"text":1667,"url":26,"identifiers":1668},"Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer Genome Atlas Research N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185–203 e113.",{"doi":1669},"10.1016\u002Fj.ccell.2017.07.007",{"id":26,"text":1671,"url":26,"identifiers":1672},"Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Ollinger R, Zwiebel M, Strong A, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554(7690):62–8.",{"doi":1673},"10.1038\u002Fnature25459",{"id":26,"text":1675,"url":26,"identifiers":1676},"Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP, Testa JR. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem. 2002;87(4):470–6.",{"doi":1677},"10.1002\u002Fjcb.10287",{"id":26,"text":1679,"url":26,"identifiers":1680},"Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30(4):355–85.",{"doi":1681},"10.1101\u002Fgad.275776.115",{"id":26,"text":1683,"url":26,"identifiers":1684},"Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res. 2018;24(6):1326–36.",{"doi":1685},"10.1158\u002F1078-0432.CCR-17-3099",{"id":26,"text":1687,"url":26,"identifiers":1688},"Iguchi E, Safgren SL, Marks DL, Olson RL, Fernandez-Zapico ME. Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language. Yale J Biol Med. 2016;89(4):575–90.",{},{"id":26,"text":1690,"url":26,"identifiers":1691},"Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 2017;170(5):875–88 e820.",{"doi":1692},"10.1016\u002Fj.cell.2017.07.007",{"id":26,"text":1694,"url":26,"identifiers":1695},"McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, Carrer A, Salz TH, Natsume S, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet. 2017;49(3):367–76.",{"doi":1696},"10.1038\u002Fng.3753",{"id":26,"text":1698,"url":26,"identifiers":1699},"Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9(1):1978.",{"doi":1700},"10.1038\u002Fs41467-018-04383-6",{"id":26,"text":1702,"url":26,"identifiers":1703},"Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, et al. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2017;3(6):774–83.",{"doi":1704},"10.1001\u002Fjamaoncol.2016.3916",{"id":26,"text":1706,"url":26,"identifiers":1707},"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–78.",{"doi":1708},"10.1038\u002Fng.3398",{"id":26,"text":1710,"url":26,"identifiers":1711},"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3.",{"doi":1712},"10.1038\u002Fnm.2344",{"id":26,"text":1714,"url":26,"identifiers":1715},"Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF. Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. Cancers (Basel). 2018;10(2). \n                    https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers10020034\n                    \n                  .",{"doi":1716},"10.3390\u002Fcancers10020034",{"id":26,"text":1718,"url":26,"identifiers":1719},"Muckenhuber A, Berger AK, Schlitter AM, Steiger K, Konukiewitz B, Trumpp A, Eils R, Werner J, Friess H, Esposito I, et al. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clin Cancer Res. 2018;24(2):351–9.",{"doi":1720},"10.1158\u002F1078-0432.CCR-17-2180",{"id":26,"text":1722,"url":26,"identifiers":1723},"Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res. 2018;24(6):1344–54.",{"doi":1724},"10.1158\u002F1078-0432.CCR-17-2994",{"id":26,"text":1726,"url":26,"identifiers":1727},"Nielsen MF, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol. 2016;22(9):2678–700.",{"doi":1728},"10.3748\u002Fwjg.v22.i9.2678",{"id":26,"text":1730,"url":26,"identifiers":1731},"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA. IL1-Induced JAK\u002FSTAT Signaling Is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2019;9(2):282–301.",{"doi":1732},"10.1158\u002F2159-8290.CD-18-0710",{"id":26,"text":1734,"url":26,"identifiers":1735},"Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.",{"doi":1736},"10.1084\u002Fjem.20162024",{"id":26,"text":1738,"url":26,"identifiers":1739},"Melstrom LG, Salazar MD, Diamond DJ. The pancreatic cancer microenvironment: A true double agent. J Surg Oncol. 2017;116(1):7–15.",{"doi":1740},"10.1002\u002Fjso.24643",{"id":26,"text":1742,"url":26,"identifiers":1743},"Masamune A, Watanabe T, Kikuta K, Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol. 2009;7(11 Suppl):S48–54.",{"doi":1744},"10.1016\u002Fj.cgh.2009.07.038",{"id":26,"text":1746,"url":26,"identifiers":1747},"Apte MV, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC, Wilson JS. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44(4):534–41.",{"doi":1748},"10.1136\u002Fgut.44.4.534",{"id":26,"text":1750,"url":26,"identifiers":1751},"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–20.",{"doi":1752},"10.1136\u002Fgutjnl-2012-302529",{"id":26,"text":1754,"url":26,"identifiers":1755},"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–60.",{"doi":1756},"10.1038\u002Fnm.4123",{"id":26,"text":1758,"url":26,"identifiers":1759},"Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10(3):301–16.",{"doi":1760},"10.1586\u002F17474124.2016.1117386",{"id":26,"text":1762,"url":26,"identifiers":1763},"Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40(1):118–28.",{"doi":1764},"10.1016\u002Fj.ctrv.2013.04.004",{"id":26,"text":1766,"url":26,"identifiers":1767},"Li N, Li Y, Li Z, Huang C, Yang Y, Lang M, Cao J, Jiang W, Xu Y, Dong J, et al. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2016;17(6). \n                    https:\u002F\u002Fdoi.org\u002F10.3390\u002Fijms17060799\n                    \n                  .",{"doi":1768},"10.3390\u002Fijms17060799",{"id":26,"text":1770,"url":26,"identifiers":1771},"Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145(5):1121–32.",{"doi":1772},"10.1053\u002Fj.gastro.2013.07.025",{"id":26,"text":1774,"url":26,"identifiers":1775},"Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719–34.",{"doi":1776},"10.1016\u002Fj.ccr.2014.04.005",{"id":26,"text":1778,"url":26,"identifiers":1779},"Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin Transl Med. 2019;8(1):10.",{"doi":1780},"10.1186\u002Fs40169-019-0226-9",{"id":26,"text":1782,"url":26,"identifiers":1783},"Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67(19):9518–27.",{"doi":1784},"10.1158\u002F0008-5472.CAN-07-0175",{"id":26,"text":1786,"url":26,"identifiers":1787},"Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, et al. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2018;155(5):1625–39 e1622.",{"doi":1788},"10.1053\u002Fj.gastro.2018.08.009",{"id":26,"text":1790,"url":26,"identifiers":1791},"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128–41.",{"doi":1792},"10.1158\u002F0008-5472.CAN-12-2731",{"id":26,"text":1794,"url":26,"identifiers":1795},"Hu H, Hang JJ, Han T, Zhuo M, Jiao F, Wang LW. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour Biol. 2016;37(7):8657–64.",{"doi":1796},"10.1007\u002Fs13277-015-4741-z",{"id":26,"text":1798,"url":26,"identifiers":1799},"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.",{"doi":1800},"10.1038\u002Fncomms12150",{"id":26,"text":1802,"url":26,"identifiers":1803},"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–62.",{"doi":1804},"10.1016\u002FS1470-2045(16)00078-4",{"id":26,"text":1806,"url":26,"identifiers":1807},"Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018;49(1):178–193.e177.",{"doi":1808},"10.1016\u002Fj.immuni.2018.06.006",{"id":26,"text":1810,"url":26,"identifiers":1811},"Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, VRK M, et al. gammadelta T Cells Support Pancreatic Oncogenesis by Restraining alphabeta T Cell Activation. Cell. 2016;166(6):1485–99 e1415.",{"doi":1812},"10.1016\u002Fj.cell.2016.07.046",{"id":26,"text":1814,"url":26,"identifiers":1815},"Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, et al. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016;6(3):270–85.",{"doi":1816},"10.1158\u002F2159-8290.CD-15-0827",{"id":26,"text":1818,"url":26,"identifiers":1819},"Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, Bar-Sagi D. IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov. 2016;6(3):247–55.",{"doi":1820},"10.1158\u002F2159-8290.CD-15-0843",{"id":26,"text":1822,"url":26,"identifiers":1823},"Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res. 2017;5(11):978–91.",{"doi":1824},"10.1158\u002F2326-6066.CIR-16-0322",{"id":26,"text":1826,"url":26,"identifiers":1827},"Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):e1240859.",{"doi":1828},"10.1080\u002F2162402X.2016.1240859",{"id":26,"text":1830,"url":26,"identifiers":1831},"Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23(7):1656–69.",{"doi":1832},"10.1158\u002F1078-0432.CCR-16-2318",{"id":26,"text":1834,"url":26,"identifiers":1835},"Yako YY, Kruger D, Smith M, Brand M. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One. 2016;11(5):e0154016.",{"doi":1836},"10.1371\u002Fjournal.pone.0154016",{"id":26,"text":1838,"url":26,"identifiers":1839},"Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 2014;345(2):157–63.",{"doi":1840},"10.1016\u002Fj.canlet.2013.07.014",{"id":26,"text":1842,"url":26,"identifiers":1843},"Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2013;257(1):17–26.",{"doi":1844},"10.1097\u002FSLA.0b013e31825ffbfb",{"id":26,"text":1846,"url":26,"identifiers":1847},"Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7.",{"doi":1848},"10.1038\u002Fnature09515",{"id":26,"text":1850,"url":26,"identifiers":1851},"Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, Chatterjee K, Wong F, Jiao Y, Kohutek ZA, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017;49(3):358–66.",{"doi":1852},"10.1038\u002Fng.3764",{"id":26,"text":1854,"url":26,"identifiers":1855},"Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1109–13.",{"doi":1856},"10.1038\u002Fnature09460",{"id":26,"text":1858,"url":26,"identifiers":1859},"Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349–61.",{"doi":1860},"10.1016\u002Fj.cell.2011.11.025",{"id":26,"text":1862,"url":26,"identifiers":1863},"Wang S, Huang S, Sun YL. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. Biomed Res Int. 2017;2017:2646148.",{},{"id":26,"text":1865,"url":26,"identifiers":1866},"Takano S, Reichert M, Bakir B, Das KK, Nishida T, Miyazaki M, Heeg S, Collins MA, Marchand B, Hicks PD, et al. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev. 2016;30(2):233–47.",{"doi":1867},"10.1101\u002Fgad.263327.115",{"id":26,"text":1869,"url":26,"identifiers":1870},"Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19(5):518–29.",{"doi":1871},"10.1038\u002Fncb3513",{"id":26,"text":1873,"url":26,"identifiers":1874},"Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol. 2017;44:43–59.",{"doi":1875},"10.1016\u002Fj.semcancer.2017.04.006",{"id":26,"text":1877,"url":26,"identifiers":1878},"Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J. EP300--a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer. 2010;126(1):114–24.",{"doi":1879},"10.1002\u002Fijc.24695",{"id":26,"text":1881,"url":26,"identifiers":1882},"Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, et al. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell. 2018;45(6):681–95 e684.",{"doi":1883},"10.1016\u002Fj.devcel.2018.05.027",{"id":26,"text":1885,"url":26,"identifiers":1886},"Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res. 2011;9(12):1608–20.",{"doi":1887},"10.1158\u002F1541-7786.MCR-10-0568",{"id":26,"text":1889,"url":26,"identifiers":1890},"Reichert M, Bakir B, Moreira L, Pitarresi JR, Feldmann K, Simon L, Suzuki K, Maddipati R, Rhim AD, Schlitter AM, et al. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Dev Cell. 2018;45(6):696–711.e698.",{"doi":1891},"10.1016\u002Fj.devcel.2018.05.025",{"id":26,"text":1893,"url":26,"identifiers":1894},"Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010;7(7):e1000307.",{"doi":1895},"10.1371\u002Fjournal.pmed.1000307",{"id":26,"text":1897,"url":26,"identifiers":1898},"Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA, et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One. 2012;7(3):e32996.",{"doi":1899},"10.1371\u002Fjournal.pone.0032996",{"id":26,"text":1901,"url":26,"identifiers":1902},"Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology. 2013;144(6):1241–8.",{"doi":1903},"10.1053\u002Fj.gastro.2013.01.072",{"id":26,"text":1905,"url":26,"identifiers":1906},"Kruger A. Premetastatic niche formation in the liver: emerging mechanisms and mouse models. J Mol Med (Berl). 2015;93(11):1193–201.",{"doi":1907},"10.1007\u002Fs00109-015-1342-7",{"id":26,"text":1909,"url":26,"identifiers":1910},"Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816–26.",{"doi":1911},"10.1038\u002Fncb3169",{"id":26,"text":1913,"url":26,"identifiers":1914},"Grunwald B, Harant V, Schaten S, Fruhschutz M, Spallek R, Hochst B, Stutzer K, Berchtold S, Erkan M, Prokopchuk O, et al. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver. Gastroenterology. 2016;151(5):1011–24 e1017.",{"doi":1915},"10.1053\u002Fj.gastro.2016.07.043",{"id":26,"text":1917,"url":26,"identifiers":1918},"Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017;9(11). \n                    https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers9110157\n                    \n                  .",{"doi":1919},"10.3390\u002Fcancers9110157",{"id":26,"text":1921,"url":26,"identifiers":1922},"Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017;114:139–52.",{"doi":1923},"10.1016\u002Fj.critrevonc.2017.03.026",{"id":26,"text":1925,"url":26,"identifiers":1926},"Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer. 2018;4(6):418–28.",{"doi":1927},"10.1016\u002Fj.trecan.2018.04.001",{"id":26,"text":1929,"url":26,"identifiers":1930},"Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96(3):457–63.",{"doi":1931},"10.1038\u002Fsj.bjc.6603559",{"id":26,"text":1933,"url":26,"identifiers":1934},"Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2007;120(6):1355–63.",{"doi":1935},"10.1002\u002Fijc.22390",{"id":26,"text":1937,"url":26,"identifiers":1938},"Kurata N, Fujita H, Ohuchida K, Mizumoto K, Mahawithitwong P, Sakai H, Onimaru M, Manabe T, Ohtsuka T, Tanaka M. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int J Oncol. 2011;39(2):473–82.",{},{"id":26,"text":1940,"url":26,"identifiers":1941},"Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR, Witkiewicz AK. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer. 2012;12:104.",{"doi":1942},"10.1186\u002F1471-2407-12-104",{"id":26,"text":1944,"url":26,"identifiers":1945},"Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res. 2005;11(9):3433–8.",{"doi":1946},"10.1158\u002F1078-0432.CCR-04-1510",{"id":26,"text":1948,"url":26,"identifiers":1949},"Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 2005;24(27):4421–32.",{"doi":1950},"10.1038\u002Fsj.onc.1208642",{"id":26,"text":1952,"url":26,"identifiers":1953},"Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, et al. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 2018;67(3):497–507.",{"doi":1954},"10.1136\u002Fgutjnl-2016-311954",{"id":26,"text":1956,"url":26,"identifiers":1957},"Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol. 2016;22(31):6987–7005.",{"doi":1958},"10.3748\u002Fwjg.v22.i31.6987",{"id":26,"text":1960,"url":26,"identifiers":1961},"Huguet F, Mukherjee S, Javle M. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol). 2014;26(9):560–8.",{"doi":1962},"10.1016\u002Fj.clon.2014.06.002",{"id":26,"text":1964,"url":26,"identifiers":1965},"Quintiliani M. Modification of radiation sensitivity: the oxygen effect. Int J Radiat Oncol Biol Phys. 1979;5(7):1069–76.",{"doi":1966},"10.1016\u002F0360-3016(79)90621-7",{"id":26,"text":1968,"url":26,"identifiers":1969},"Matsumoto S, Kishimoto S, Saito K, Takakusagi Y, Munasinghe JP, Devasahayam N, Hart CP, Gillies RJ, Mitchell JB, Krishna MC. Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice. Cancer Res. 2018;78(14):3783–92.",{"doi":1970},"10.1158\u002F0008-5472.CAN-18-0491",{"id":26,"text":1972,"url":26,"identifiers":1973},"Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H, Sturzbecher HW. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000;19(23):2791–5.",{"doi":1974},"10.1038\u002Fsj.onc.1203578",{"id":26,"text":1976,"url":26,"identifiers":1977},"Mathews LA, Cabarcas SM, Hurt EM, Zhang X, Jaffee EM, Farrar WL. Increased expression of DNA repair genes in invasive human pancreatic cancer cells. Pancreas. 2011;40(5):730–9.",{"doi":1978},"10.1097\u002FMPA.0b013e31821ae25b",{"id":26,"text":1980,"url":26,"identifiers":1981},"Wang F, Xia X, Yang C, Shen J, Mai J, Kim HC, Kirui D, Kang Y, Fleming JB, Koay EJ, et al. SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res. 2018;24(13):3176–85.",{"doi":1982},"10.1158\u002F1078-0432.CCR-17-3435",{"id":26,"text":1984,"url":26,"identifiers":1985},"Cordes N, Frick S, Brunner TB, Pilarsky C, Grutzmann R, Sipos B, Kloppel G, McKenna WG, Bernhard EJ. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene. 2007;26(48):6851–62.",{"doi":1986},"10.1038\u002Fsj.onc.1210498",{"id":26,"text":1988,"url":26,"identifiers":1989},"Hehlgans S, Eke I, Storch K, Haase M, Baretton GB, Cordes N. Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. Radiother Oncol. 2009;92(3):362–70.",{"doi":1990},"10.1016\u002Fj.radonc.2009.07.004",{"id":26,"text":1992,"url":26,"identifiers":1993},"Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017;23(1):137–48.",{"doi":1994},"10.1158\u002F1078-0432.CCR-16-0870",{"id":26,"text":1996,"url":26,"identifiers":1997},"Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):801–8.",{"doi":1998},"10.1016\u002Fj.ijrobp.2006.12.053",{"id":26,"text":2000,"url":26,"identifiers":2001},"Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12.",{"doi":2002},"10.1200\u002FJCO.2011.34.8904",{"id":26,"text":2004,"url":26,"identifiers":2005},"Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665–72.",{"doi":2006},"10.1002\u002Fcncr.24059",{"id":26,"text":2008,"url":26,"identifiers":2009},"Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170(6):1062–78.",{"doi":2010},"10.1016\u002Fj.cell.2017.08.028",{"id":26,"text":2012,"url":26,"identifiers":2013},"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13(11):828–51.",{"doi":2014},"10.1038\u002Fnrd4389",{"id":26,"text":2016,"url":26,"identifiers":2017},"Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res. 2004;64(16):5659–63.",{"doi":2018},"10.1158\u002F0008-5472.CAN-04-0807",{"id":26,"text":2020,"url":26,"identifiers":2021},"Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111(5):817–22.",{"doi":2022},"10.1038\u002Fbjc.2014.215",{"id":26,"text":2024,"url":26,"identifiers":2025},"Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605–10.",{"doi":2026},"10.1200\u002FJCO.2009.25.7550",{"id":26,"text":2028,"url":26,"identifiers":2029},"Kim YJ, Jung K, Baek DS, Hong SS, Kim YS. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin beta1-driven Src-Akt bypass signaling. Oncogene. 2017;36(18):2543–52.",{"doi":2030},"10.1038\u002Fonc.2016.407",{"id":26,"text":2032,"url":26,"identifiers":2033},"Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res. 2005;3(7):413–23.",{"doi":2034},"10.1158\u002F1541-7786.MCR-04-0206",{"id":26,"text":2036,"url":26,"identifiers":2037},"Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3(14):1787–808.",{"doi":2038},"10.4155\u002Ffmc.11.121",{"id":26,"text":2040,"url":26,"identifiers":2041},"Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI, et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature. 2013;497(7451):638–42.",{"doi":2042},"10.1038\u002Fnature12205",{"id":26,"text":2044,"url":26,"identifiers":2045},"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.",{"doi":2046},"10.1200\u002FJCO.2006.07.9525",{"id":26,"text":2048,"url":26,"identifiers":2049},"Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Ormanns S, Haas M, Modest DP, Kirchner T, et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol. 2013;48(4):544–8.",{"doi":2050},"10.1007\u002Fs00535-013-0767-4",{"id":26,"text":2052,"url":26,"identifiers":2053},"Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, et al. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia. 2011;13(11):1026–34.",{"doi":2054},"10.1593\u002Fneo.111016",{"id":26,"text":2056,"url":26,"identifiers":2057},"Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2012;22(3):304–17.",{"doi":2058},"10.1016\u002Fj.ccr.2012.07.024",{"id":26,"text":2060,"url":26,"identifiers":2061},"Schneeweis C, Wirth M, Saur D, Reichert M, Schneider G. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes. Small GTPases. 2018;9(6):457–64.",{"doi":2062},"10.1080\u002F21541248.2016.1262935",{"id":26,"text":2064,"url":26,"identifiers":2065},"Diersch S, Wirth M, Schneeweis C, Jors S, Geisler F, Siveke JT, Rad R, Schmid RM, Saur D, Rustgi AK, et al. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells. Oncogene. 2016;35(29):3880–6.",{"doi":2066},"10.1038\u002Fonc.2015.437",{"id":26,"text":2068,"url":26,"identifiers":2069},"Bergmann L, Maute L, Heil G, Russel J, Weidmann E, Koberle D, Fuxius S, Weigang-Kohler K, Aulitzky WE, Wormann B, et al. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur J Cancer. 2015;51(1):27–36.",{"doi":2070},"10.1016\u002Fj.ejca.2014.10.010",{"id":26,"text":2072,"url":26,"identifiers":2073},"Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, Ikenoue T, Tateishi K, Nakai Y, Isayama H, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013;73(7):2221–34.",{"doi":2074},"10.1158\u002F0008-5472.CAN-12-1453",{"id":26,"text":2076,"url":26,"identifiers":2077},"Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018;34(5):807–22 e807.",{"doi":2078},"10.1016\u002Fj.ccell.2018.10.001",{"id":26,"text":2080,"url":26,"identifiers":2081},"Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, et al. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016;29(1):75–89.",{"doi":2082},"10.1016\u002Fj.ccell.2015.11.011",{"id":26,"text":2084,"url":26,"identifiers":2085},"Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D, Gorgulu K, Dantes Z, Wormann SM, Diakopoulos KN, et al. Mutant KRAS-driven cancers depend on PTPN11\u002FSHP2 phosphatase. Nat Med. 2018;24(7):954–60.",{"doi":2086},"10.1038\u002Fs41591-018-0024-8",{"id":26,"text":2088,"url":26,"identifiers":2089},"Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016;8(4). \n                    https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers8040045\n                    \n                  .",{"doi":2090},"10.3390\u002Fcancers8040045",{"id":26,"text":2092,"url":26,"identifiers":2093},"Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, et al. A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012;2(8):685–93.",{"doi":2094},"10.1158\u002F2159-8290.CD-11-0347",{"id":26,"text":2096,"url":26,"identifiers":2097},"Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et al. Selective requirement of PI3K\u002FPDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013;23(3):406–20.",{"doi":2098},"10.1016\u002Fj.ccr.2013.01.023",{"id":26,"text":2100,"url":26,"identifiers":2101},"Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015;21(2):396–404.",{"doi":2102},"10.1158\u002F1078-0432.CCR-14-1591",{"id":26,"text":2104,"url":26,"identifiers":2105},"Ischenko I, Petrenko O, Hayman MJ. A MEK\u002FPI3K\u002FHDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Oncotarget. 2015;6(18):15814–27.",{"doi":2106},"10.18632\u002Foncotarget.4538",{"id":26,"text":2108,"url":26,"identifiers":2109},"Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, et al. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Mol Cancer Ther. 2015;14(1):40–7.",{"doi":2110},"10.1158\u002F1535-7163.MCT-14-0030",{"id":26,"text":2112,"url":26,"identifiers":2113},"Ciuffreda L, Del Curatolo A, Falcone I, Conciatori F, Bazzichetto C, Cognetti F, Corbo V, Scarpa A, Milella M. Lack of growth inhibitory synergism with combined MAPK\u002FPI3K inhibition in preclinical models of pancreatic cancer. Ann Oncol. 2017;28(11):2896–8.",{"doi":2114},"10.1093\u002Fannonc\u002Fmdx335",{"id":26,"text":2116,"url":26,"identifiers":2117},"Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017;3(4):516–22.",{"doi":2118},"10.1001\u002Fjamaoncol.2016.5383",{"id":26,"text":2120,"url":26,"identifiers":2121},"Stoy C, Sundaram A, Rios Garcia M, Wang X, Seibert O, Zota A, Wendler S, Mannle D, Hinz U, Sticht C, et al. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. EMBO Mol Med. 2015;7(8):1048–62.",{"doi":2122},"10.15252\u002Femmm.201404837",{"id":26,"text":2124,"url":26,"identifiers":2125},"Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, et al. Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015;29(6):1267–78.",{"doi":2126},"10.1038\u002Fleu.2014.340",{"id":26,"text":2128,"url":26,"identifiers":2129},"Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886–918.",{"doi":2130},"10.3390\u002Fijms13021886",{"id":26,"text":2132,"url":26,"identifiers":2133},"Wei F, Zhang Y, Geng L, Zhang P, Wang G, Liu Y. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Int J Mol Sci. 2015;16(2):3267–82.",{"doi":2134},"10.3390\u002Fijms16023267",{"id":26,"text":2136,"url":26,"identifiers":2137},"Utomo WK, Narayanan V, Biermann K, van Eijck CH, Bruno MJ, Peppelenbosch MP, Braat H. mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Lett. 2014;346(2):309–17.",{"doi":2138},"10.1016\u002Fj.canlet.2014.01.014",{"id":26,"text":2140,"url":26,"identifiers":2141},"Lou HZ, Weng XC, Pan HM, Pan Q, Sun P, Liu LL, Chen B. The novel mTORC1\u002F2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. Biochem Biophys Res Commun. 2014;450(2):973–8.",{"doi":2142},"10.1016\u002Fj.bbrc.2014.06.081",{"id":26,"text":2144,"url":26,"identifiers":2145},"Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, et al. Targeting mTOR dependency in pancreatic cancer. Gut. 2014;63(9):1481–9.",{"doi":2146},"10.1136\u002Fgutjnl-2013-306202",{"id":26,"text":2148,"url":26,"identifiers":2149},"Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One. 2013;8(2):e57289.",{"doi":2150},"10.1371\u002Fjournal.pone.0057289",{"id":26,"text":2152,"url":26,"identifiers":2153},"Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E. Dual PI3K\u002FmTOR Inhibitors Induce Rapid Overactivation of the MEK\u002FERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Mol Cancer Ther. 2015;14(4):1014–23.",{"doi":2154},"10.1158\u002F1535-7163.MCT-14-0669",{"id":26,"text":2156,"url":26,"identifiers":2157},"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–8.",{"doi":2158},"10.1158\u002F0008-5472.CAN-05-2925",{"id":26,"text":2160,"url":26,"identifiers":2161},"Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B, Ceyhan GO, Knauer SK, Weichert W, Schmid RM, et al. MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer. 2018;118(3):366–77.",{"doi":2162},"10.1038\u002Fbjc.2017.421",{"id":26,"text":2164,"url":26,"identifiers":2165},"Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, et al. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Cancer Res. 2016;76(23):6911–23.",{"doi":2166},"10.1158\u002F0008-5472.CAN-16-0810",{"id":26,"text":2168,"url":26,"identifiers":2169},"Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, et al. The clinical effect of the dual-targeting strategy involving PI3K\u002FAKT\u002FmTOR and RAS\u002FMEK\u002FERK pathways in patients with advanced cancer. Clin Cancer Res. 2012;18(8):2316–25.",{"doi":2170},"10.1158\u002F1078-0432.CCR-11-2381",{"id":26,"text":2172,"url":26,"identifiers":2173},"Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27(2):193–8.",{"doi":2174},"10.1200\u002FJCO.2008.18.9514",{"id":26,"text":2176,"url":26,"identifiers":2177},"Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010;10:368.",{"doi":2178},"10.1186\u002F1471-2407-10-368",{"id":26,"text":2180,"url":26,"identifiers":2181},"Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol. 2016;6:99.",{"doi":2182},"10.3389\u002Ffonc.2016.00099",{"id":26,"text":2184,"url":26,"identifiers":2185},"Kordes S, Klumpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2015;75(6):1135–41.",{"doi":2186},"10.1007\u002Fs00280-015-2730-y",{"id":26,"text":2188,"url":26,"identifiers":2189},"Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014;15(3):365–79.",{"doi":2190},"10.1007\u002Fs11864-014-0294-4",{"id":26,"text":2192,"url":26,"identifiers":2193},"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–61.",{"doi":2194},"10.1126\u002Fscience.1171362",{"id":26,"text":2196,"url":26,"identifiers":2197},"Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3(8):1309–16.",{},{"id":26,"text":2199,"url":26,"identifiers":2200},"Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617–22.",{"doi":2201},"10.1200\u002FJCO.2010.28.1386",{"id":26,"text":2203,"url":26,"identifiers":2204},"Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12(3):256–62.",{"doi":2205},"10.1016\u002FS1470-2045(11)70004-3",{"id":26,"text":2207,"url":26,"identifiers":2208},"Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231–7.",{"doi":2209},"10.1200\u002FJCO.2008.20.0238",{"id":26,"text":2211,"url":26,"identifiers":2212},"Craven KE, Gore J, Korc M. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett. 2016;381(1):201–10.",{"doi":2213},"10.1016\u002Fj.canlet.2015.11.047",{"id":26,"text":2215,"url":26,"identifiers":2216},"Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003;22(37):5784–91.",{"doi":2217},"10.1038\u002Fsj.onc.1206678",{"id":26,"text":2219,"url":26,"identifiers":2220},"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111(6):1132–8.",{"doi":2221},"10.1038\u002Fbjc.2014.418",{"id":26,"text":2223,"url":26,"identifiers":2224},"Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1\u002FBRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg. 2018;226(4):630–7 e631.",{"doi":2225},"10.1016\u002Fj.jamcollsurg.2017.12.021",{"id":26,"text":2227,"url":26,"identifiers":2228},"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387–93.",{"doi":2229},"10.1016\u002Fj.molonc.2011.07.001",{"id":26,"text":2231,"url":26,"identifiers":2232},"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\u002F2 mutation. J Clin Oncol. 2015;33(3):244–50.",{"doi":2233},"10.1200\u002FJCO.2014.56.2728",{"id":26,"text":2235,"url":26,"identifiers":2236},"Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H 3rd. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\u002Fmetastatic pancreatic cancer. Ann Oncol. 2015;26(4):804–11.",{"doi":2237},"10.1093\u002Fannonc\u002Fmdu581",{"id":26,"text":2239,"url":26,"identifiers":2240},"Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018;89:19–26.",{"doi":2241},"10.1016\u002Fj.ejca.2017.11.004",{"id":26,"text":2243,"url":26,"identifiers":2244},"O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018;124(7):1374–82.",{"doi":2245},"10.1002\u002Fcncr.31218",{"id":26,"text":2247,"url":26,"identifiers":2248},"Perkhofer L, Schmitt A, Romero Carrasco MC, Ihle M, Hampp S, Ruess DA, Hessmann E, Russell R, Lechel A, Azoitei N, et al. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res. 2017;77(20):5576–90.",{"doi":2249},"10.1158\u002F0008-5472.CAN-17-0634",{"id":26,"text":2251,"url":26,"identifiers":2252},"Hessmann E, Johnsen SA, Siveke JT, Ellenrieder V. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut. 2017;66(1):168–79.",{"doi":2253},"10.1136\u002Fgutjnl-2016-312539",{"id":26,"text":2255,"url":26,"identifiers":2256},"Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sanchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21(10):1163–71.",{"doi":2257},"10.1038\u002Fnm.3952",{"id":26,"text":2259,"url":26,"identifiers":2260},"Krantz BA, O'Reilly EM. Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? Clin Cancer Res. 2018;24(10):2241–50.",{"doi":2261},"10.1158\u002F1078-0432.CCR-16-3169",{"id":26,"text":2263,"url":26,"identifiers":2264},"McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, et al. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology. 2019. \n                    https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.gastro.2019.05.004\n                    \n                  .",{"doi":2265},"10.1053\u002Fj.gastro.2019.05.004",{"id":26,"text":2267,"url":26,"identifiers":2268},"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.",{"doi":2269},"10.1038\u002Fnrc3239",{"id":26,"text":2271,"url":26,"identifiers":2272},"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.",{"doi":2273},"10.1056\u002FNEJMoa1003466",{"id":26,"text":2275,"url":26,"identifiers":2276},"Sahin IH, Askan G, Hu ZI, O'Reilly EM. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? Ann Oncol. 2017;28(12):2950–61.",{"doi":2277},"10.1093\u002Fannonc\u002Fmdx503",{"id":26,"text":2279,"url":26,"identifiers":2280},"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.",{"doi":2281},"10.1126\u002Fscience.aaa1348",{"id":26,"text":2283,"url":26,"identifiers":2284},"Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512–6.",{"doi":2285},"10.1038\u002Fnature24462",{"id":26,"text":2287,"url":26,"identifiers":2288},"Bauer C, Kuhnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Lett. 2016;381(1):259–68.",{"doi":2289},"10.1016\u002Fj.canlet.2016.02.057",{"id":26,"text":2291,"url":26,"identifiers":2292},"Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92(3):441–50.",{"doi":2293},"10.1002\u002Fijc.1205",{"id":26,"text":2295,"url":26,"identifiers":2296},"Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17(1):94–100 discussion p. 100-101.",{"doi":2297},"10.1007\u002Fs11605-012-2064-6",{"id":26,"text":2299,"url":26,"identifiers":2300},"Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY, Weiner DB. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res. 2013;1(3):179–89.",{"doi":2301},"10.1158\u002F2326-6066.CIR-13-0001",{"id":26,"text":2303,"url":26,"identifiers":2304},"NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer [\n                    https:\u002F\u002Fglobenewswire.com\u002Fnews-release\u002F2016\u002F05\u002F09\u002F837878\u002F0\u002Fen\u002FNewLink-Genetics-Announces-Results-from-Phase-3-IMPRESS-Trial-of-Algenpantucel-L-for-Patients-with-Resected-Pancreatic-Cancer.html\n                    \n                  ]. Accessed 30 July.",{},{"id":26,"text":2306,"url":26,"identifiers":2307},"Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829–40.",{"doi":2308},"10.1016\u002FS1470-2045(14)70236-0",{"id":26,"text":2310,"url":26,"identifiers":2311},"Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325–33.",{"doi":2312},"10.1200\u002FJCO.2014.57.4244",{"id":26,"text":2314,"url":26,"identifiers":2315},"Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90.",{"doi":2316},"10.1126\u002Fscience.aad1253",{"id":26,"text":2318,"url":26,"identifiers":2319},"Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016;375(23):2255–62.",{"doi":2320},"10.1056\u002FNEJMoa1609279",{"id":26,"text":2322,"url":26,"identifiers":2323},"Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F, et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother. 2011;60(8):1097–107.",{"doi":2324},"10.1007\u002Fs00262-011-1023-5",{"id":26,"text":2326,"url":26,"identifiers":2327},"Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95.",{"doi":2328},"10.1172\u002FJCI59643",{"id":26,"text":2330,"url":26,"identifiers":2331},"Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40\u002FCD40L engagement in the immune system. Immunol Rev. 2009;229(1):152–72.",{"doi":2332},"10.1111\u002Fj.1600-065X.2009.00782.x",{"id":26,"text":2334,"url":26,"identifiers":2335},"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612–6.",{"doi":2336},"10.1126\u002Fscience.1198443",{"id":26,"text":2338,"url":26,"identifiers":2339},"Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.",{"doi":2340},"10.1016\u002Fj.cell.2010.01.022",{"id":26,"text":2342,"url":26,"identifiers":2343},"Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer. 2011;128(4):897–907.",{"doi":2344},"10.1002\u002Fijc.25399",{"id":26,"text":2346,"url":26,"identifiers":2347},"Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ. 2014;21(12):1825–37.",{"doi":2348},"10.1038\u002Fcdd.2014.96",{"id":26,"text":2350,"url":26,"identifiers":2351},"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11(7):1018–30.",{"doi":2352},"10.1016\u002Fj.celrep.2015.04.031",{"id":26,"text":2354,"url":26,"identifiers":2355},"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–48.",{"doi":2356},"10.1056\u002FNEJMoa1709866",{"id":26,"text":2358,"url":26,"identifiers":2359},"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20(6). \n                    https:\u002F\u002Fdoi.org\u002F10.3390\u002Fijms20061283\n                    \n                  .",{"doi":2360},"10.3390\u002Fijms20061283",{"id":26,"text":2362,"url":26,"identifiers":2363},"Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016;44(6):1444–54.",{"doi":2364},"10.1016\u002Fj.immuni.2016.05.014",{"id":26,"text":2366,"url":26,"identifiers":2367},"Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front Immunol. 2018;9:2166.",{"doi":2368},"10.3389\u002Ffimmu.2018.02166",{"id":26,"text":2370,"url":26,"identifiers":2371},"Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, et al. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel\u002FGemcitabine Versus Nab-Paclitaxel\u002FGemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018;36(4):359–66.",{"doi":2372},"10.1200\u002FJCO.2017.74.9564",{"id":26,"text":2374,"url":26,"identifiers":2375},"Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018;14(1):13–22.",{"doi":2376},"10.2217\u002Ffon-2017-0338",{"id":26,"text":2378,"url":26,"identifiers":2379},"Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, et al. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018;19(4):316–27.",{"doi":2380},"10.1080\u002F15384047.2017.1416937",{"id":26,"text":2382,"url":26,"identifiers":2383},"Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, et al. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One. 2017;12(7):e0180181.",{"doi":2384},"10.1371\u002Fjournal.pone.0180181",{"id":26,"text":2386,"url":26,"identifiers":2387},"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80.",{"doi":2388},"10.1126\u002Fscience.aaa6204",{"id":26,"text":2390,"url":26,"identifiers":2391},"Albeituni SH, Ding C, Yan J. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J. 2013;19(6):490–501.",{"doi":2392},"10.1097\u002FPPO.0000000000000006",{"id":26,"text":2394,"url":26,"identifiers":2395},"Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63(11):1769–81.",{"doi":2396},"10.1136\u002Fgutjnl-2013-306271",{"id":26,"text":2398,"url":26,"identifiers":2399},"Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\u002FCCR2 axis. Clin Cancer Res. 2013;19(13):3404–15.",{"doi":2400},"10.1158\u002F1078-0432.CCR-13-0525",{"id":26,"text":2402,"url":26,"identifiers":2403},"Linehan D, Noel MS, Hezel AF, Wang-Gillam A, Eskens F, Sleijfer S, Desar IME, Erdkamp F, Wilmink J, Diehl J, et al. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced\u002Fmetastatic pancreatic cancer: Correlation with blood monocyte counts. J Clin Oncol. 2018;36(5_suppl):92.",{"doi":2404},"10.1200\u002FJCO.2018.36.5_suppl.92",{"id":26,"text":2406,"url":26,"identifiers":2407},"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1\u002FCSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–69.",{"doi":2408},"10.1158\u002F0008-5472.CAN-13-3723",{"id":26,"text":2410,"url":26,"identifiers":2411},"Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy. 2015;7(4):363–76.",{"doi":2412},"10.2217\u002Fimt.15.9",{"id":26,"text":2414,"url":26,"identifiers":2415},"Vokes EE. Combined modality therapy of solid tumours. Lancet. 1997;349(Suppl 2):SII4–6.",{"doi":2416},"10.1016\u002FS0140-6736(97)90011-8",{"id":26,"text":2418,"url":26,"identifiers":2419},"Niyazi M, Maihoefer C, Krause M, Rodel C, Budach W, Belka C. Radiotherapy and “new” drugs-new side effects? Radiat Oncol. 2011;6:177.",{"doi":2420},"10.1186\u002F1748-717X-6-177",{"id":26,"text":2422,"url":26,"identifiers":2423},"Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys. 2002;54(4):1180–93.",{"doi":2424},"10.1016\u002FS0360-3016(02)03788-4",{"id":26,"text":2426,"url":26,"identifiers":2427},"Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 2008;14(16):5142–9.",{"doi":2428},"10.1158\u002F1078-0432.CCR-07-4072",{"id":26,"text":2430,"url":26,"identifiers":2431},"Demols A, Mahin C, Maréchal R, Delaunoit T, Borbath I, Hendlisz A, Jacquy C, Mitine C, Laethem JV. Cetuximab plus chemoradiation combined therapy for locally advanced inoperable pancreatic adenocarcima: A phase I study. J Clin Oncol. 2008;26(15_suppl):4629.",{"doi":2432},"10.1200\u002Fjco.2008.26.15_suppl.4629",{"id":26,"text":2434,"url":26,"identifiers":2435},"Munter M, Timke C, Abdollahi A, Friess H, Jaeger D, Heeger S, Buchler M, Debus J, Huber P, Krempien R. Final results of a phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol. 2008;26(15_suppl):4613.",{"doi":2436},"10.1200\u002Fjco.2008.26.15_suppl.4613",{"id":26,"text":2438,"url":26,"identifiers":2439},"Arnoletti JP, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, et al. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011;67(4):891–7.",{"doi":2440},"10.1007\u002Fs00280-010-1383-0",{"id":26,"text":2442,"url":26,"identifiers":2443},"Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, et al. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Transl Oncol. 2014;7(1):55–64.",{"doi":2444},"10.1593\u002Ftlo.13724",{"id":26,"text":2446,"url":26,"identifiers":2447},"Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, Camphausen K, Tofilon PJ. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res. 2014;20(1):110–9.",{"doi":2448},"10.1158\u002F1078-0432.CCR-13-2136",{"id":26,"text":2450,"url":26,"identifiers":2451},"Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu WF, Lin S, Ma HB, Wang XJ, Wu WY. Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther. 2013;7:149–59.",{"doi":2452},"10.2147\u002FDDDT.S42390",{"id":26,"text":2454,"url":26,"identifiers":2455},"Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galban S, Galban CJ, Ross BD, Lawrence TS, Rehemtulla A, et al. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther. 2012;11(5):1193–202.",{"doi":2456},"10.1158\u002F1535-7163.MCT-12-0098",{"id":26,"text":2458,"url":26,"identifiers":2459},"Park JH, Jung KH, Kim SJ, Fang Z, Yan HH, Son MK, Kim J, Kang YW, Lee JE, Han B, et al. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget. 2017;8(68):112893–906.",{"doi":2460},"10.18632\u002Foncotarget.22850",{"id":26,"text":2462,"url":26,"identifiers":2463},"Yang L, Yang G, Ding Y, Dai Y, Xu S, Guo Q, Xie A, Hu G. Inhibition of PI3K\u002FAKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro. J Cancer. 2018;9(5):890–900.",{"doi":2464},"10.7150\u002Fjca.21306",{"id":26,"text":2466,"url":26,"identifiers":2467},"Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y. PI3K\u002FAkt\u002FmTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 2014;5:e1437.",{"doi":2468},"10.1038\u002Fcddis.2014.415",{"id":26,"text":2470,"url":26,"identifiers":2471},"Durrant DE, Das A, Dyer S, Tavallai S, Dent P, Kukreja RC. Targeted Inhibition of Phosphoinositide 3-Kinase\u002FMammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. Mol Pharmacol. 2015;88(3):512–23.",{"doi":2472},"10.1124\u002Fmol.115.099143",{"id":26,"text":2474,"url":26,"identifiers":2475},"Lomax ME, Folkes LK, O'Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (R Coll Radiol). 2013;25(10):578–85.",{"doi":2476},"10.1016\u002Fj.clon.2013.06.007",{"id":26,"text":2478,"url":26,"identifiers":2479},"O'Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60(4):547–60.",{"doi":2480},"10.1016\u002Fj.molcel.2015.10.040",{"id":26,"text":2482,"url":26,"identifiers":2483},"Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287–94.",{"doi":2484},"10.1038\u002Fnature10760",{"id":26,"text":2486,"url":26,"identifiers":2487},"Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012;13(11):1072–81.",{"doi":2488},"10.4161\u002Fcbt.21093",{"id":26,"text":2490,"url":26,"identifiers":2491},"Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441.",{"doi":2492},"10.1038\u002Fcddis.2012.181",{"id":26,"text":2494,"url":26,"identifiers":2495},"Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quiros Fernandez S, Lau A, Richards FM, Jodrell DI. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Mol Cancer Ther. 2018;17(8):1670–82.",{"doi":2496},"10.1158\u002F1535-7163.MCT-18-0010",{"id":26,"text":2498,"url":26,"identifiers":2499},"Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al. Mechanism of radiosensitization by the Chk1\u002F2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010;70(12):4972–81.",{"doi":2500},"10.1158\u002F0008-5472.CAN-09-3573",{"id":26,"text":2502,"url":26,"identifiers":2503},"Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone DM, Maybaum J, Lawrence TS, Morgan MA. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia. 2012;14(6):519–25.",{"doi":2504},"10.1593\u002Fneo.12538",{"id":26,"text":2506,"url":26,"identifiers":2507},"Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res. 2013;19(16):4412–21.",{"doi":2508},"10.1158\u002F1078-0432.CCR-12-3748",{"id":26,"text":2510,"url":26,"identifiers":2511},"Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A, Biankin AV, Grimmond SM, Australian Pancreatic Cancer Genome I, et al. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clin Cancer Res. 2014;20(12):3187–97.",{"doi":2512},"10.1158\u002F1078-0432.CCR-14-0048",{"id":26,"text":2514,"url":26,"identifiers":2515},"Tuli R, Surmak AJ, Reyes J, Armour M, Hacker-Prietz A, Wong J, DeWeese TL, Herman JM. Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. Transl Oncol. 2014. \n                    https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.tranon.2014.04.003\n                    \n                  .",{"doi":2516},"10.1016\u002Fj.tranon.2014.04.003",{"id":26,"text":2518,"url":26,"identifiers":2519},"Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012;18(8):2344–51.",{"doi":2520},"10.1158\u002F1078-0432.CCR-11-2425",{"id":26,"text":2522,"url":26,"identifiers":2523},"Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280(1):249–79.",{"doi":2524},"10.1111\u002Fimr.12573",{"id":26,"text":2526,"url":26,"identifiers":2527},"Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, et al. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res. 2015;21(16):3727–39.",{"doi":2528},"10.1158\u002F1078-0432.CCR-14-2824",{"id":26,"text":2530,"url":26,"identifiers":2531},"Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Martinez-Torrecuadrada JL, et al. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clin Cancer Res. 2019;25(11):3352-65.",{"doi":2532},"10.1158\u002F1078-0432.CCR-18-2811",{"id":26,"text":2534,"url":26,"identifiers":2535},"Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803.",{"doi":2536},"10.1016\u002FS1470-2045(15)00054-6",{"id":26,"text":2538,"url":26,"identifiers":2539},"Shi F, Wang X, Teng F, Kong L, Yu J. Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy. Cancer Biol Ther. 2017;18(3):137–41.",{"doi":2540},"10.1080\u002F15384047.2016.1276133",{"id":26,"text":2542,"url":26,"identifiers":2543},"Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017;9(2):167–80.",{"doi":2544},"10.15252\u002Femmm.201606674",{"id":26,"text":2546,"url":26,"identifiers":2547},"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)\u002FM1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602.",{"doi":2548},"10.1016\u002Fj.ccr.2013.09.014",{"id":26,"text":2550,"url":26,"identifiers":2551},"Timke C, Winnenthal HS, Klug F, Roeder FF, Bonertz A, Reissfelder C, Rochet N, Koch M, Tjaden C, Buechler MW, et al. Randomized controlled phase I\u002FII study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. BMC Cancer. 2011;11:134.",{"doi":2552},"10.1186\u002F1471-2407-11-134",{"id":26,"text":2554,"url":26,"identifiers":2555},"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41(5):843–52.",{"doi":2556},"10.1016\u002Fj.immuni.2014.10.019",{"id":26,"text":2558,"url":26,"identifiers":2559},"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.",{"doi":2560},"10.1038\u002Fncomms15618",{"id":26,"text":2562,"url":26,"identifiers":2563},"Baird JR, Friedman D, Cottam B, Dubensky TW Jr, Kanne DB, Bambina S, Bahjat K, Crittenden MR, Gough MJ. Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. Cancer Res. 2016;76(1):50–61.",{"doi":2564},"10.1158\u002F0008-5472.CAN-14-3619",{"id":26,"text":2566,"url":26,"identifiers":2567},"Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Res. 2018;78(15):4282–91.",{"doi":2568},"10.1158\u002F0008-5472.CAN-17-3821",{"id":26,"text":2570,"url":26,"identifiers":2571},"Lee V, Rodriguez C, Shupe E-M, Chen L, Parkinson R, Durham JN, Sugar E, Wilt C, McIntyre KR, Hacker-Prietz A, et al. Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC). J Clin Oncol. 2017;35(15_suppl):TPS4154.",{"doi":2572},"10.1200\u002FJCO.2017.35.15_suppl.TPS4154",{"id":2574,"createTime":2575,"updateTime":2575,"relativeEntities":2576,"slug":2577,"properties":2578,"entityType":829,"verifyStatus":25,"verifyTime":2593,"verifyNote":830,"syncStatus":28,"languages":2594,"translateLanguages":26,"viewCount":36,"primaryUrl":2595,"fullTextUrl":26,"authors":2596,"publicationType":918,"publisherRelationship":2735,"citationCount":2767,"citationInfo":2768,"publishDate":2770,"publishYear":2771,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":2772,"isForceReanalyzing":1256},"c797aa24-5df2-40e8-bddf-43f991f270bb","2024-12-27T20:30:14.839+00:00",[],"Recommendations-for-implementing-stereotactic-radiotherapy-in-peripheral-stage-IA-non-small-cell-lung-cancer-report-from-the-Quality-Assurance-Working-Party-of-the-randomised-phase-III-ROSEL-study",{"mag":2579,"keywords":2581,"pmc":2582,"openalex":2584,"abstract":2586,"title":2587,"pm":2589,"doi":2591},{"VOID":2580},"2140057952",{},{"VOID":2583},"2631491",{"VOID":2585},"W2140057952",{},{"EN":2588},"Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study",{"VOID":2590},"19138400",{"VOID":2592},"10.1186\u002F1748-717x-4-1","2024-12-27T20:30:14.838+00:00",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-4-1",[2597,2619,2640,2657,2674,2696,2713],{"id":2598,"sortIndex":135,"researcher":26,"roles":2599,"affiliations":2600,"properties":2612},"d580860a-2c3e-49e6-b570-834fe20cb9f1",[],[2601],{"id":2602,"sortIndex":36,"affiliation":2603,"properties":26},"4b705fab-1cef-411c-bb88-c54e54788fc0",{"id":2604,"createTime":2605,"updateTime":2606,"relativeEntities":2607,"slug":2608,"properties":2609,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"420c9484-5414-48dc-8a05-b569596bf1ef","2024-01-16T16:16:02.792+00:00","2025-01-14T07:18:52.518+00:00",[],"Department-of-Radiation-Oncology-VU-University-Medical-Center-Amsterdam-Netherlands",{"title":2610},{"VI":2611},"Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands",{"openalex":2613,"orcid":2615,"title":2617},{"VOID":2614},"A5077453712",{"VOID":2616},"https:\u002F\u002Forcid.org\u002F0000-0003-3995-2204",{"EN":2618},"Suresh Senan",{"id":2620,"sortIndex":162,"researcher":26,"roles":2621,"affiliations":2622,"properties":2633},"5a641e87-f840-436d-8387-85afe48b421f",[],[2623],{"id":2624,"sortIndex":36,"affiliation":2625,"properties":26},"fe799390-ff77-4a9c-a337-179f6c0623bc",{"id":2626,"createTime":2627,"updateTime":2627,"relativeEntities":2628,"slug":2629,"properties":2630,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"8c5ffc52-32c0-4519-9897-7dee8a1be60e","2024-12-27T20:30:14.851+00:00",[],"Department-of-Radiation-Therapy-Catharina-Hospital-Eindhoven-Netherlands",{"title":2631},{"EN":2632},"Department of Radiation Therapy, Catharina Hospital, Eindhoven, Netherlands",{"openalex":2634,"orcid":2636,"title":2638},{"VOID":2635},"A5011238287",{"VOID":2637},"https:\u002F\u002Forcid.org\u002F0000-0001-9535-6074",{"EN":2639},"D. Schuring",{"id":2641,"sortIndex":36,"researcher":26,"roles":2642,"affiliations":2643,"properties":2650},"5f8ea2cb-94db-4b12-84a7-1d0b84195042",[],[2644],{"id":2645,"sortIndex":36,"affiliation":2646,"properties":26},"26b253eb-481a-409f-aa88-ff7960c8279f",{"id":2626,"createTime":2627,"updateTime":2627,"relativeEntities":2647,"slug":2629,"properties":2648,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2649},{"EN":2632},{"openalex":2651,"orcid":2653,"title":2655},{"VOID":2652},"A5074824252",{"VOID":2654},"https:\u002F\u002Forcid.org\u002F0000-0003-2268-0492",{"EN":2656},"Coen Hurkmans",{"id":2658,"sortIndex":115,"researcher":26,"roles":2659,"affiliations":2660,"properties":2667},"1d0154bd-4027-40bc-851e-47f6c1d0e2ad",[],[2661],{"id":2662,"sortIndex":36,"affiliation":2663,"properties":26},"ae7a5fcf-a5db-4e8a-9568-4ce16820282e",{"id":2604,"createTime":2605,"updateTime":2606,"relativeEntities":2664,"slug":2608,"properties":2665,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2666},{"VI":2611},{"openalex":2668,"orcid":2670,"title":2672},{"VOID":2669},"A5070640954",{"VOID":2671},"https:\u002F\u002Forcid.org\u002F0000-0002-5069-1386",{"EN":2673},"J.P. Cuijpers",{"id":2675,"sortIndex":59,"researcher":26,"roles":2676,"affiliations":2677,"properties":2689},"fa429887-5a62-46a4-93be-068a8a6ab80c",[],[2678],{"id":2679,"sortIndex":36,"affiliation":2680,"properties":26},"745c5032-4349-4b6f-80a8-a49da8004f56",{"id":2681,"createTime":2682,"updateTime":2683,"relativeEntities":2684,"slug":2685,"properties":2686,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"fba72791-d7ad-4202-ac80-2205aa9adf7d","2023-12-08T01:26:40.522+00:00","2024-12-27T20:30:14.889+00:00",[],"Department-of-Radiation-Oncology-University-Medical-Center-Groningen-Groningen-Netherlands",{"title":2687},{"VI":2688},"Department of Radiation Oncology, University Medical Center Groningen, Groningen, Netherlands",{"openalex":2690,"orcid":2692,"title":2694},{"VOID":2691},"A5025849204",{"VOID":2693},"https:\u002F\u002Forcid.org\u002F0000-0002-9972-6690",{"EN":2695},"Joachim Widder",{"id":2697,"sortIndex":114,"researcher":26,"roles":2698,"affiliations":2699,"properties":2706},"7a619433-d612-40be-a576-75f55f74afdc",[],[2700],{"id":2701,"sortIndex":36,"affiliation":2702,"properties":26},"f8fb0bb7-ffe9-41e4-8cfe-283d270376f6",{"id":2604,"createTime":2605,"updateTime":2606,"relativeEntities":2703,"slug":2608,"properties":2704,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2705},{"VI":2611},{"openalex":2707,"orcid":2709,"title":2711},{"VOID":2708},"A5036402068",{"VOID":2710},"https:\u002F\u002Forcid.org\u002F0000-0002-8740-2517",{"EN":2712},"Frank J. Lagerwaard",{"id":2714,"sortIndex":111,"researcher":26,"roles":2715,"affiliations":2716,"properties":2728},"13d9ca0c-83c9-4b57-84f5-bc61929c4314",[],[2717],{"id":2718,"sortIndex":36,"affiliation":2719,"properties":26},"581d78be-8868-4822-b929-0ddd74a61e60",{"id":2720,"createTime":2721,"updateTime":2722,"relativeEntities":2723,"slug":2724,"properties":2725,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d69e147a-c22a-4044-9ef3-9e92b5d5a236","2023-12-12T22:31:52.568+00:00","2024-12-27T20:30:14.916+00:00",[],"Department-of-Radiation-Oncology-University-Medical-Center-Utrecht-Utrecht-Netherlands",{"title":2726},{"VI":2727},"Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands",{"openalex":2729,"orcid":2731,"title":2733},{"VOID":2730},"A5002901679",{"VOID":2732},"https:\u002F\u002Forcid.org\u002F0000-0002-4146-6419",{"EN":2734},"Uulke A. van der Heide",{"url":26,"publisher":2736,"properties":2763},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2737,"slug":663,"properties":2738,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2741,"manageAffiliations":2742,"indexDatabases":2743,"url":747,"thumbnailPath":26,"statistic":2758,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2739,"title":2740},{"VOID":666},{"EN":668},[],[],[2744,2751],{"id":708,"indexDatabase":2745,"url":723,"indexYears":26,"academicFieldIds":2750,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":2746,"label":2747,"description":2748,"key":719,"publicationTags":2749,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":2752,"url":741,"indexYears":742,"academicFieldIds":2757,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":2753,"label":2754,"description":2755,"key":738,"publicationTags":2756,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":2759,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":2760,"totalCitation":768,"totalCitationByYear":2761,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":2762,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"volume":2764,"issue":2766},{"VOID":2765},"4",{"VOID":951},277,{"total":2767,"publishYear":26,"statisticByYear":2769},{"2012":255,"2013":287,"2014":255,"2015":260,"2016":239,"2017":336,"2018":103,"2019":50,"2020":52,"2021":356,"2022":162,"2023":111,"2024":162},"2009-12-01",2009,[2773,2777,2781,2785,2789,2793,2797,2801,2805,2809,2813,2817,2821,2825,2829,2833,2837,2840,2843,2847,2851,2855,2859,2863,2867,2871,2875,2879,2883,2886,2890,2894,2898,2902,2905,2908,2912,2916,2920,2924,2928,2932,2936,2940,2944,2948,2952,2956,2960,2964,2968,2972,2976,2980,2984,2988,2992,2996],{"id":26,"text":2774,"url":26,"identifiers":2775},"Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003, 41: 1-11. 10.1016\u002FS0169-5002(03)00152-1",{"doi":2776},"10.1016\u002FS0169-5002(03)00152-1",{"id":26,"text":2778,"url":26,"identifiers":2779},"Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M: Clinical outcomes of a phase I\u002FII study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63: 1427-1431. 10.1016\u002Fj.ijrobp.2005.05.034",{"doi":2780},"10.1016\u002Fj.ijrobp.2005.05.034",{"id":26,"text":2782,"url":26,"identifiers":2783},"Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2: S94-100. 10.1097\u002FJTO.0b013e318074de34",{"doi":2784},"10.1097\u002FJTO.0b013e318074de34",{"id":26,"text":2786,"url":26,"identifiers":2787},"McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD: Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2006,63(4):1010-1015.",{"doi":2788},"10.1016\u002Fj.ijrobp.2005.03.073",{"id":26,"text":2790,"url":26,"identifiers":2791},"Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S: Outcome After Stereotactic Radiotherapy in 'High-Risk' Patients With Stage I Non-small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys 2007, 69: S87-S88.",{"doi":2792},"10.1016\u002Fj.ijrobp.2007.07.159",{"id":26,"text":2794,"url":26,"identifiers":2795},"Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer 2004, 101: 1623-1631. 10.1002\u002Fcncr.20539",{"doi":2796},"10.1002\u002Fcncr.20539",{"id":26,"text":2798,"url":26,"identifiers":2799},"El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, Urda SJ, Luketich JD, Landreneau RJ: Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg 2006, 82: 408-415. 10.1016\u002Fj.athoracsur.2006.02.029",{"doi":2800},"10.1016\u002Fj.athoracsur.2006.02.029",{"id":26,"text":2802,"url":26,"identifiers":2803},"Strand TE, Rostad H, Moller B, Norstein J: Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 2006, 61: 710-715. 10.1136\u002Fthx.2005.056481",{"doi":2804},"10.1136\u002Fthx.2005.056481",{"id":26,"text":2806,"url":26,"identifiers":2807},"Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallieres E, Goldstraw P: The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2: 593-602. 10.1097\u002F01.JTO.0000283002.04296.e6",{"doi":2808},"10.1097\u002FJTO.0b013e31807a2f81",{"id":26,"text":2810,"url":26,"identifiers":2811},"Timmerman RD, Park C, Kavanagh BD: The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2007, 2: S101-S112. 10.1097\u002FJTO.0b013e318074e4fa",{"doi":2812},"10.1097\u002FJTO.0b013e318074e4fa",{"id":26,"text":2814,"url":26,"identifiers":2815},"Pasic A, Brokx HA, Vonk NA, Paul RM, Postmus PE, Sutedja TG: Cost-effectiveness of early intervention: comparison between intraluminal bronchoscopic treatment and surgical resection for T1N0 lung cancer patients. Respiration 2004, 71: 391-396. 10.1159\u002F000079645",{"doi":2816},"10.1159\u002F000079645",{"id":26,"text":2818,"url":26,"identifiers":2819},"Timmerman RD, Paulus R, Galvin J, Michalski J, Straube WL, Bradley J, Fakiris A, Bezjak A, Videtic G, Choy H: Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early Stage Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2007, 69: S86.",{"doi":2820},"10.1016\u002Fj.ijrobp.2007.07.156",{"id":26,"text":2822,"url":26,"identifiers":2823},"Xiao Y, Straube WL, Bosch WR, Timmerman RD, Galvin JM: Dosimetric Evaluation of Heterogeneity Corrections for RTOG 0236: Hypofractionated Radiotherapy of Inoperable Stage I\u002FII Non-small Cell Lung Cancer. Int J Radat Oncol Biol Phys 2007, 69: S46-S47. 10.1016\u002Fj.ijrobp.2007.07.085",{"doi":2824},"10.1016\u002Fj.ijrobp.2007.07.085",{"id":26,"text":2826,"url":26,"identifiers":2827},"Hiraoka M, Ishikura S: A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer. J Thorac Oncol 2007, 2: S115-S117. 10.1097\u002FJTO.0b013e318074de1b",{"doi":2828},"10.1097\u002FJTO.0b013e318074de1b",{"id":26,"text":2830,"url":26,"identifiers":2831},"Schuring D, Hurkmans CW: Developing and evaluating stereotactic lung RT trials: What we should know about the influence of inhomogeneity corrections on dose. Radiat Oncol 2008, 3: 21. 10.1186\u002F1748-717X-3-21",{"doi":2832},"10.1186\u002F1748-717X-3-21",{"id":26,"text":2834,"url":26,"identifiers":2835},"Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S: Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. Int J Radiat Oncol Biol Phys 2005, 63: 253-260.",{"doi":2836},"10.1016\u002Fj.ijrobp.2005.05.045",{"id":26,"text":2838,"url":26,"identifiers":2839},"Timmerman RD, Michalski J, Galvin J, Fowler JF, Choy H, Gore E, Johnstone D: RTOG 0236 : A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I\u002FII Non-Small Cell Lung Cancer. RTOG 2007.",{},{"id":26,"text":2841,"url":26,"identifiers":2842},"Timmerman RD, Galvin J, Gore E, Pass H, Edelman MJ, Kong FP: RTOG 0618 A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with operable stage I\u002FII non-small cell lung cancer. RTOG 2007.",{},{"id":26,"text":2844,"url":26,"identifiers":2845},"Bosmans G, Buijsen J, Dekker A, Velders M, Boersma L, De Ruysscher D, Minken A, Lambin P: An \"in silico\" clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patients. Radiother Oncol 2006, 81: 73-80. 10.1016\u002Fj.radonc.2006.08.009",{"doi":2846},"10.1016\u002Fj.radonc.2006.08.009",{"id":26,"text":2848,"url":26,"identifiers":2849},"Chen GT, Kung JH, Beaudette KP: Artifacts in computed tomography scanning of moving objects. Semin Radiat Oncol 2004, 14: 19-26. 10.1053\u002Fj.semradonc.2003.10.004",{"doi":2850},"10.1053\u002Fj.semradonc.2003.10.004",{"id":26,"text":2852,"url":26,"identifiers":2853},"Keall P: 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 2004, 14: 81-90. 10.1053\u002Fj.semradonc.2003.10.006",{"doi":2854},"10.1053\u002Fj.semradonc.2003.10.006",{"id":26,"text":2856,"url":26,"identifiers":2857},"Rietzel E, Pan T, Chen GT: Four-dimensional computed tomography: image formation and clinical protocol. Med Phys 2005, 32: 874-889. 10.1118\u002F1.1869852",{"doi":2858},"10.1118\u002F1.1869852",{"id":26,"text":2860,"url":26,"identifiers":2861},"Seki S, Kunieda E, Takeda A, Nagaoka T, Deloar HM, Kawase T, Fukada J, Kawaguchi O, Uematsu M, Kubo A: Differences in the definition of internal target volumes using slow CT alone or in combination with thin-slice CT under breath-holding conditions during the planning of stereotactic radiotherapy for lung cancer. Radiother Oncol 2007, 85: 443-449.",{"doi":2862},"10.1016\u002Fj.radonc.2007.10.010",{"id":26,"text":2864,"url":26,"identifiers":2865},"Wurstbauer K, Deutschmann H, Kopp P, Sedlmayer F: Radiotherapy planning for lung cancer: slow CTs allow the drawing of tighter margins. Radiother Oncol 2005, 75: 165-170. 10.1016\u002Fj.radonc.2005.02.003",{"doi":2866},"10.1016\u002Fj.radonc.2005.02.003",{"id":26,"text":2868,"url":26,"identifiers":2869},"Letourneau D, Finlay M, O'sullivan B, Waldron JN, Cummings BJ, Ringash J, Kim JJ, Bayley AJ, Dawson LA: Lack of influence of intravenous contrast on head and neck IMRT dose distributions. Acta Oncol 2008, 47: 90-94. 10.1080\u002F02841860701418861",{"doi":2870},"10.1080\u002F02841860701418861",{"id":26,"text":2872,"url":26,"identifiers":2873},"Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S: Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2008, 70: 685-692.",{"doi":2874},"10.1016\u002Fj.ijrobp.2007.10.053",{"id":26,"text":2876,"url":26,"identifiers":2877},"Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA: American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004, 60: 1026-1032. 10.1016\u002Fj.ijrobp.2004.06.114",{"doi":2878},"10.1016\u002Fj.ijrobp.2004.07.701",{"id":26,"text":2880,"url":26,"identifiers":2881},"Bradley JD, Nofal AN, El Naga IM, Lu W, Liu J, Hubenschmidt J, Low DA, Drzymala RE, Khullar D: Comparison of helical, maximum intensity projection (MIP), and averaged intensity (AI) 4D CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. Radiother Oncol 2006, 81: 264-268. 10.1016\u002Fj.radonc.2006.10.009",{"doi":2882},"10.1016\u002Fj.radonc.2006.10.009",{"id":26,"text":2884,"url":26,"identifiers":2885},"Riegel AC, Chang JY, Vedam SS, Johnson V, Chi PC, Pan T: Cine Computed Tomography Without Respiratory Surrogate in Planning Stereotactic Radiotherapy for Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2008. DOI: 10.1016\u002Fj.ijrobp.2008.04.047",{},{"id":26,"text":2887,"url":26,"identifiers":2888},"van Sornsen de Koste JR, Lagerwaard FJ, Nijssen-Visser MR, Graveland WJ, Senan S: Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. Int J Radiat Oncol Biol Phys 2003, 56: 348-354. 10.1016\u002FS0360-3016(02)04467-X",{"doi":2889},"10.1016\u002FS0360-3016(02)04467-X",{"id":26,"text":2891,"url":26,"identifiers":2892},"Sonke JJ, Lebesque J, van Herk M: Variability of four-dimensional computed tomography patient models. Int J Radiat Oncol Biol Phys 2008, 70: 590-598.",{"doi":2893},"10.1016\u002Fj.ijrobp.2007.08.067",{"id":26,"text":2895,"url":26,"identifiers":2896},"Wolthaus JWH, Schneider C, Sonke JJ, van Herk M, Belderbos JSA, Rossi MMG, Lebesque JV, Damen EFM: Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. Int J Radat Oncol Biol Phys 2006, 65: 1560-1571. 10.1016\u002Fj.ijrobp.2006.04.031",{"doi":2897},"10.1016\u002Fj.ijrobp.2006.04.031",{"id":26,"text":2899,"url":26,"identifiers":2900},"Dieleman EM, Senan S, Vincent A, Lagerwaard FJ, Slotman BJ, van Sornsen de Koste JR: Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 2007, 67: 775-780.",{"doi":2901},"10.1016\u002Fj.ijrobp.2006.09.054",{"id":26,"text":2903,"url":26,"identifiers":2904},"ICRU report 62 prescribing, recording and reporting photon beam therapy (Supplement to ICRU report 50) 1999, 33: 1-51.",{},{"id":26,"text":2906,"url":26,"identifiers":2907},"Hall WH, Guiou M, Lee NY, Dublin A, Narayan S, Vijayakumar S, Purdy JA, Chen AM: Development and Validation of A Standardized Method for Contouring THE Brachial Plexus: Preliminary Dosimetric Analysis Among Patients Treated with IMRT for Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2008, 72;1: S385.",{},{"id":26,"text":2909,"url":26,"identifiers":2910},"Madu CN, Quint DJ, Normolle DP, Marsh RB, Wang EY, Pierce LJ: Definition of the supraclavicular and infraclavicular nodes: implications for three-dimensional CT-based conformal radiation therapy. Radiology 2001, 221: 333-339. 10.1148\u002Fradiol.2212010247",{"doi":2911},"10.1148\u002Fradiol.2212010247",{"id":26,"text":2913,"url":26,"identifiers":2914},"Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, McRae DA, Zhang Y, Yousefi S, Levy E, Chang T, Jamis-Dow C, Banovac F, Anderson ED: Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol 2007, 2: 39. 10.1186\u002F1748-717X-2-39",{"doi":2915},"10.1186\u002F1748-717X-2-39",{"id":26,"text":2917,"url":26,"identifiers":2918},"Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Britton KR, Jingu K, Takai K, Mitsuya M, Nemoto K, Yamada S: A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85: 429-434. 10.1016\u002Fj.radonc.2007.10.017",{"doi":2919},"10.1016\u002Fj.radonc.2007.10.017",{"id":26,"text":2921,"url":26,"identifiers":2922},"Sinha B, McGarry RC: Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana university experience. Int J Radiat Oncol Biol Phys 2007, 66: 1120-1124.",{"doi":2923},"10.1016\u002Fj.ijrobp.2006.06.042",{"id":26,"text":2925,"url":26,"identifiers":2926},"Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ: Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 2008, 13: 309-319. 10.1634\u002Ftheoncologist.2007-0195",{"doi":2927},"10.1634\u002Ftheoncologist.2007-0195",{"id":26,"text":2929,"url":26,"identifiers":2930},"Brock J, Ashley S, Bedford J, Nioutsikou E, Partridge M, Brada M: Review of Hypofractionated Small Volume Radiotherapy for Early-stage Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol) 2008, 20: 666-676.",{"doi":2931},"10.1016\u002Fj.clon.2008.06.005",{"id":26,"text":2933,"url":26,"identifiers":2934},"Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24: 4833-4839. 10.1200\u002FJCO.2006.07.5937",{"doi":2935},"10.1200\u002FJCO.2006.07.5937",{"id":26,"text":2937,"url":26,"identifiers":2938},"Senan S, Haasbeek NJ, Smit EF, Lagerwaard FJ: Stereotactic radiotherapy for centrally located early-stage lung tumors. J Clin Oncol 2007, 25: 464. 10.1200\u002FJCO.2006.09.8178",{"doi":2939},"10.1200\u002FJCO.2006.09.8178",{"id":26,"text":2941,"url":26,"identifiers":2942},"Knöös T, Wieslander E, Cozzi L, Brink C, Fogliata A, Albers D, Nyström H, Lassen S: Comparison of dose calculation algorithms for treatment planning in external photon beam therapy for clinical situations. Phys Med Biol 2006, 51: 5785-5807. 10.1088\u002F0031-9155\u002F51\u002F22\u002F005",{"doi":2943},"10.1088\u002F0031-9155\u002F51\u002F22\u002F005",{"id":26,"text":2945,"url":26,"identifiers":2946},"Wolthaus JW, Sonke JJ, van Herk M, Belderbos JS, Rossi MM, Lebesque JV, Damen EM: Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 2008, 70: 1229-1238.",{"doi":2947},"10.1016\u002Fj.ijrobp.2007.11.042",{"id":26,"text":2949,"url":26,"identifiers":2950},"Guckenberger M, Krieger T, Baier K, Richter A, Polat B, Flentje M: Four Dimensional Target Volume Generation in Pulmonary Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 2007,69(1):S191.",{"doi":2951},"10.1016\u002Fj.ijrobp.2007.07.345",{"id":26,"text":2953,"url":26,"identifiers":2954},"Admiraal MA, Schuring D, Hurkmans CW: Dose calculations accounting for breathing motion in stereotactic lung radiotherapy based on 4D-CT and the internal target volume. Radiother Oncol 2008, 86: 55-60. 10.1016\u002Fj.radonc.2007.11.022",{"doi":2955},"10.1016\u002Fj.radonc.2007.11.022",{"id":26,"text":2957,"url":26,"identifiers":2958},"Mutaf YD, Brinkmann DH: Optimization of internal margin to account for dosimetric effects of respiratory motion. Int J Radiat Oncol Biol Phys 2008, 70: 1561-1570.",{"doi":2959},"10.1016\u002Fj.ijrobp.2007.12.025",{"id":26,"text":2961,"url":26,"identifiers":2962},"Giraud P, Yorke E, Jiang S, Simon L, Rosenzweig K, Mageras G: Reduction of organ motion effects in IMRT and conformal 3D radiation delivery by using gating and tracking techniques. Cancer Radiother 2006, 10: 269-282.",{"doi":2963},"10.1016\u002Fj.canrad.2006.05.009",{"id":26,"text":2965,"url":26,"identifiers":2966},"Burnett SS, Sixel KE, Cheung PC, Hoisak JD: A study of tumor motion management in the conformal radiotherapy of lung cancer. Radiother Oncol 2008, 86: 77-85. 10.1016\u002Fj.radonc.2007.11.017",{"doi":2967},"10.1016\u002Fj.radonc.2007.11.017",{"id":26,"text":2969,"url":26,"identifiers":2970},"Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, Abdulrahman R, Timmerman R: Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys 2008, 70: 1571-1578.",{"doi":2971},"10.1016\u002Fj.ijrobp.2007.12.023",{"id":26,"text":2973,"url":26,"identifiers":2974},"Underberg RWM, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S: Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. Int J Radiat Oncol Biol Phys 2005, 62: 554-560.",{"doi":2975},"10.1016\u002Fj.ijrobp.2005.01.032",{"id":26,"text":2977,"url":26,"identifiers":2978},"Purdie TG, Bissonnette JP, Franks K, Bezjak A, Payne D, Sie F, Sharpe MB, Jaffray DA: Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position. Int J Radiat Oncol Biol Phys 2007, 68: 243-252.",{"doi":2979},"10.1016\u002Fj.ijrobp.2006.12.022",{"id":26,"text":2981,"url":26,"identifiers":2982},"Korreman SS, Juhler-Nottrup T, Boyer AL: Respiratory gated beam delivery cannot facilitate margin reduction, unless combined with respiratory correlated image guidance. Radiother Oncol 2008, 86: 61-68. 10.1016\u002Fj.radonc.2007.10.038",{"doi":2983},"10.1016\u002Fj.radonc.2007.10.038",{"id":26,"text":2985,"url":26,"identifiers":2986},"Ionascu D, Jiang SB, Nishioka S, Shirato H, Berbeco RI: Internal-external correlation investigations of respiratory induced motion of lung tumors. Med Phys 2007, 34: 3893-3903. 10.1118\u002F1.2779941",{"doi":2987},"10.1118\u002F1.2779941",{"id":26,"text":2989,"url":26,"identifiers":2990},"Geraghty PR, Kee ST, McFarlane G, Razavi MK, Sze DY, Dake MD: CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate. Radiology 2003, 229: 475-481. 10.1148\u002Fradiol.2291020499",{"doi":2991},"10.1148\u002Fradiol.2291020499",{"id":26,"text":2993,"url":26,"identifiers":2994},"Jiang SB: Radiotherapy of mobile tumors. Semin Radiat Oncol 2006, 16: 239-248. 10.1016\u002Fj.semradonc.2006.04.007",{"doi":2995},"10.1016\u002Fj.semradonc.2006.04.007",{"id":26,"text":2997,"url":26,"identifiers":2998},"Guckenberger M, Wilbert J, Krieger T, Richter A, Baier K, Meyer J, Flentje M: Four-dimensional treatment planning for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69: 276-285.",{"doi":2999},"10.1016\u002Fj.ijrobp.2007.04.074",{"id":3001,"createTime":3002,"updateTime":3002,"relativeEntities":3003,"slug":3004,"properties":3005,"entityType":829,"verifyStatus":25,"verifyTime":3020,"verifyNote":830,"syncStatus":28,"languages":3021,"translateLanguages":26,"viewCount":36,"primaryUrl":3022,"fullTextUrl":26,"authors":3023,"publicationType":918,"publisherRelationship":3064,"citationCount":3096,"citationInfo":3097,"publishDate":3099,"publishYear":3100,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":3101,"isForceReanalyzing":1256},"8f40b974-5526-4fe5-bf82-5d24bc1780a7","2025-02-01T17:15:53.689+00:00",[],"Stereotactic-body-radiotherapy-for-low-risk-prostate-cancer-five-year-outcomes",{"mag":3006,"keywords":3008,"pmc":3009,"openalex":3011,"abstract":3013,"title":3014,"pm":3016,"doi":3018},{"VOID":3007},"2171127338",{},{"VOID":3010},"3022740",{"VOID":3012},"W2171127338",{},{"EN":3015},"Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes",{"VOID":3017},"21219625",{"VOID":3019},"10.1186\u002F1748-717x-6-3","2025-02-01T17:15:53.688+00:00",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-6-3",[3024,3043],{"id":3025,"sortIndex":36,"researcher":26,"roles":3026,"affiliations":3027,"properties":3038},"02751f31-d164-416f-aff3-5c364c3df9ee",[],[3028],{"id":3029,"sortIndex":36,"affiliation":3030,"properties":26},"d789f3d7-463a-41d9-a706-57c01dc036e0",{"id":3031,"createTime":3032,"updateTime":3032,"relativeEntities":3033,"slug":3034,"properties":3035,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b73d605e-1ef5-4712-be34-811b38ba34fc","2025-02-01T17:15:53.739+00:00",[],"Naples-Radiation-Oncology-PA-USA",{"title":3036},{"EN":3037},"Naples Radiation Oncology, PA, USA",{"openalex":3039,"title":3041},{"VOID":3040},"A5109245116",{"EN":3042},"Debra Freeman",{"id":3044,"sortIndex":115,"researcher":26,"roles":3045,"affiliations":3046,"properties":3057},"e5d3c863-1887-49c2-87b6-d29e18e72ecc",[],[3047],{"id":3048,"sortIndex":36,"affiliation":3049,"properties":26},"6b059bbd-c94d-4d4f-aa0f-37e551a38e20",{"id":3050,"createTime":3051,"updateTime":3051,"relativeEntities":3052,"slug":3053,"properties":3054,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"62cae4eb-7383-4c90-8426-a50daedf42f5","2025-02-01T17:15:53.783+00:00",[],"Department-of-Radiation-Oncology-UCLA-School-of-Medicine-CA-USA",{"title":3055},{"EN":3056},"Department of Radiation Oncology, UCLA School of Medicine, CA, USA",{"openalex":3058,"orcid":3060,"title":3062},{"VOID":3059},"A5023026845",{"VOID":3061},"https:\u002F\u002Forcid.org\u002F0000-0002-2400-5717",{"EN":3063},"Christopher King",{"url":26,"publisher":3065,"properties":3092},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3066,"slug":663,"properties":3067,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3070,"manageAffiliations":3071,"indexDatabases":3072,"url":747,"thumbnailPath":26,"statistic":3087,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":3068,"title":3069},{"VOID":666},{"EN":668},[],[],[3073,3080],{"id":708,"indexDatabase":3074,"url":723,"indexYears":26,"academicFieldIds":3079,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":3075,"label":3076,"description":3077,"key":719,"publicationTags":3078,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":3081,"url":741,"indexYears":742,"academicFieldIds":3086,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":3082,"label":3083,"description":3084,"key":738,"publicationTags":3085,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":3088,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":3089,"totalCitation":768,"totalCitationByYear":3090,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":3091,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"volume":3093,"issue":3095},{"VOID":3094},"6",{"VOID":951},216,{"total":3096,"publishYear":26,"statisticByYear":3098},{"2012":516,"2013":244,"2014":286,"2015":239,"2016":239,"2017":51,"2018":298,"2019":53,"2020":53,"2021":162,"2022":111,"2023":111,"2024":111},"2011-12-01",2011,[3102,3106,3110,3114,3118,3122,3126,3130,3134,3138,3142,3146,3150,3154,3157,3161,3165,3168,3172,3176,3180,3184,3188,3192,3196,3200,3204,3207,3211,3215,3219,3223,3227,3230,3233],{"id":26,"text":3103,"url":26,"identifiers":3104},"Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999, 43: 1095-1101. 10.1016\u002FS0360-3016(98)00438-6.",{"doi":3105},"10.1016\u002FS0360-3016(98)00438-6",{"id":26,"text":3107,"url":26,"identifiers":3108},"Fowler JF, Ritter MA, Chappell RJ, Brenner DJ: What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003, 56: 1093-1104. 10.1016\u002FS0360-3016(03)00132-9.",{"doi":3109},"10.1016\u002FS0360-3016(03)00132-9",{"id":26,"text":3111,"url":26,"identifiers":3112},"Dasu A: Is the alpha\u002Fbeta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol). 2007, 19: 289-301.",{"doi":3113},"10.1016\u002Fj.clon.2007.02.007",{"id":26,"text":3115,"url":26,"identifiers":3116},"Macias V, Biete A: Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009, 11: 437-445. 10.1007\u002Fs12094-009-0382-2.",{"doi":3117},"10.1007\u002Fs12094-009-0382-2",{"id":26,"text":3119,"url":26,"identifiers":3120},"Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS: High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004, 171: 1098-1104. 10.1097\u002F01.ju.0000113299.34404.22.",{"doi":3121},"10.1097\u002F01.ju.0000113299.34404.22",{"id":26,"text":3123,"url":26,"identifiers":3124},"Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS: High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol. 2010, 33 (5): 481-8. 10.1097\u002FCOC.0b013e3181b9cd2f.",{"doi":3125},"10.1097\u002FCOC.0b013e3181b9cd2f",{"id":26,"text":3127,"url":26,"identifiers":3128},"Yoshioka Y, Konishi K, Oh RJ, Sumida I, Yamazaki H, Nakamura S, Nishimura K, Nonomura N, Okuyama A, Inoue T: High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol. 2006, 80: 62-68. 10.1016\u002Fj.radonc.2006.06.011.",{"doi":3129},"10.1016\u002Fj.radonc.2006.06.011",{"id":26,"text":3131,"url":26,"identifiers":3132},"Aluwini S, van Rooij P, Hoogeman M, Bangma C, Kirkels WJ, Incrocci L, Kolkman-Deurloo IK: CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol. 2010, 24: 865-869. 10.1089\u002Fend.2009.0438.",{"doi":3133},"10.1089\u002Fend.2009.0438",{"id":26,"text":3135,"url":26,"identifiers":3136},"Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM: Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009, 8: 387-392.",{"doi":3137},"10.1177\u002F153303460900800509",{"id":26,"text":3139,"url":26,"identifiers":3140},"Fuller DB, Naitoh J, Lee C, Hardy S, Jin H: Virtual HDR(SM) CyberKnife Treatment for Localized Prostatic Carcinoma: Dosimetry Comparison With HDR Brachytherapy and Preliminary Clinical Observations. Int J Radiat Oncol Biol Phys. 2008, 70: 1588-1597. 10.1016\u002Fj.ijrobp.2007.11.067.",{"doi":3141},"10.1016\u002Fj.ijrobp.2007.11.067",{"id":26,"text":3143,"url":26,"identifiers":3144},"Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010, 10: 1-10.1186\u002F1471-2490-10-1.",{"doi":3145},"10.1186\u002F1471-2490-10-1",{"id":26,"text":3147,"url":26,"identifiers":3148},"King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009, 73: 1043-1048. 10.1016\u002Fj.ijrobp.2008.05.059.",{"doi":3149},"10.1016\u002Fj.ijrobp.2008.05.059",{"id":26,"text":3151,"url":26,"identifiers":3152},"Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007, 67: 1099-1105. 10.1016\u002Fj.ijrobp.2006.10.050.",{"doi":3153},"10.1016\u002Fj.ijrobp.2006.10.050",{"id":26,"text":3155,"url":26,"identifiers":3156},"Townsend NC, Huth BJ, Ding W, Garber B, Mooreville M, Arrigo S, Lamond J, Brady LW: Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. 2010,",{},{"id":26,"text":3158,"url":26,"identifiers":3159},"Lloyd-Davies RW, Collins CD, Swan AV: Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology. 1990, 36: 107-111. 10.1016\u002F0090-4295(90)80207-4.",{"doi":3160},"10.1016\u002F0090-4295(90)80207-4",{"id":26,"text":3162,"url":26,"identifiers":3163},"Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, Ma L: Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys. 2008, 35: 4041-4048. 10.1118\u002F1.2968333.",{"doi":3164},"10.1118\u002F1.2968333",{"id":26,"text":3166,"url":26,"identifiers":3167},"Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M, Ma L: Dose gradient gear target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010,",{},{"id":26,"text":3169,"url":26,"identifiers":3170},"Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L: Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72: 236-246. 10.1016\u002Fj.ijrobp.2008.04.051.",{"doi":3171},"10.1016\u002Fj.ijrobp.2008.04.051",{"id":26,"text":3173,"url":26,"identifiers":3174},"Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995, 31: 1341-1346. 10.1016\u002F0360-3016(95)00060-C.",{"doi":3175},"10.1016\u002F0360-3016(95)00060-C",{"id":26,"text":3177,"url":26,"identifiers":3178},"Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM: The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008, 112: 55-60. 10.1002\u002Fcncr.23139.",{"doi":3179},"10.1002\u002Fcncr.23139",{"id":26,"text":3181,"url":26,"identifiers":3182},"D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A, Coleman CN: Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys. 1997, 39: 335-340.",{"doi":3183},"10.1016\u002FS0360-3016(97)00320-9",{"id":26,"text":3185,"url":26,"identifiers":3186},"D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002, 95: 281-286.",{"doi":3187},"10.1002\u002Fcncr.10657",{"id":26,"text":3189,"url":26,"identifiers":3190},"D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998, 280: 969-974.",{"doi":3191},"10.1001\u002Fjama.280.11.969",{"id":26,"text":3193,"url":26,"identifiers":3194},"Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA: Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level \u003C or = 10 ng\u002Fml: radiation therapy or surgery?. Int J Radiat Oncol Biol Phys. 1997, 38: 723-729. 10.1016\u002FS0360-3016(97)00123-5.",{"doi":3195},"10.1016\u002FS0360-3016(97)00123-5",{"id":26,"text":3197,"url":26,"identifiers":3198},"Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA: Radical prostatectomy, external beam radiotherapy \u003C72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds\u002Fexternal beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004, 58: 25-33. 10.1016\u002FS0360-3016(03)00784-3.",{"doi":3199},"10.1016\u002FS0360-3016(03)00784-3",{"id":26,"text":3201,"url":26,"identifiers":3202},"Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, Ziaja EL, Brabbins DS, Vicini FA: A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000, 88: 425-432. 10.1002\u002F(SICI)1097-0142(20000115)88:2\u003C425::AID-CNCR25>3.0.CO;2-Z.",{"doi":3203},"10.1002\u002F(SICI)1097-0142(20000115)88:2\u003C425::AID-CNCR25>3.0.CO;2-Z",{"id":26,"text":3205,"url":26,"identifiers":3206},"King CR, Brooks JD, Gill H, Presti JCJ: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010,",{},{"id":26,"text":3208,"url":26,"identifiers":3209},"Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE: Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009, 93: 185-191. 10.1016\u002Fj.radonc.2009.09.001.",{"doi":3210},"10.1016\u002Fj.radonc.2009.09.001",{"id":26,"text":3212,"url":26,"identifiers":3213},"Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H: Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008, 71: 330-337. 10.1016\u002Fj.ijrobp.2007.10.004.",{"doi":3214},"10.1016\u002Fj.ijrobp.2007.10.004",{"id":26,"text":3216,"url":26,"identifiers":3217},"Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W: 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001, 51: 31-40.",{"doi":3218},"10.1016\u002FS0360-3016(01)01601-7",{"id":26,"text":3220,"url":26,"identifiers":3221},"Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001, 28: 555-565. 10.1016\u002FS0094-0143(05)70163-4.",{"doi":3222},"10.1016\u002FS0094-0143(05)70163-4",{"id":26,"text":3224,"url":26,"identifiers":3225},"Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005, 63: 1463-1468. 10.1016\u002Fj.ijrobp.2005.05.054.",{"doi":3226},"10.1016\u002Fj.ijrobp.2005.05.054",{"id":26,"text":3228,"url":26,"identifiers":3229},"Katz AJ, Santoro M: Quality of life and efficacy for stereotactic body radiotherapy for treatment of organ confined prostate cancer. Annual Meeting of the Association for Radiation Oncology. San Diego, CA. 2010",{},{"id":26,"text":3231,"url":26,"identifiers":3232},"Ponsky LE, Lillibridge C, Brindle J, Zhang Y, Wessels B, Einstein DB: Stereotactic robotic radiosurgery for localized prostate cancer: Initial evaluation of acute toxicities. 2009 ASCO Annual Meeting. Orlando, Florida. 2009",{},{"id":26,"text":3234,"url":26,"identifiers":3235},"Oermann E, Hanscom HS, Lei S, Suy S, Chen V, Collins BT, Dritschilo A, Lynch JH, Dawson NA, Collins SP: Hypofractionated robotic radiosurgery for the treatment of clinically localized prostate cancer: Early biochemical results and acute toxicity. 2010 ASCO Annual Meeting Chicago, IL. 2010",{},{"id":3237,"createTime":3238,"updateTime":3239,"relativeEntities":3240,"slug":3241,"properties":3242,"entityType":829,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":3257,"translateLanguages":26,"viewCount":36,"primaryUrl":3258,"fullTextUrl":26,"authors":3259,"publicationType":918,"publisherRelationship":3433,"citationCount":364,"citationInfo":3461,"publishDate":3463,"publishYear":3464,"citationAnalyzeStatus":3465,"lastCitationAnalyze":3239,"indexDatabases":26,"openAccess":26,"references":3466,"isForceReanalyzing":1256},"5fae4039-7c97-4069-b768-99d0539ac403","2024-04-11T13:22:04.349+00:00","2024-04-11T14:53:47.346+00:00",[],"Radio-induced-malignancies-after-breast-cancer-postoperative-radiotherapy-in-patients-with-Li-Fraumeni-syndrome",{"mag":3243,"keywords":3245,"pmc":3246,"openalex":3248,"abstract":3250,"title":3251,"pm":3253,"doi":3255},{"VOID":3244},"2151054497",{},{"VOID":3247},"2988810",{"VOID":3249},"W2151054497",{},{"EN":3252},"Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome",{"VOID":3254},"21059199",{"VOID":3256},"10.1186\u002F1748-717x-5-104",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-5-104",[3260,3278,3296,3310,3329,3350,3368,3387,3401,3419],{"id":3261,"sortIndex":162,"researcher":26,"roles":3262,"affiliations":3263,"properties":3273},"a37dc25c-56f8-489c-97a9-1aabbfb8e4ec",[],[3264],{"id":26,"sortIndex":36,"affiliation":3265,"properties":26},{"id":3266,"createTime":3267,"updateTime":3267,"relativeEntities":3268,"slug":3269,"properties":3270,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"87f68331-fa87-4f22-93b6-234e549ae04f","2024-04-14T11:26:49.391+00:00",[],"Department-of-Breast-Surgery-Institut-Gustave-Roussy-Villejuif-France",{"title":3271},{"EN":3272},"Department of Breast Surgery, Institut Gustave Roussy, Villejuif, France",{"openalex":3274,"title":3276},{"VOID":3275},"A5042010719",{"EN":3277},"L. Barreau",{"id":3279,"sortIndex":50,"researcher":26,"roles":3280,"affiliations":3281,"properties":3291},"f5db0785-e4f5-4839-b812-22661dca4866",[],[3282],{"id":26,"sortIndex":36,"affiliation":3283,"properties":26},{"id":3284,"createTime":3285,"updateTime":3285,"relativeEntities":3286,"slug":3287,"properties":3288,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"31622b29-e104-4260-9ca8-fdb7b9b751bf","2024-04-11T13:22:04.424+00:00",[],"University-of-Florence-University-of-Florence-Italy",{"title":3289},{"EN":3290},"University of Florence, University of Florence, Italy",{"openalex":3292,"title":3294},{"VOID":3293},"A5054266059",{"EN":3295},"H. Marsiglia",{"id":3297,"sortIndex":135,"researcher":26,"roles":3298,"affiliations":3299,"properties":3305},"a4dfecc2-b8e3-40b8-bb60-0501f7481a50",[],[3300],{"id":26,"sortIndex":36,"affiliation":3301,"properties":26},{"id":3266,"createTime":3267,"updateTime":3267,"relativeEntities":3302,"slug":3269,"properties":3303,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3304},{"EN":3272},{"openalex":3306,"title":3308},{"VOID":3307},"A5052321517",{"EN":3309},"C. Pachet",{"id":3311,"sortIndex":158,"researcher":26,"roles":3312,"affiliations":3313,"properties":3324},"8d13f2fd-c091-4e7b-873e-501820822dfa",[],[3314],{"id":26,"sortIndex":36,"affiliation":3315,"properties":26},{"id":3316,"createTime":3317,"updateTime":3318,"relativeEntities":3319,"slug":3320,"properties":3321,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"076ed368-5f12-4312-8eb5-4db7b160d879","2023-12-12T17:34:51.886+00:00","2025-06-11T20:28:17.167+00:00",[],"Department-of-Pathology-Institut-Gustave-Roussy-Villejuif-France",{"title":3322},{"VI":3323},"Department of Pathology, Institut Gustave Roussy, Villejuif, France",{"openalex":3325,"title":3327},{"VOID":3326},"A5059694416",{"EN":3328},"Marie‐Christine Mathieu",{"id":3330,"sortIndex":52,"researcher":26,"roles":3331,"affiliations":3332,"properties":3343},"d96a849d-1067-47c9-8b1a-e18d25a4354f",[],[3333],{"id":26,"sortIndex":36,"affiliation":3334,"properties":26},{"id":3335,"createTime":3336,"updateTime":3337,"relativeEntities":3338,"slug":3339,"properties":3340,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"787c3d55-9370-4685-824c-8703b9e4f69c","2023-12-30T22:12:49.107+00:00","2024-10-09T21:13:52.731+00:00",[],"Department-of-Radiation-Oncology-Institut-Gustave-Roussy-Villejuif-France",{"title":3341},{"VI":3342},"Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France",{"openalex":3344,"orcid":3346,"title":3348},{"VOID":3345},"A5076536874",{"VOID":3347},"https:\u002F\u002Forcid.org\u002F0000-0001-5675-9989",{"EN":3349},"C. Bourgier",{"id":3351,"sortIndex":111,"researcher":26,"roles":3352,"affiliations":3353,"properties":3363},"3959aabd-fb37-4af0-9073-67d8d09b90f9",[],[3354],{"id":26,"sortIndex":36,"affiliation":3355,"properties":26},{"id":3356,"createTime":3357,"updateTime":3357,"relativeEntities":3358,"slug":3359,"properties":3360,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"c1606b60-2480-40bb-a21a-fe7962ad85d3","2024-04-11T13:22:04.391+00:00",[],"Genetic-Department-Academic-Hospital-Rouen-France",{"title":3361},{"EN":3362},"Genetic Department, Academic Hospital, Rouen, France",{"openalex":3364,"title":3366},{"VOID":3365},"A5021709517",{"EN":3367},"Thierry Frébourg",{"id":3369,"sortIndex":115,"researcher":26,"roles":3370,"affiliations":3371,"properties":3380},"61c73425-2456-41fe-8a9a-d9db164517b9",[],[3372],{"id":26,"sortIndex":36,"affiliation":3373,"properties":26},{"id":3374,"createTime":3375,"updateTime":3375,"relativeEntities":3376,"slug":26,"properties":3377,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6b4b8c39-4003-41bc-be3e-1f46b15b75a5","2024-01-26T19:58:17.626+00:00",[],{"title":3378},{"VI":3379},"Department of Breast Oncology, Institut Gustave Roussy, Villejuif, France",{"openalex":3381,"orcid":3383,"title":3385},{"VOID":3382},"A5083142899",{"VOID":3384},"https:\u002F\u002Forcid.org\u002F0000-0003-2106-9165",{"EN":3386},"Suzette Delaloge",{"id":3388,"sortIndex":114,"researcher":26,"roles":3389,"affiliations":3390,"properties":3396},"66d73717-9645-4e07-a19e-cadcb71160bf",[],[3391],{"id":26,"sortIndex":36,"affiliation":3392,"properties":26},{"id":3374,"createTime":3375,"updateTime":3375,"relativeEntities":3393,"slug":26,"properties":3394,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3395},{"VI":3379},{"openalex":3397,"title":3399},{"VOID":3398},"A5034189406",{"EN":3400},"Arslane Skander Rahal",{"id":3402,"sortIndex":59,"researcher":26,"roles":3403,"affiliations":3404,"properties":3414},"8ae1714f-09b4-4506-8d34-aab6defcb410",[],[3405],{"id":26,"sortIndex":36,"affiliation":3406,"properties":26},{"id":3407,"createTime":3408,"updateTime":3408,"relativeEntities":3409,"slug":3410,"properties":3411,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b0a0b6e4-bec9-4612-96eb-39047ce227dc","2024-04-11T13:22:04.382+00:00",[],"Department-of-Genetics-Counseling-Institut-Gustave-Roussy-Villejuif-France",{"title":3412},{"EN":3413},"Department of Genetics Counseling, Institut Gustave Roussy, Villejuif, France",{"openalex":3415,"title":3417},{"VOID":3416},"A5083715943",{"EN":3418},"Olivier Caron",{"id":3420,"sortIndex":36,"researcher":26,"roles":3421,"affiliations":3422,"properties":3428},"03c1de09-4e51-438b-8fa1-1465b043a001",[],[3423],{"id":26,"sortIndex":36,"affiliation":3424,"properties":26},{"id":3335,"createTime":3336,"updateTime":3337,"relativeEntities":3425,"slug":3339,"properties":3426,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3427},{"VI":3342},{"openalex":3429,"title":3431},{"VOID":3430},"A5031857075",{"EN":3432},"S. Heymann",{"url":26,"publisher":3434,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3435,"slug":663,"properties":3436,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3439,"manageAffiliations":3440,"indexDatabases":3441,"url":747,"thumbnailPath":26,"statistic":3456,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":3437,"title":3438},{"VOID":666},{"EN":668},[],[],[3442,3449],{"id":708,"indexDatabase":3443,"url":723,"indexYears":26,"academicFieldIds":3448,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":3444,"label":3445,"description":3446,"key":719,"publicationTags":3447,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":3450,"url":741,"indexYears":742,"academicFieldIds":3455,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":3451,"label":3452,"description":3453,"key":738,"publicationTags":3454,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":3457,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":3458,"totalCitation":768,"totalCitationByYear":3459,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":3460,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"total":364,"publishYear":26,"statisticByYear":3462},{"2012":158,"2013":50,"2014":52,"2015":298,"2016":52,"2017":51,"2018":53,"2019":124,"2020":222,"2021":336,"2022":239,"2023":298},"2010-12-01",2010,"ERROR_IN_ANALYZE_CITATION",[3467,3471,3475,3478,3482,3485,3488,3491,3495,3499,3502,3506,3510,3514,3518,3522,3526,3529,3533,3537,3541,3545,3549,3553,3557,3561,3565,3569],{"id":26,"text":3468,"url":26,"identifiers":3469},"Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969, 71: 747-752.",{"doi":3470},"10.7326\u002F0003-4819-71-4-747",{"id":26,"text":3472,"url":26,"identifiers":3473},"Gonzalez KD, Noltner KA, Buzin CH, et al.: Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27: 1250-1256. 10.1200\u002FJCO.2008.16.6959",{"doi":3474},"10.1200\u002FJCO.2008.16.6959",{"id":26,"text":3476,"url":26,"identifiers":3477},"Li FP, Fraumeni JF Jr, Mulvihill JJ, et al.: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48: 5358-5362.",{},{"id":26,"text":3479,"url":26,"identifiers":3480},"Varley JM: Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21: 313-320. 10.1002\u002Fhumu.10185",{"doi":3481},"10.1002\u002Fhumu.10185",{"id":26,"text":3483,"url":26,"identifiers":3484},"Olivier M, Goldgar DE, Sodha N, et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63: 6643-6650.",{},{"id":26,"text":3486,"url":26,"identifiers":3487},"Lee SB, Kim SH, Bell DW, et al.: Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001, 61: 8062-8067.",{},{"id":26,"text":3489,"url":26,"identifiers":3490},"Varley J: TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 2003, 222: 117-129.",{},{"id":26,"text":3492,"url":26,"identifiers":3493},"Varley J, Haber DA: Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res 2003, 5: 123-125. 10.1186\u002Fbcr582",{"doi":3494},"10.1186\u002Fbcr582",{"id":26,"text":3496,"url":26,"identifiers":3497},"Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408: 307-310. 10.1038\u002F35042675",{"doi":3498},"10.1038\u002F35042675",{"id":26,"text":3500,"url":26,"identifiers":3501},"Vousden KH: Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002, 1602: 47-59.",{},{"id":26,"text":3503,"url":26,"identifiers":3504},"Gasco M, Shami S, Crook T: The p53 pathway in breast cancer. Breast Cancer Res 2002, 4: 70-76. 10.1186\u002Fbcr426",{"doi":3505},"10.1186\u002Fbcr426",{"id":26,"text":3507,"url":26,"identifiers":3508},"Wang QE, Zhu Q, Wani MA, et al.: Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage. DNA Repair (Amst) 2003, 2: 483-499. 10.1016\u002FS1568-7864(03)00002-8",{"doi":3509},"10.1016\u002FS1568-7864(03)00002-8",{"id":26,"text":3511,"url":26,"identifiers":3512},"Fei P, El-Deiry WS: P53 and radiation responses. Oncogene 2003, 22: 5774-5783. 10.1038\u002Fsj.onc.1206677",{"doi":3513},"10.1038\u002Fsj.onc.1206677",{"id":26,"text":3515,"url":26,"identifiers":3516},"Bougeard G, Brugieres L, Chompret A, et al.: Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 2003, 22: 840-846. 10.1038\u002Fsj.onc.1206155",{"doi":3517},"10.1038\u002Fsj.onc.1206155",{"id":26,"text":3519,"url":26,"identifiers":3520},"Kony SJ, de Vathaire F, Chompret A, et al.: Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997, 350: 91-95. 10.1016\u002FS0140-6736(97)01116-1",{"doi":3521},"10.1016\u002FS0140-6736(97)01116-1",{"id":26,"text":3523,"url":26,"identifiers":3524},"Hisada M, Garber JE, Fung CY, et al.: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998, 90: 606-611. 10.1093\u002Fjnci\u002F90.8.606",{"doi":3525},"10.1093\u002Fjnci\u002F90.8.606",{"id":26,"text":3527,"url":26,"identifiers":3528},"Nutting C, Camplejohn RS, Gilchrist R, et al.: A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 2000, 12: 300-304.",{},{"id":26,"text":3530,"url":26,"identifiers":3531},"Limacher JM, Frebourg T, Natarajan-Ame S, et al.: Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001, 96: 238-242. 10.1002\u002Fijc.1021",{"doi":3532},"10.1002\u002Fijc.1021",{"id":26,"text":3534,"url":26,"identifiers":3535},"Salmon A, Amikam D, Sodha N, et al.: Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) 2007, 19: 490-493.",{"doi":3536},"10.1016\u002Fj.clon.2007.05.001",{"id":26,"text":3538,"url":26,"identifiers":3539},"Bollet MA, Sigal-Zafrani B, Mazeau V, et al.: Age remains the first prognostic factor for loco-regional breast cancer recurrence in young ( \u003C 40 years) women treated with breast conserving surgery first. Radiother Oncol 2007, 82: 272-280. 10.1016\u002Fj.radonc.2007.01.001",{"doi":3540},"10.1016\u002Fj.radonc.2007.01.001",{"id":26,"text":3542,"url":26,"identifiers":3543},"Prise en charge du cancer du sein infiltrant de la femme non ménopausée Oncologie 2009, 11: 507-532. 10.1007\u002Fs10269-009-1818-6",{"doi":3544},"10.1007\u002Fs10269-009-1818-6",{"id":26,"text":3546,"url":26,"identifiers":3547},"Livasy CA, Karaca G, Nanda R, et al.: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19: 264-271. 10.1038\u002Fmodpathol.3800528",{"doi":3548},"10.1038\u002Fmodpathol.3800528",{"id":26,"text":3550,"url":26,"identifiers":3551},"Veronesi U, Marubini E, Del Vecchio M, et al.: Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995, 87: 19-27. 10.1093\u002Fjnci\u002F87.1.19",{"doi":3552},"10.1093\u002Fjnci\u002F87.1.19",{"id":26,"text":3554,"url":26,"identifiers":3555},"Fowble BL, Schultz DJ, Overmoyer B, et al.: The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994, 30: 23-33.",{"doi":3556},"10.1016\u002F0360-3016(94)90515-0",{"id":26,"text":3558,"url":26,"identifiers":3559},"Rubino C, de Vathaire F, Shamsaldin A, et al.: Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003, 89: 840-846. 10.1038\u002Fsj.bjc.6601138",{"doi":3560},"10.1038\u002Fsj.bjc.6601138",{"id":26,"text":3562,"url":26,"identifiers":3563},"Delia D, Goi K, Mizutani S, et al.: Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 1997, 14: 2137-2147. 10.1038\u002Fsj.onc.1201050",{"doi":3564},"10.1038\u002Fsj.onc.1201050",{"id":26,"text":3566,"url":26,"identifiers":3567},"Mitchel RE, Jackson JS, Carlisle SM: Upper dose thresholds for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 2004, 162: 20-30. 10.1667\u002FRR3190",{"doi":3568},"10.1667\u002FRR3190",{"id":26,"text":3570,"url":26,"identifiers":3571},"Tinat J, Bougeard G, Baert-Desurmont S, et al.: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27: e108-109. author reply e110 10.1200\u002FJCO.2009.22.7967",{"doi":3572},"10.1200\u002FJCO.2009.22.7967",{"id":3574,"createTime":3575,"updateTime":3576,"relativeEntities":3577,"slug":3578,"properties":3579,"entityType":829,"verifyStatus":25,"verifyTime":3576,"verifyNote":830,"syncStatus":28,"languages":3595,"translateLanguages":26,"viewCount":36,"primaryUrl":3596,"fullTextUrl":26,"authors":3597,"publicationType":918,"publisherRelationship":3856,"citationCount":763,"citationInfo":3884,"publishDate":3886,"publishYear":3887,"citationAnalyzeStatus":3465,"lastCitationAnalyze":3888,"indexDatabases":26,"openAccess":26,"references":3889,"isForceReanalyzing":1256},"82074362-94fe-47a0-9ee0-89195ce0ffc1","2024-04-13T20:33:33.895+00:00","2025-01-20T12:59:23.281+00:00",[],"High-dose-stereotactic-body-radiotherapy-correlates-increased-local-control-and-overall-survival-in-patients-with-inoperable-hepatocellular-carcinoma",{"mag":3580,"keywords":3582,"pmc":3583,"openalex":3585,"abstract":3587,"title":3589,"pm":3591,"doi":3593},{"VOID":3581},"2131219951",{},{"VOID":3584},"4231524",{"VOID":3586},"W2131219951",{"EN":3588},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\n          \u003Cjats:sec>\n            \u003Cjats:title>Background\u003C\u002Fjats:title>\n            \u003Cjats:p>Recent studies using stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) have reported high tumor response and local control. However, the optimal SBRT dose remains unknown, and it is still not clear whether a dose response relationship for local control (LC) and overall survival (OS) exist or not. We performed this study to determine whether a dose response relationship for LC and OS is observed in SBRT for inoperable HCC.\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>\n          \u003Cjats:sec>\n            \u003Cjats:title>Methods\u003C\u002Fjats:title>\n            \u003Cjats:p>Between 2003 and 2011, 108 patients with HCC were treated with SBRT. All patients were unsuitable for surgery or local ablation and had incomplete response to transarterial chemoembolization. Eighty-two patients with a longest tumor diameter (LD) less than or equal to 7.0 cm who were treated with 3-fraction SBRT and were analyzed. This cohort comprised 74 Child-Turcotte-Pugh (CTP) class A patients and 8 CTP class B7 patients. The median LD was 3.0 cm (range, 1.0–7.0 cm), and the median dose was 51 Gy (range, 33–60 Gy).\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>\n          \u003Cjats:sec>\n            \u003Cjats:title>Results\u003C\u002Fjats:title>\n            \u003Cjats:p>LC and OS rates at 2 years after SBRT were 87% and 63%, respectively, with a median follow-up duration of 30 months for all patients. The 2-year LC\u002FOS rates for patients treated with doses of > 54, 45–54, and < 45 Gy were 100\u002F71, 78\u002F64, and 64%\u002F30%, respectively (p = .009\u002Fp < .001). Multivariate analysis revealed that the SBRT dose (p = .005) and Barcelona Clinic Liver Cancer stage (p = .015) were significant prognostic factors for OS. Correlation analysis revealed a positive linear relationship between the SBRT dose and LC (p = .006, R = .899)\u002FOS (p = .002, R = .940) at 2 years. Based on the tumor-control probability model, a dose of 54.8 Gy provides 2-year LC with a 90% probability. Five patients experienced grade 3 or higher gastrointestinal toxicity, and 6 had deteriorating of CTP score by greater than or equal to 2 within 3 months of SBRT.\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>\n          \u003Cjats:sec>\n            \u003Cjats:title>Conclusions\u003C\u002Fjats:title>\n            \u003Cjats:p>This study demonstrated a dose response relationship for LC and OS with SBRT for HCC. Higher LC rates resulting from an increased dose may translate into survival benefits for patients with HCC.\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>",{"EN":3590},"High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma",{"VOID":3592},"24160944",{"VOID":3594},"10.1186\u002F1748-717x-8-250",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-8-250",[3598,3618,3638,3658,3678,3698,3712,3726,3740,3754,3768,3784,3800,3820,3836],{"id":3599,"sortIndex":158,"researcher":26,"roles":3600,"affiliations":3601,"properties":3611},"9ab5b0dd-08a4-44cb-a4f1-81185d1860b7",[],[3602],{"id":26,"sortIndex":36,"affiliation":3603,"properties":26},{"id":3604,"createTime":3605,"updateTime":3605,"relativeEntities":3606,"slug":3607,"properties":3608,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"90438e2e-2581-4bcb-a5b8-d7f8e4bbe5e9","2024-04-13T20:33:34.317+00:00",[],"Division-of-Heavy-Ion-Clinical-Research-Korea-Institute-of-Radiological-Medical-Science-Seoul-Republic-of-Korea",{"title":3609},{"EN":3610},"Division of Heavy Ion Clinical Research, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea",{"openalex":3612,"orcid":3614,"title":3616},{"VOID":3613},"A5013722838",{"VOID":3615},"https:\u002F\u002Forcid.org\u002F0000-0002-7361-4930",{"EN":3617},"So Young Kim",{"id":3619,"sortIndex":103,"researcher":26,"roles":3620,"affiliations":3621,"properties":3631},"0797d72e-ba00-4555-b28f-a5424efbe7ee",[],[3622],{"id":26,"sortIndex":36,"affiliation":3623,"properties":26},{"id":3624,"createTime":3625,"updateTime":3625,"relativeEntities":3626,"slug":3627,"properties":3628,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1c5cf7e8-9e6f-43cd-855a-28fa9e6dcf33","2024-04-13T20:33:34.468+00:00",[],"Department-of-Surgery-Korea-Institute-of-Radiological-Medical-Science-Seoul-Republic-of-Korea",{"title":3629},{"EN":3630},"Department of Surgery, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea",{"openalex":3632,"orcid":3634,"title":3636},{"VOID":3633},"A5013978939",{"VOID":3635},"https:\u002F\u002Forcid.org\u002F0000-0002-8187-4134",{"EN":3637},"Sang Bum Kim",{"id":3639,"sortIndex":116,"researcher":26,"roles":3640,"affiliations":3641,"properties":3651},"68831f43-2f09-425b-b1d0-582eadfdf9cd",[],[3642],{"id":26,"sortIndex":36,"affiliation":3643,"properties":26},{"id":3644,"createTime":3645,"updateTime":3645,"relativeEntities":3646,"slug":3647,"properties":3648,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"7e15e07e-bb22-4e8a-95b2-5ecdb5f004a2","2024-04-13T20:33:33.910+00:00",[],"Department-of-Internal-Medicine-Korea-Institute-of-Radiological-Medical-Science-Seoul-Republic-of-Korea",{"title":3649},{"EN":3650},"Department of Internal Medicine, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea",{"openalex":3652,"orcid":3654,"title":3656},{"VOID":3653},"A5038890216",{"VOID":3655},"https:\u002F\u002Forcid.org\u002F0000-0002-6225-7755",{"EN":3657},"Jin Kim",{"id":3659,"sortIndex":114,"researcher":26,"roles":3660,"affiliations":3661,"properties":3671},"f6220e88-e029-4352-9c6d-6220994edca4",[],[3662],{"id":26,"sortIndex":36,"affiliation":3663,"properties":26},{"id":3664,"createTime":3665,"updateTime":3665,"relativeEntities":3666,"slug":3667,"properties":3668,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6467d3b5-84b3-4f6a-8fba-0edf11b39585","2024-04-13T20:33:34.026+00:00",[],"Department-of-Radiation-Oncology-Kyung-Hee-University-Gangdong-Hospital-Seoul-Republic-of-Korea",{"title":3669},{"EN":3670},"Department of Radiation Oncology, Kyung Hee University Gangdong Hospital, Seoul, Republic of Korea",{"openalex":3672,"orcid":3674,"title":3676},{"VOID":3673},"A5026945708",{"VOID":3675},"https:\u002F\u002Forcid.org\u002F0000-0003-0637-4110",{"EN":3677},"Sun Hyun Bae",{"id":3679,"sortIndex":162,"researcher":26,"roles":3680,"affiliations":3681,"properties":3691},"f7ef993c-ddf2-42a3-8fac-df9e45eae898",[],[3682],{"id":26,"sortIndex":36,"affiliation":3683,"properties":26},{"id":3684,"createTime":3685,"updateTime":3685,"relativeEntities":3686,"slug":3687,"properties":3688,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"34a41412-884a-4d28-8f9e-f7b9c67cba01","2024-04-13T20:33:34.116+00:00",[],"Department-of-Radiation-Oncology-Korea-Institute-of-Radiological-Medical-Science-Seoul-Republic-of-Korea",{"title":3689},{"EN":3690},"Department of Radiation Oncology, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea",{"openalex":3692,"orcid":3694,"title":3696},{"VOID":3693},"A5023873827",{"VOID":3695},"https:\u002F\u002Forcid.org\u002F0000-0001-7411-9088",{"EN":3697},"Young Seok Seo",{"id":3699,"sortIndex":356,"researcher":26,"roles":3700,"affiliations":3701,"properties":3707},"a474b1f4-8df9-4538-a480-e79bd9de613b",[],[3702],{"id":26,"sortIndex":36,"affiliation":3703,"properties":26},{"id":3624,"createTime":3625,"updateTime":3625,"relativeEntities":3704,"slug":3627,"properties":3705,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3706},{"EN":3630},{"openalex":3708,"title":3710},{"VOID":3709},"A5069189000",{"EN":3711},"Eung‐Ho Cho",{"id":3713,"sortIndex":111,"researcher":26,"roles":3714,"affiliations":3715,"properties":3721},"21757613-d48c-4d63-b09e-fe7ea727b16d",[],[3716],{"id":26,"sortIndex":36,"affiliation":3717,"properties":26},{"id":3684,"createTime":3685,"updateTime":3685,"relativeEntities":3718,"slug":3687,"properties":3719,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3720},{"EN":3690},{"openalex":3722,"title":3724},{"VOID":3723},"A5000117390",{"EN":3725},"Hyun Jung Yoo",{"id":3727,"sortIndex":52,"researcher":26,"roles":3728,"affiliations":3729,"properties":3735},"7575305d-2b21-460d-b6fb-ac703529c852",[],[3730],{"id":26,"sortIndex":36,"affiliation":3731,"properties":26},{"id":3644,"createTime":3645,"updateTime":3645,"relativeEntities":3732,"slug":3647,"properties":3733,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3734},{"EN":3650},{"openalex":3736,"title":3738},{"VOID":3737},"A5034044059",{"EN":3739},"Chul Ju Han",{"id":3741,"sortIndex":115,"researcher":26,"roles":3742,"affiliations":3743,"properties":3749},"d0dada02-839c-411e-9872-b06a00585db0",[],[3744],{"id":26,"sortIndex":36,"affiliation":3745,"properties":26},{"id":3684,"createTime":3685,"updateTime":3685,"relativeEntities":3746,"slug":3687,"properties":3747,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3748},{"EN":3690},{"openalex":3750,"title":3752},{"VOID":3751},"A5041533546",{"EN":3753},"Misook Kim",{"id":3755,"sortIndex":59,"researcher":26,"roles":3756,"affiliations":3757,"properties":3763},"5c200cc4-db52-4682-8235-f35b978efbb0",[],[3758],{"id":26,"sortIndex":36,"affiliation":3759,"properties":26},{"id":3684,"createTime":3685,"updateTime":3685,"relativeEntities":3760,"slug":3687,"properties":3761,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3762},{"EN":3690},{"openalex":3764,"title":3766},{"VOID":3765},"A5042440821",{"EN":3767},"Chul Koo Cho",{"id":3769,"sortIndex":36,"researcher":26,"roles":3770,"affiliations":3771,"properties":3777},"7575e0da-8c5d-4688-b307-6cfa8fb84b85",[],[3772],{"id":26,"sortIndex":36,"affiliation":3773,"properties":26},{"id":3684,"createTime":3685,"updateTime":3685,"relativeEntities":3774,"slug":3687,"properties":3775,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3776},{"EN":3690},{"openalex":3778,"orcid":3780,"title":3782},{"VOID":3779},"A5060065448",{"VOID":3781},"https:\u002F\u002Forcid.org\u002F0000-0002-5279-3087",{"EN":3783},"Won Il Jang",{"id":3785,"sortIndex":53,"researcher":26,"roles":3786,"affiliations":3787,"properties":3793},"38b86c2c-1bb5-4bac-91af-9a90021a9dab",[],[3788],{"id":26,"sortIndex":36,"affiliation":3789,"properties":26},{"id":3644,"createTime":3645,"updateTime":3645,"relativeEntities":3790,"slug":3647,"properties":3791,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3792},{"EN":3650},{"openalex":3794,"orcid":3796,"title":3798},{"VOID":3795},"A5049815426",{"VOID":3797},"https:\u002F\u002Forcid.org\u002F0009-0000-5690-9174",{"EN":3799},"Su Cheol Park",{"id":3801,"sortIndex":50,"researcher":26,"roles":3802,"affiliations":3803,"properties":3813},"1a8a14d4-ad0b-426f-a521-a4ee3463c32a",[],[3804],{"id":26,"sortIndex":36,"affiliation":3805,"properties":26},{"id":3806,"createTime":3807,"updateTime":3807,"relativeEntities":3808,"slug":3809,"properties":3810,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"7ec07050-c69e-4d7e-8e41-3e3c1d56e7c6","2024-04-13T20:33:34.387+00:00",[],"Cyberknife-Center-Korea-Institute-of-Radiological-Medical-Science-Seoul-Republic-of-Korea",{"title":3811},{"EN":3812},"Cyberknife Center, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea",{"openalex":3814,"orcid":3816,"title":3818},{"VOID":3815},"A5079279144",{"VOID":3817},"https:\u002F\u002Forcid.org\u002F0000-0001-9440-9744",{"EN":3819},"Dong Han Lee",{"id":3821,"sortIndex":135,"researcher":26,"roles":3822,"affiliations":3823,"properties":3829},"8eebad48-2527-4de4-bf60-80f029ac8461",[],[3824],{"id":26,"sortIndex":36,"affiliation":3825,"properties":26},{"id":3684,"createTime":3685,"updateTime":3685,"relativeEntities":3826,"slug":3687,"properties":3827,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3828},{"EN":3690},{"openalex":3830,"orcid":3832,"title":3834},{"VOID":3831},"A5005151130",{"VOID":3833},"https:\u002F\u002Forcid.org\u002F0000-0002-0108-0247",{"EN":3835},"Jung Sook Kang",{"id":3837,"sortIndex":298,"researcher":26,"roles":3838,"affiliations":3839,"properties":3849},"7758c7a8-88f1-44b7-ace5-61edf1377964",[],[3840],{"id":26,"sortIndex":36,"affiliation":3841,"properties":26},{"id":3842,"createTime":3843,"updateTime":3843,"relativeEntities":3844,"slug":3845,"properties":3846,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3432fb3d-9af9-4583-b0ec-7839e8f1dfc9","2024-04-13T20:33:33.945+00:00",[],"Department-of-Radiology-Korea-Institute-of-Radiological-Medical-Science-Seoul-Republic-of-Korea",{"title":3847},{"EN":3848},"Department of Radiology, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea",{"openalex":3850,"orcid":3852,"title":3854},{"VOID":3851},"A5042147885",{"VOID":3853},"https:\u002F\u002Forcid.org\u002F0000-0003-0645-6028",{"EN":3855},"Young Han Kim",{"url":26,"publisher":3857,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3858,"slug":663,"properties":3859,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3862,"manageAffiliations":3863,"indexDatabases":3864,"url":747,"thumbnailPath":26,"statistic":3879,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":3860,"title":3861},{"VOID":666},{"EN":668},[],[],[3865,3872],{"id":708,"indexDatabase":3866,"url":723,"indexYears":26,"academicFieldIds":3871,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":3867,"label":3868,"description":3869,"key":719,"publicationTags":3870,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":3873,"url":741,"indexYears":742,"academicFieldIds":3878,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":3874,"label":3875,"description":3876,"key":738,"publicationTags":3877,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":3880,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":3881,"totalCitation":768,"totalCitationByYear":3882,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":3883,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"total":763,"publishYear":26,"statisticByYear":3885},{"2013":115,"2014":103,"2015":336,"2016":51,"2017":237,"2018":356,"2019":234,"2020":237,"2021":516,"2022":116,"2023":103,"2024":115},"2013-12-01",2013,"2024-04-14T06:58:48.179+00:00",[3890,3894,3898,3902,3906,3910,3914,3918,3922,3926,3929,3933,3937,3941,3945,3949,3953,3957,3961,3965,3969,3973,3977,3981,3985,3989,3993,3996,4000,4004,4007,4011,4015,4019,4023,4027,4031,4035,4038,4042],{"id":26,"text":3891,"url":26,"identifiers":3892},"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69-90. 10.3322\u002Fcaac.20107",{"doi":3893},"10.3322\u002Fcaac.20107",{"id":26,"text":3895,"url":26,"identifiers":3896},"Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000, 32: 1224-1229. 10.1053\u002Fjhep.2000.20456",{"doi":3897},"10.1053\u002Fjhep.2000.20456",{"id":26,"text":3899,"url":26,"identifiers":3900},"Ryu M, Shimamura Y, Kinoshita T, Konishi M, Kawano N, Iwasaki M, Furuse J, Yoshino M, Moriyama N, Sugita M: Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol 1997, 27: 251-257. 10.1093\u002Fjjco\u002F27.4.251",{"doi":3901},"10.1093\u002Fjjco\u002F27.4.251",{"id":26,"text":3903,"url":26,"identifiers":3904},"Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P: Metroticket Investigator Study Group: Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10: 35-43. 10.1016\u002FS1470-2045(08)70284-5",{"doi":3905},"10.1016\u002FS1470-2045(08)70284-5",{"id":26,"text":3907,"url":26,"identifiers":3908},"Schwarz RE, Smith DD: Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg 2008, 195: 829-836. 10.1016\u002Fj.amjsurg.2007.10.010",{"doi":3909},"10.1016\u002Fj.amjsurg.2007.10.010",{"id":26,"text":3911,"url":26,"identifiers":3912},"Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012, 107: 569-577. 10.1038\u002Fajg.2011.425",{"doi":3913},"10.1038\u002Fajg.2011.425",{"id":26,"text":3915,"url":26,"identifiers":3916},"Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129: 122-130. 10.1053\u002Fj.gastro.2005.04.009",{"doi":3917},"10.1053\u002Fj.gastro.2005.04.009",{"id":26,"text":3919,"url":26,"identifiers":3920},"Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM: Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009, 9: 31-39. 10.1186\u002F1471-230X-9-31",{"doi":3921},"10.1186\u002F1471-230X-9-31",{"id":26,"text":3923,"url":26,"identifiers":3924},"Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37: 429-442. 10.1053\u002Fjhep.2003.50047",{"doi":3925},"10.1053\u002Fjhep.2003.50047",{"id":26,"text":3927,"url":26,"identifiers":3928},"Ingold JA, Reed GB, Kaplan HS, Bagshaw MA: Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965, 93: 200-208.",{},{"id":26,"text":3930,"url":26,"identifiers":3931},"Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, Lawrence TS: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18: 2210-2218.",{"doi":3932},"10.1200\u002FJCO.2000.18.11.2210",{"id":26,"text":3934,"url":26,"identifiers":3935},"Seong J, Park HC, Han KH, Chon CY: Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003, 55: 329-336. 10.1016\u002FS0360-3016(02)03929-9",{"doi":3936},"10.1016\u002FS0360-3016(02)03929-9",{"id":26,"text":3938,"url":26,"identifiers":3939},"Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, Nam HR, Ahn YC, Huh SJ: Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005, 61: 1143-1150. 10.1016\u002Fj.ijrobp.2004.08.028",{"doi":3940},"10.1016\u002Fj.ijrobp.2004.08.028",{"id":26,"text":3942,"url":26,"identifiers":3943},"Kim YI, Park HC, Lim Do H, Park HJ, Kang SW, Park SY, Kim JS, Han Y, Paik SW: Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 2012, 30: 189-196. 10.3857\u002Froj.2012.30.4.189",{"doi":3944},"10.3857\u002Froj.2012.30.4.189",{"id":26,"text":3946,"url":26,"identifiers":3947},"Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA: American Society for Therapeutic Radiology and Oncology; American College of Radiology: American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 76: 326-332. 10.1016\u002Fj.ijrobp.2009.09.042",{"doi":3948},"10.1016\u002Fj.ijrobp.2009.09.042",{"id":26,"text":3950,"url":26,"identifiers":3951},"Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE: Multi-institutional phase I\u002FII trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27: 1572-1578. 10.1200\u002FJCO.2008.19.6329",{"doi":3952},"10.1200\u002FJCO.2008.19.6329",{"id":26,"text":3954,"url":26,"identifiers":3955},"Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutcher GJ, Lawrence TS: Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 1995, 31: 883-891. 10.1016\u002F0360-3016(94)00471-4",{"doi":3956},"10.1016\u002F0360-3016(94)00471-4",{"id":26,"text":3958,"url":26,"identifiers":3959},"Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53: 810-821. 10.1016\u002FS0360-3016(02)02846-8",{"doi":3960},"10.1016\u002FS0360-3016(02)02846-8",{"id":26,"text":3962,"url":26,"identifiers":3963},"Blomgren H, Lax I, Naslund I, Svanstrom R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34: 861-870. 10.3109\u002F02841869509127197",{"doi":3964},"10.3109\u002F02841869509127197",{"id":26,"text":3966,"url":26,"identifiers":3967},"Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26: 657-664. 10.1200\u002FJCO.2007.14.3529",{"doi":3968},"10.1200\u002FJCO.2007.14.3529",{"id":26,"text":3970,"url":26,"identifiers":3971},"Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR: Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011, 81: e447-e453. 10.1016\u002Fj.ijrobp.2011.04.011",{"doi":3972},"10.1016\u002Fj.ijrobp.2011.04.011",{"id":26,"text":3974,"url":26,"identifiers":3975},"Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E: Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Trea 2010, 9: 479-487.",{"doi":3976},"10.1177\u002F153303461000900506",{"id":26,"text":3978,"url":26,"identifiers":3979},"Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, Su YF, Fan CY, Chang YW: Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012, 84: 355-361. 10.1016\u002Fj.ijrobp.2011.11.058",{"doi":3980},"10.1016\u002Fj.ijrobp.2011.11.058",{"id":26,"text":3982,"url":26,"identifiers":3983},"Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA: Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol 2013, 31: 1631-1639. 10.1200\u002FJCO.2012.44.1659",{"doi":3984},"10.1200\u002FJCO.2012.44.1659",{"id":26,"text":3986,"url":26,"identifiers":3987},"Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH, Kim YH, Lee DH: Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010, 102: 209-214. 10.1002\u002Fjso.21593",{"doi":3988},"10.1002\u002Fjso.21593",{"id":26,"text":3990,"url":26,"identifiers":3991},"Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung DH, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012, 118: 5424-5431. 10.1002\u002Fcncr.27533",{"doi":3992},"10.1002\u002Fcncr.27533",{"id":26,"text":3994,"url":26,"identifiers":3995},"Kim JG, Lee DH, Lee DH, Kim MS, Cho CK, Yoo SY, Yang KM, Oh WY, Ji YH: A study of the reduction of organ motion from respiration. Korea J Med Phys 2004, 125: 179-186.",{},{"id":26,"text":3997,"url":26,"identifiers":3998},"Takeda A, Kunieda E, Shigematsu N, Hossain DM, Kawase T, Ohashi T, Fukada J, Kawaguchi O, Uematsu M, Takeda T, Takemasa K, Takahashi T, Kubo A: Small lung tumors: long-scan-time CT for planning of hypofractionated stereotactic radiation therapy–initial findings. Radiology 2005, 237: 295-300. 10.1148\u002Fradiol.2371032102",{"doi":3999},"10.1148\u002Fradiol.2371032102",{"id":26,"text":4001,"url":26,"identifiers":4002},"Nakamura M, Narita Y, Matsuo Y, Narabayashi M, Nakata M, Yano S, Miyabe Y, Matsugi K, Sawada A, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M: Geometrical differences in target volumes between slow CT and 4D CT imaging in stereotactic body radiotherapy for lung tumors in the upper and middle lobe. Med Phys 2008, 35: 4142-4148. 10.1118\u002F1.2968096",{"doi":4003},"10.1118\u002F1.2968096",{"id":26,"text":4005,"url":26,"identifiers":4006},"Kim MS, Ha SH, Lee DH, Ji YH, Yoo SY, Cho CK, Yang KM, Yoo HJ, Seo YS, Park CI, Kim IH, Ye SJ, Park JH, Kim KB: Distortion of the dose profile in a 3-dimensional moving phantom to simulate tumor motion during image-guided radiosurgery. J Korean Soc Ther Radiol Oncol 2007, 25: 268-277.",{},{"id":26,"text":4008,"url":26,"identifiers":4009},"Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30: 52-60. 10.1055\u002Fs-0030-1247132",{"doi":4010},"10.1055\u002Fs-0030-1247132",{"id":26,"text":4012,"url":26,"identifiers":4013},"Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31: 1237-1248. 10.1016\u002F0360-3016(94)00418-K",{"doi":4014},"10.1016\u002F0360-3016(94)00418-K",{"id":26,"text":4016,"url":26,"identifiers":4017},"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK: Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76: S94-S100. 10.1016\u002Fj.ijrobp.2009.06.092",{"doi":4018},"10.1016\u002Fj.ijrobp.2009.06.092",{"id":26,"text":4020,"url":26,"identifiers":4021},"Goitein M, Schultheiss TE: Strategies for treating possible tumor extension: some theoretical considerations. Int J Radiat Oncol Biol Phys 1985, 11: 1519-1528. 10.1016\u002F0360-3016(85)90341-4",{"doi":4022},"10.1016\u002F0360-3016(85)90341-4",{"id":26,"text":4024,"url":26,"identifiers":4025},"Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303: 1070-1076. 10.1001\u002Fjama.2010.261",{"doi":4026},"10.1001\u002Fjama.2010.261",{"id":26,"text":4028,"url":26,"identifiers":4029},"Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO: Dose–response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54: 150-155.",{"doi":4030},"10.1016\u002FS0360-3016(02)02864-X",{"id":26,"text":4032,"url":26,"identifiers":4033},"Bae SH, Kim MS, Cho CK, Kang JK, Lee SY, Lee KN, Lee DH, Han CJ, Yang KY, Kim SB: Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int J Radiat Oncol Biol Phys 2012, 84: e469-e474. 10.1016\u002Fj.ijrobp.2012.06.005",{"doi":4034},"10.1016\u002Fj.ijrobp.2012.06.005",{"id":26,"text":4036,"url":26,"identifiers":4037},"Bae SH, Kim MS, Kim SY, Jang WI, Cho CK, Yoo HJ, Kim KB, Lee DH, Han CJ: Yang KY. Kim SB: Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies. Int J Colorectal Dis; 2013. [Epub ahead of print]",{},{"id":26,"text":4039,"url":26,"identifiers":4040},"Waki K, Aikata H, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Takahashi S, Toyota N, Ito K, Chayama K: Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol 2010, 25: 597-604. 10.1111\u002Fj.1440-1746.2009.06125.x",{"doi":4041},"10.1111\u002Fj.1440-1746.2009.06125.x",{"id":26,"text":4043,"url":26,"identifiers":4044},"Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J: A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012, 57: 794-802. 10.1016\u002Fj.jhep.2012.05.007",{"doi":4045},"10.1016\u002Fj.jhep.2012.05.007",{"id":4047,"createTime":4048,"updateTime":4048,"relativeEntities":4049,"slug":4050,"properties":4051,"entityType":829,"verifyStatus":25,"verifyTime":4048,"verifyNote":830,"syncStatus":28,"languages":4066,"translateLanguages":26,"viewCount":36,"primaryUrl":4067,"fullTextUrl":26,"authors":4068,"publicationType":918,"publisherRelationship":4179,"citationCount":4211,"citationInfo":4212,"publishDate":4214,"publishYear":4215,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":4216,"isForceReanalyzing":1256},"ad548a43-f627-4b5b-90a4-f245c84d3c25","2024-09-23T23:40:27.726+00:00",[],"A-comparison-of-long-term-survivors-and-short-term-survivors-with-glioblastoma-subventricular-zone-involvement-a-predictive-factor-for-survival-",{"mag":4052,"keywords":4054,"pmc":4055,"openalex":4057,"abstract":4059,"title":4060,"pm":4062,"doi":4064},{"VOID":4053},"2041296416",{},{"VOID":4056},"4011838",{"VOID":4058},"W2041296416",{},{"EN":4061},"A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival?",{"VOID":4063},"24758192",{"VOID":4065},"10.1186\u002F1748-717x-9-95",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-9-95",[4069,4090,4107,4124,4145,4162],{"id":4070,"sortIndex":115,"researcher":26,"roles":4071,"affiliations":4072,"properties":4083},"8aa7344c-29a3-4dac-8c9c-debd90f8b936",[],[4073],{"id":4074,"sortIndex":36,"affiliation":4075,"properties":26},"0bcb2d4c-44b8-435c-be05-4c490628e414",{"id":4076,"createTime":4077,"updateTime":4077,"relativeEntities":4078,"slug":4079,"properties":4080,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"befb986b-b62b-4c6e-8620-289e48d5b863","2024-09-23T23:40:27.736+00:00",[],"Department-of-Radiation-Oncology-University-Hospital-of-Heidelbergy-Heidelberg-Im-Neuenheimer-Feld-400-69120-Germany",{"title":4081},{"EN":4082},"Department of Radiation Oncology, University Hospital of Heidelbergy, Heidelberg, Im Neuenheimer Feld 400, 69120, Germany",{"openalex":4084,"orcid":4086,"title":4088},{"VOID":4085},"A5061995639",{"VOID":4087},"https:\u002F\u002Forcid.org\u002F0000-0003-3006-2379",{"EN":4089},"Tilman Bostel",{"id":4091,"sortIndex":36,"researcher":26,"roles":4092,"affiliations":4093,"properties":4100},"3cfaf21e-d5fe-4199-afdc-0b88021617b5",[],[4094],{"id":4095,"sortIndex":36,"affiliation":4096,"properties":26},"44058b54-738e-4585-ba20-32e6070988c6",{"id":4076,"createTime":4077,"updateTime":4077,"relativeEntities":4097,"slug":4079,"properties":4098,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4099},{"EN":4082},{"openalex":4101,"orcid":4103,"title":4105},{"VOID":4102},"A5076635156",{"VOID":4104},"https:\u002F\u002Forcid.org\u002F0000-0001-8463-514X",{"EN":4106},"Sebastian Adeberg",{"id":4108,"sortIndex":114,"researcher":26,"roles":4109,"affiliations":4110,"properties":4117},"6419133a-4156-481c-999d-b169d3e5aa32",[],[4111],{"id":4112,"sortIndex":36,"affiliation":4113,"properties":26},"c391d7e1-3547-4acd-9514-5c8146996af7",{"id":4076,"createTime":4077,"updateTime":4077,"relativeEntities":4114,"slug":4079,"properties":4115,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4116},{"EN":4082},{"openalex":4118,"orcid":4120,"title":4122},{"VOID":4119},"A5045520915",{"VOID":4121},"https:\u002F\u002Forcid.org\u002F0000-0001-8402-6694",{"EN":4123},"Laila König",{"id":4125,"sortIndex":162,"researcher":26,"roles":4126,"affiliations":4127,"properties":4138},"837beb09-c345-4c94-b80b-aa98e7c9c0ee",[],[4128],{"id":4129,"sortIndex":36,"affiliation":4130,"properties":26},"45fbbc50-9f5a-48be-9985-8b0c434b0da1",{"id":4131,"createTime":4132,"updateTime":4132,"relativeEntities":4133,"slug":4134,"properties":4135,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4da57f56-f477-4258-9265-92f5ff4a2b14","2024-09-23T23:40:27.755+00:00",[],"Heidelberg-Ion-Therapy-Center-HIT-Heidelberg-Im-Neuenheimer-Feld-450-69120-Germany",{"title":4136},{"EN":4137},"Heidelberg Ion Therapy Center (HIT), Heidelberg, Im Neuenheimer Feld 450, 69120, Germany",{"openalex":4139,"orcid":4141,"title":4143},{"VOID":4140},"A5061037633",{"VOID":4142},"https:\u002F\u002Forcid.org\u002F0000-0002-6934-2864",{"EN":4144},"Stephanie E. Combs",{"id":4146,"sortIndex":111,"researcher":26,"roles":4147,"affiliations":4148,"properties":4155},"7ad92de4-d9dd-428f-9577-5e65f75a0ce3",[],[4149],{"id":4150,"sortIndex":36,"affiliation":4151,"properties":26},"31b647a8-df86-4797-85b9-7b02462776f8",{"id":4131,"createTime":4132,"updateTime":4132,"relativeEntities":4152,"slug":4134,"properties":4153,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4154},{"EN":4137},{"openalex":4156,"orcid":4158,"title":4160},{"VOID":4157},"A5078003238",{"VOID":4159},"https:\u002F\u002Forcid.org\u002F0000-0002-6411-4811",{"EN":4161},"Jürgen Debus",{"id":4163,"sortIndex":59,"researcher":26,"roles":4164,"affiliations":4165,"properties":4172},"f11b7685-9e28-4683-8a91-a4a11cd809bc",[],[4166],{"id":4167,"sortIndex":36,"affiliation":4168,"properties":26},"bf86524a-077a-47bc-bc08-944a1860f6d7",{"id":4076,"createTime":4077,"updateTime":4077,"relativeEntities":4169,"slug":4079,"properties":4170,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4171},{"EN":4082},{"openalex":4173,"orcid":4175,"title":4177},{"VOID":4174},"A5021544846",{"VOID":4176},"https:\u002F\u002Forcid.org\u002F0000-0001-9960-3052",{"EN":4178},"Thomas Welzel",{"url":26,"publisher":4180,"properties":4207},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4181,"slug":663,"properties":4182,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4185,"manageAffiliations":4186,"indexDatabases":4187,"url":747,"thumbnailPath":26,"statistic":4202,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":4183,"title":4184},{"VOID":666},{"EN":668},[],[],[4188,4195],{"id":708,"indexDatabase":4189,"url":723,"indexYears":26,"academicFieldIds":4194,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":4190,"label":4191,"description":4192,"key":719,"publicationTags":4193,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":4196,"url":741,"indexYears":742,"academicFieldIds":4201,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":4197,"label":4198,"description":4199,"key":738,"publicationTags":4200,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":4203,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":4204,"totalCitation":768,"totalCitationByYear":4205,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":4206,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"volume":4208,"issue":4210},{"VOID":4209},"9",{"VOID":951},139,{"total":4211,"publishYear":26,"statisticByYear":4213},{"2014":59,"2015":135,"2016":53,"2017":103,"2018":234,"2019":239,"2020":103,"2021":234,"2022":124,"2023":53,"2024":158},"2014-12-01",2014,[4217,4221,4225,4229,4233,4237,4241,4245,4249,4253,4257,4261,4265,4269,4273,4277,4281,4285,4288,4292,4296,4300,4304],{"id":26,"text":4218,"url":26,"identifiers":4219},"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009,10(5):459-466. 10.1016\u002FS1470-2045(09)70025-7",{"doi":4220},"10.1016\u002FS1470-2045(09)70025-7",{"id":26,"text":4222,"url":26,"identifiers":4223},"Forsyth PA, Cairncross JG: Treatment of malignant glioma in adults. Curr Opin Neurol 1995,8(6):414-418. 10.1097\u002F00019052-199512000-00002",{"doi":4224},"10.1097\u002F00019052-199512000-00002",{"id":26,"text":4226,"url":26,"identifiers":4227},"Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P: Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999,46(2):183-188. 10.1002\u002F1531-8249(199908)46:2\u003C183::AID-ANA7>3.0.CO;2-7",{"doi":4228},"10.1002\u002F1531-8249(199908)46:2\u003C183::AID-ANA7>3.0.CO;2-7",{"id":26,"text":4230,"url":26,"identifiers":4231},"Smoll NR, Schaller K, Gautschi OP: Long-term survival of patients with glioblastoma multiforme (GBM). J Clin Neurosci 2013,20(5):670-675. 10.1016\u002Fj.jocn.2012.05.040",{"doi":4232},"10.1016\u002Fj.jocn.2012.05.040",{"id":26,"text":4234,"url":26,"identifiers":4235},"Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003,99(3):467-473. 10.3171\u002Fjns.2003.99.3.0467",{"doi":4236},"10.3171\u002Fjns.2003.99.3.0467",{"id":26,"text":4238,"url":26,"identifiers":4239},"Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004,6(3):227-235. 10.1215\u002FS1152851703000620",{"doi":4240},"10.1215\u002FS1152851703000620",{"id":26,"text":4242,"url":26,"identifiers":4243},"Chaichana KL, Pendleton C, Chambless L, Camara-Quintana J, Nathan JK, Hassam-Malani L, Li G, Harsh GR, Thompson RC, Lim M: Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. J Clin Neurosci 2013,20(10):1422-6. 10.1016\u002Fj.jocn.2013.02.007",{"doi":4244},"10.1016\u002Fj.jocn.2013.02.007",{"id":26,"text":4246,"url":26,"identifiers":4247},"Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008,26(25):4189-4199. 10.1200\u002FJCO.2007.11.5964",{"doi":4248},"10.1200\u002FJCO.2007.11.5964",{"id":26,"text":4250,"url":26,"identifiers":4251},"Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M: Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 2007,83(1):91-93. 10.1007\u002Fs11060-006-9292-0",{"doi":4252},"10.1007\u002Fs11060-006-9292-0",{"id":26,"text":4254,"url":26,"identifiers":4255},"Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS: Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 2007,9(4):424-429. 10.1215\u002F15228517-2007-023",{"doi":4256},"10.1215\u002F15228517-2007-023",{"id":26,"text":4258,"url":26,"identifiers":4259},"Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S: Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol 2013,15(1):91-96. 10.1093\u002Fneuonc\u002Fnos268",{"doi":4260},"10.1093\u002Fneuonc\u002Fnos268",{"id":26,"text":4262,"url":26,"identifiers":4263},"Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G: Long-term survival with glioblastoma multiforme. Brain 2007,130(Pt 10):2596-2606.",{"doi":4264},"10.1093\u002Fbrain\u002Fawm204",{"id":26,"text":4266,"url":26,"identifiers":4267},"Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A: Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013,19(18):5146-57. 10.1158\u002F1078-0432.CCR-13-0017",{"doi":4268},"10.1158\u002F1078-0432.CCR-13-0017",{"id":26,"text":4270,"url":26,"identifiers":4271},"Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T: Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 2009,151(11):1349-1358. 10.1007\u002Fs00701-009-0387-1",{"doi":4272},"10.1007\u002Fs00701-009-0387-1",{"id":26,"text":4274,"url":26,"identifiers":4275},"Scheithauer BW, Fuller GN, VandenBerg SR: The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology. Brain Pathol 2008,18(3):307-316. 10.1111\u002Fj.1750-3639.2008.00179.x",{"doi":4276},"10.1111\u002Fj.1750-3639.2008.00179.x",{"id":26,"text":4278,"url":26,"identifiers":4279},"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005,352(10):987-996. 10.1056\u002FNEJMoa043330",{"doi":4280},"10.1056\u002FNEJMoa043330",{"id":26,"text":4282,"url":26,"identifiers":4283},"Devaux BC, O'Fallon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993,78(5):767-775. 10.3171\u002Fjns.1993.78.5.0767",{"doi":4284},"10.3171\u002Fjns.1993.78.5.0767",{"id":26,"text":4286,"url":26,"identifiers":4287},"Wang X, Liu YH, Xie F, You C, Mao Q: [A clinical and molecular study of long-term survival glioblastomas]. Zhonghua Wai Ke Za Zhi 2013,51(2):166-170.",{},{"id":26,"text":4289,"url":26,"identifiers":4290},"Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005,64(6):479-489.",{"doi":4291},"10.1093\u002Fjnen\u002F64.6.479",{"id":26,"text":4293,"url":26,"identifiers":4294},"Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, Berger MS, Chang SM: Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 2005,102(4):622-628. 10.3171\u002Fjns.2005.102.4.0622",{"doi":4295},"10.3171\u002Fjns.2005.102.4.0622",{"id":26,"text":4297,"url":26,"identifiers":4298},"Aguirre A, Gallo V: Postnatal neurogenesis and gliogenesis in the olfactory bulb from NG2-expressing progenitors of the subventricular zone. J Neurosci 2004,24(46):10530-10541. 10.1523\u002FJNEUROSCI.3572-04.2004",{"doi":4299},"10.1523\u002FJNEUROSCI.3572-04.2004",{"id":26,"text":4301,"url":26,"identifiers":4302},"Chaichana KL, McGirt MJ, Frazier J, Attenello F, Guerrero-Cazares H, Quinones-Hinojosa A: Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. J Neurooncol 2008,89(2):219-224. 10.1007\u002Fs11060-008-9609-2",{"doi":4303},"10.1007\u002Fs11060-008-9609-2",{"id":26,"text":4305,"url":26,"identifiers":4306},"Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, Group AL-GS: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006,7(5):392-401. 10.1016\u002FS1470-2045(06)70665-9",{"doi":4307},"10.1016\u002FS1470-2045(06)70665-9",{"id":4309,"createTime":4310,"updateTime":4311,"relativeEntities":4312,"slug":4313,"properties":4314,"entityType":829,"verifyStatus":25,"verifyTime":4329,"verifyNote":830,"syncStatus":28,"languages":4330,"translateLanguages":26,"viewCount":36,"primaryUrl":4331,"fullTextUrl":26,"authors":4332,"publicationType":918,"publisherRelationship":4524,"citationCount":4552,"citationInfo":4553,"publishDate":4555,"publishYear":4556,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":4557,"isForceReanalyzing":1256},"378bf3df-76fa-4ef9-8dbf-f80f18096758","2024-04-16T02:10:22.186+00:00","2024-12-23T01:02:14.313+00:00",[],"Stereotactic-Body-Radiotherapy-SBRT-for-liver-metastasis-clinical-outcomes-from-the-international-multi-institutional-RSSearch-Patient-Registry",{"mag":4315,"keywords":4317,"pmc":4318,"openalex":4320,"abstract":4322,"title":4323,"pm":4325,"doi":4327},{"VOID":4316},"2801291604",{},{"VOID":4319},"5811977",{"VOID":4321},"W2801291604",{},{"EN":4324},"Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry",{"VOID":4326},"29439707",{"VOID":4328},"10.1186\u002Fs13014-018-0969-2","2024-12-23T01:02:14.312+00:00",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13014-018-0969-2",[4333,4352,4375,4393,4411,4431,4449,4468,4486,4504],{"id":4334,"sortIndex":115,"researcher":26,"roles":4335,"affiliations":4336,"properties":4345},"3da95811-fc8c-4e79-a16d-9828e59ad1ab",[],[4337],{"id":26,"sortIndex":36,"affiliation":4338,"properties":26},{"id":4339,"createTime":4340,"updateTime":4340,"relativeEntities":4341,"slug":26,"properties":4342,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"901ab204-016e-495d-97be-0cced6b0de1c","2024-01-11T01:33:08.288+00:00",[],{"title":4343},{"VI":4344},"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany",{"openalex":4346,"orcid":4348,"title":4350},{"VOID":4347},"A5039691793",{"VOID":4349},"https:\u002F\u002Forcid.org\u002F0000-0003-1391-1308",{"EN":4351},"Oliver Blanck",{"id":4353,"sortIndex":50,"researcher":26,"roles":4354,"affiliations":4355,"properties":4370},"7f3e870c-3ebd-4614-8e5c-af1629f20578",[],[4356],{"id":4357,"sortIndex":36,"affiliation":4358,"properties":4367},"9b99096d-529b-4387-a5da-e1be0098e584",{"id":4359,"createTime":4360,"updateTime":4361,"relativeEntities":4362,"slug":4363,"properties":4364,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0dedef46-e239-477c-adb3-fc81c2b102d8","2024-02-08T01:15:58.108+00:00","2024-09-23T03:47:05.520+00:00",[],"Department-of-Radiation-Oncology-University-of-Pennsylvania-Philadelphia-PA-United-States",{"title":4365},{"VI":4366},"Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States",{"title":4368},{"VI":4369},"Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA",{"openalex":4371,"title":4373},{"VOID":4372},"A5076285367",{"EN":4374},"James D. Kolker",{"id":4376,"sortIndex":52,"researcher":26,"roles":4377,"affiliations":4378,"properties":4388},"355a3f52-2bb3-4f84-9140-9c0b9671f4c1",[],[4379],{"id":26,"sortIndex":36,"affiliation":4380,"properties":26},{"id":4381,"createTime":4382,"updateTime":4382,"relativeEntities":4383,"slug":4384,"properties":4385,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"563ae3a4-e884-4f11-9c7b-7042f5156aaf","2024-04-16T02:10:22.314+00:00",[],"The-Radiosurgery-Society-San-Mateo-CA-USA",{"title":4386},{"EN":4387},"The Radiosurgery Society, San Mateo, CA, USA",{"openalex":4389,"title":4391},{"VOID":4390},"A5031400806",{"EN":4392},"Joanne Davis",{"id":4394,"sortIndex":111,"researcher":26,"roles":4395,"affiliations":4396,"properties":4406},"c07070b1-ced9-418e-ab37-3a5eeba8e91d",[],[4397],{"id":26,"sortIndex":36,"affiliation":4398,"properties":26},{"id":4399,"createTime":4400,"updateTime":4400,"relativeEntities":4401,"slug":4402,"properties":4403,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ea6ee5a3-3b92-4d6e-be52-8792c12041a8","2024-04-16T02:10:22.247+00:00",[],"Department-of-Radiation-Oncology-Memorial-Regional-Hospital-Hollywood-FL-USA",{"title":4404},{"EN":4405},"Department of Radiation Oncology, Memorial Regional Hospital, Hollywood, FL, USA",{"openalex":4407,"title":4409},{"VOID":4408},"A5016732255",{"EN":4410},"Srinath Sundararaman",{"id":4412,"sortIndex":158,"researcher":26,"roles":4413,"affiliations":4414,"properties":4424},"ebfde811-a9bd-4dd1-aae1-43f6c6992325",[],[4415],{"id":26,"sortIndex":36,"affiliation":4416,"properties":26},{"id":4417,"createTime":4418,"updateTime":4418,"relativeEntities":4419,"slug":4420,"properties":4421,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"50347922-a665-4dde-9e5b-f83356453af5","2024-04-16T02:10:22.288+00:00",[],"Department-of-Radiation-Oncology-Medstar-Franklin-Square-Medical-Center-Baltimore-MD-USA",{"title":4422},{"EN":4423},"Department of Radiation Oncology, Medstar Franklin Square Medical Center, Baltimore, MD, USA",{"openalex":4425,"orcid":4427,"title":4429},{"VOID":4426},"A5088992361",{"VOID":4428},"https:\u002F\u002Forcid.org\u002F0000-0002-4066-822X",{"EN":4430},"David Perry",{"id":4432,"sortIndex":59,"researcher":26,"roles":4433,"affiliations":4434,"properties":4444},"97f61ae6-da67-4168-8ea7-58d2b6a2e835",[],[4435],{"id":26,"sortIndex":36,"affiliation":4436,"properties":26},{"id":4437,"createTime":4438,"updateTime":4438,"relativeEntities":4439,"slug":4440,"properties":4441,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3cef5192-f81a-4e40-8cb0-099d95f9f8dc","2024-04-16T02:10:22.235+00:00",[],"Department-of-Radiation-Oncology-Centura-Health-Colorado-Springs-CO-USA",{"title":4442},{"EN":4443},"Department of Radiation Oncology, Centura Health, Colorado Springs, CO, USA",{"openalex":4445,"title":4447},{"VOID":4446},"A5033886756",{"EN":4448},"Anuj V. Peddada",{"id":4450,"sortIndex":36,"researcher":26,"roles":4451,"affiliations":4452,"properties":4463},"25d3e27c-08c8-467a-af96-f65d10c204cd",[],[4453],{"id":26,"sortIndex":36,"affiliation":4454,"properties":26},{"id":4455,"createTime":4456,"updateTime":4457,"relativeEntities":4458,"slug":4459,"properties":4460,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0766e6fd-bd6a-440e-9093-357e55ebe828","2024-04-16T02:10:22.196+00:00","2025-06-11T20:26:30.705+00:00",[],"Geisinger-Health-System-100-N-Academy-Ave-Danville-PA-17822-USA",{"title":4461},{"EN":4462},"Geisinger Health System, 100 N Academy Ave, Danville, PA, 17822, USA",{"openalex":4464,"title":4466},{"VOID":4465},"A5007170568",{"EN":4467},"Anand Mahadevan",{"id":4469,"sortIndex":162,"researcher":26,"roles":4470,"affiliations":4471,"properties":4481},"a3245616-8f01-4847-b954-b69e9e887ff0",[],[4472],{"id":26,"sortIndex":36,"affiliation":4473,"properties":26},{"id":4474,"createTime":4475,"updateTime":4475,"relativeEntities":4476,"slug":4477,"properties":4478,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b5d7e052-3adb-4c0a-a33c-5900bb63b926","2024-04-16T02:10:22.260+00:00",[],"Department-of-Radiation-Oncology-New-Jersey-CyberKnife-at-Community-Medical-Center-Toms-River-NJ-USA",{"title":4479},{"EN":4480},"Department of Radiation Oncology, New Jersey CyberKnife at Community Medical Center, Toms River, NJ, USA",{"openalex":4482,"title":4484},{"VOID":4483},"A5019661851",{"EN":4485},"David J. D’Ambrosio",{"id":4487,"sortIndex":114,"researcher":26,"roles":4488,"affiliations":4489,"properties":4499},"d30d6695-d60a-43bd-a96b-ef2c492ce7a2",[],[4490],{"id":26,"sortIndex":36,"affiliation":4491,"properties":26},{"id":4492,"createTime":4493,"updateTime":4493,"relativeEntities":4494,"slug":4495,"properties":4496,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"645f4fd2-3d8f-42b5-b9d2-3f588683e82e","2024-04-16T02:10:22.221+00:00",[],"Department-of-Radiation-Oncology-Crozer-Keystone-Health-Care-Center-Philadelphia-CyberKnife-Havertown-PA-USA",{"title":4497},{"EN":4498},"Department of Radiation Oncology, Crozer Keystone Health Care Center, Philadelphia CyberKnife, Havertown, PA, USA",{"openalex":4500,"title":4502},{"VOID":4501},"A5071938424",{"EN":4503},"Rachelle Lanciano",{"id":4505,"sortIndex":135,"researcher":26,"roles":4506,"affiliations":4507,"properties":4517},"d10309af-859b-48a7-8668-aba26e6b3cf0",[],[4508],{"id":26,"sortIndex":36,"affiliation":4509,"properties":26},{"id":4510,"createTime":4511,"updateTime":4511,"relativeEntities":4512,"slug":4513,"properties":4514,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1aba3039-c215-45cf-9361-9b27d7905dd3","2024-04-16T02:10:22.275+00:00",[],"Department-of-Radiation-Oncology-St-Mary-s-Medical-Center-Huntington-WV-USA",{"title":4515},{"EN":4516},"Department of Radiation Oncology, St. Mary’s Medical Center, Huntington, WV, USA",{"openalex":4518,"orcid":4520,"title":4522},{"VOID":4519},"A5063095503",{"VOID":4521},"https:\u002F\u002Forcid.org\u002F0000-0002-8704-887X",{"EN":4523},"Shubham Sharma",{"url":26,"publisher":4525,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4526,"slug":663,"properties":4527,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4530,"manageAffiliations":4531,"indexDatabases":4532,"url":747,"thumbnailPath":26,"statistic":4547,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":4528,"title":4529},{"VOID":666},{"EN":668},[],[],[4533,4540],{"id":708,"indexDatabase":4534,"url":723,"indexYears":26,"academicFieldIds":4539,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":4535,"label":4536,"description":4537,"key":719,"publicationTags":4538,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":4541,"url":741,"indexYears":742,"academicFieldIds":4546,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":4542,"label":4543,"description":4544,"key":738,"publicationTags":4545,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":4548,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":4549,"totalCitation":768,"totalCitationByYear":4550,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":4551,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},138,{"total":4552,"publishYear":26,"statisticByYear":4554},{"2018":111,"2019":516,"2020":234,"2021":396,"2022":244,"2023":255,"2024":111},"2018-12-01",2018,[4558,4562,4566,4570,4574,4578,4582,4586,4590,4594,4598,4602,4606,4610,4613,4616,4619,4623,4627,4631,4635,4639,4643,4647,4650,4654,4658,4662,4666,4669,4673,4677,4681,4685,4689,4693,4697,4701,4704,4708,4712,4715,4719,4723,4727,4731,4735,4739],{"id":26,"text":4559,"url":26,"identifiers":4560},"Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol. 2014 Jun 28;20(24):7602–21.",{"doi":4561},"10.3748\u002Fwjg.v20.i24.7602",{"id":26,"text":4563,"url":26,"identifiers":4564},"Null K, Null R. Liver Metastases. Curr Treat Options Gastroenterol. 1999;2(1):49–57.",{"doi":4565},"10.1007\u002Fs11938-999-0018-1",{"id":26,"text":4567,"url":26,"identifiers":4568},"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.",{"doi":4569},"10.3322\u002Fcaac.21387",{"id":26,"text":4571,"url":26,"identifiers":4572},"Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.",{"doi":4573},"10.1002\u002Fpath.1711500308",{"id":26,"text":4575,"url":26,"identifiers":4576},"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13(1):8–10.",{"doi":4577},"10.1200\u002FJCO.1995.13.1.8",{"id":26,"text":4579,"url":26,"identifiers":4580},"Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.",{"doi":4581},"10.1016\u002FS1470-2045(13)70447-9",{"id":26,"text":4583,"url":26,"identifiers":4584},"Smith JJ, ‘Angelica D MI. Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin North Am 201529(1):61–84.",{"doi":4585},"10.1016\u002Fj.hoc.2014.09.003",{"id":26,"text":4587,"url":26,"identifiers":4588},"Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(29):4575–80.",{"doi":4589},"10.1200\u002FJCO.2007.11.0833",{"id":26,"text":4591,"url":26,"identifiers":4592},"Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol. 2014;91(1):9–34.",{"doi":4593},"10.1016\u002Fj.critrevonc.2014.01.001",{"id":26,"text":4595,"url":26,"identifiers":4596},"Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–58.",{"doi":4597},"10.1097\u002F01.sla.0000141198.92114.f6",{"id":26,"text":4599,"url":26,"identifiers":4600},"Hellman S, Weichselbaum RR. Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol. 2005;2(2):60–1.",{"doi":4601},"10.1038\u002Fncponc0075",{"id":26,"text":4603,"url":26,"identifiers":4604},"Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the radiation therapy oncology group pilot study. Int J Radiat Oncol Biol Phys. 1981;7(5):587–91.",{"doi":4605},"10.1016\u002F0360-3016(81)90370-9",{"id":26,"text":4607,"url":26,"identifiers":4608},"Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(31):3980–6.",{"doi":4609},"10.1200\u002FJCO.2013.49.9202",{"id":26,"text":4611,"url":26,"identifiers":4612},"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–100.",{"doi":4018},{"id":26,"text":4614,"url":26,"identifiers":4615},"Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237–48.",{"doi":4014},{"id":26,"text":4617,"url":26,"identifiers":4618},"Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810–21.",{"doi":3960},{"id":26,"text":4620,"url":26,"identifiers":4621},"Kini VR, Vedam SS, Keall PJ, Patil S, Chen C, Mohan R. Patient training in respiratory-gated radiotherapy. Med Dosim off J am Assoc. Med Dosim. 2003;28(1):7–11.",{"doi":4622},"10.1016\u002FS0958-3947(02)00136-X",{"id":26,"text":4624,"url":26,"identifiers":4625},"Brock KK, McShan DL, Ten Haken RK, Hollister SJ, Dawson LA, Balter JM. Inclusion of organ deformation in dose calculations. Med Phys. 2003;30(3):290–5.",{"doi":4626},"10.1118\u002F1.1539039",{"id":26,"text":4628,"url":26,"identifiers":4629},"Dawson LA, Balter JM. Interventions to reduce organ motion effects in radiation delivery. Semin Radiat Oncol. 2004;14(1):76–80.",{"doi":4630},"10.1053\u002Fj.semradonc.2003.10.010",{"id":26,"text":4632,"url":26,"identifiers":4633},"Dawson LA, Brock KK, Kazanjian S, Fitch D, McGinn CJ, Lawrence TS, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51(5):1410–21.",{"doi":4634},"10.1016\u002FS0360-3016(01)02653-0",{"id":26,"text":4636,"url":26,"identifiers":4637},"Hara W, Soltys SG, Gibbs IC. CyberKnife robotic radiosurgery system for tumor treatment. Expert Rev Anticancer Ther. 2007;7(11):1507–15.",{"doi":4638},"10.1586\u002F14737140.7.11.1507",{"id":26,"text":4640,"url":26,"identifiers":4641},"Rosu M, Dawson LA, Balter JM, McShan DL, Lawrence TS, Ten Haken RK. Alterations in normal liver doses due to organ motion. Int J Radiat Oncol Biol Phys. 2003;57(5):1472–9.",{"doi":4642},"10.1016\u002Fj.ijrobp.2003.08.025",{"id":26,"text":4644,"url":26,"identifiers":4645},"Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–93.",{"doi":4646},"10.1016\u002Fj.ijrobp.2009.08.020",{"id":26,"text":4648,"url":26,"identifiers":4649},"Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol Stockh Swed. 1995;34(6):861–70.",{"doi":3964},{"id":26,"text":4651,"url":26,"identifiers":4652},"Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\u002FII trial. J Clin Oncol Off J Am Soc Clin Oncol. 2001s;19(1):164–70.",{"doi":4653},"10.1200\u002FJCO.2001.19.1.164",{"id":26,"text":4655,"url":26,"identifiers":4656},"Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol Stockh Swed. 2006;45(7):823–30.",{"doi":4657},"10.1080\u002F02841860600904854",{"id":26,"text":4659,"url":26,"identifiers":4660},"Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, Nowak PCJM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol Stockh Swed. 2006;45(7):831–7.",{"doi":4661},"10.1080\u002F02841860600897934",{"id":26,"text":4663,"url":26,"identifiers":4664},"Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371–8.",{"doi":4665},"10.1016\u002Fj.ijrobp.2005.01.002",{"id":26,"text":4667,"url":26,"identifiers":4668},"Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I\u002FII trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.",{"doi":3952},{"id":26,"text":4670,"url":26,"identifiers":4671},"Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91.",{"doi":4672},"10.1200\u002FJCO.2008.20.0600",{"id":26,"text":4674,"url":26,"identifiers":4675},"Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–7.",{"doi":4676},"10.1245\u002Fs10434-010-1405-5",{"id":26,"text":4678,"url":26,"identifiers":4679},"Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, et al. A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases. Ann Surg Oncol. 2016;23(1):218–24.",{"doi":4680},"10.1245\u002Fs10434-015-4579-z",{"id":26,"text":4682,"url":26,"identifiers":4683},"Davis JN, Medbery C, Sharma S, Perry D, Pablo J, D’Ambrosio DJ, et al. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol. 2015;4(1):55–63.",{"doi":4684},"10.1007\u002Fs13566-014-0177-0",{"id":26,"text":4686,"url":26,"identifiers":4687},"Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, et al. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiat Oncol Lond Engl. 2015;10:113.",{"doi":4688},"10.1186\u002Fs13014-015-0417-5",{"id":26,"text":4690,"url":26,"identifiers":4691},"Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience. Radiat Oncol Lond Engl. 2017;12(1):35.",{"doi":4692},"10.1186\u002Fs13014-017-0773-4",{"id":26,"text":4694,"url":26,"identifiers":4695},"Davis JN, Medbery C, Sharma S, Danish A, Mahadevan A. The RSSearch™ registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol Lond Engl. 2013;8:275.",{"doi":4696},"10.1186\u002F1748-717X-8-275",{"id":26,"text":4698,"url":26,"identifiers":4699},"Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol. 2007;67(3):793–8.",{"doi":4700},"10.1016\u002Fj.ijrobp.2006.10.025",{"id":26,"text":4702,"url":26,"identifiers":4703},"Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P, et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009;29(8):3381–4.",{},{"id":26,"text":4705,"url":26,"identifiers":4706},"Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–42.",{"doi":4707},"10.1016\u002Fj.ijrobp.2012.12.021",{"id":26,"text":4709,"url":26,"identifiers":4710},"Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–9.",{"doi":4711},"10.1002\u002Fcncr.25997",{"id":26,"text":4713,"url":26,"identifiers":4714},"Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1585–91.",{"doi":4672},{"id":26,"text":4716,"url":26,"identifiers":4717},"Katsoulakis E, Riaz N, Cannon DM, Goodman K, Spratt DE, Lovelock M, et al. Image-guided radiation therapy for liver tumors: gastrointestinal histology matters. Am J Clin Oncol. 2014;37(6):561–7.",{"doi":4718},"10.1097\u002FCOC.0b013e318282a86b",{"id":26,"text":4720,"url":26,"identifiers":4721},"Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;123(2):227–33.",{"doi":4722},"10.1016\u002Fj.radonc.2017.01.013",{"id":26,"text":4724,"url":26,"identifiers":4725},"Dieterich S, Gibbs IC. The CyberKnife in clinical use: current roles, future expectations. Front Radiat Ther Oncol. 2011;43:181–94.",{"doi":4726},"10.1159\u002F000322423",{"id":26,"text":4728,"url":26,"identifiers":4729},"Jung J, Song SY, Yoon SM, Kwak J, Yoon K, Choi W, et al. Verification of accuracy of CyberKnife tumor-tracking radiation therapy using patient-specific lung phantoms. Int J Radiat Oncol Biol Phys. 2015;92(4):745–53.",{"doi":4730},"10.1016\u002Fj.ijrobp.2015.02.055",{"id":26,"text":4732,"url":26,"identifiers":4733},"Chan M, Grehn M, Cremers F, Siebert F-A, Wurster S, Huttenlocher S, et al. Dosimetric implications of residual tracking errors during robotic SBRT of liver metastases. Int J Radiat Oncol Biol Phys. 2017;97(4):839–48.",{"doi":4734},"10.1016\u002Fj.ijrobp.2016.11.041",{"id":26,"text":4736,"url":26,"identifiers":4737},"Rossi L, Breedveld S, Aluwini S, Noncoplanar Beam HB. Angle class solutions to replace time-consuming patient-specific beam angle optimization in robotic prostate stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(4):762–70.",{"doi":4738},"10.1016\u002Fj.ijrobp.2015.03.013",{"id":26,"text":4740,"url":26,"identifiers":4741},"Colvill E, Booth J, Nill S, Fast M, Bedford J, Oelfke U, et al. A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: a multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;119(1):159–65.",{"doi":4742},"10.1016\u002Fj.radonc.2016.03.006",{"id":4744,"createTime":4745,"updateTime":4746,"relativeEntities":4747,"slug":4748,"properties":4749,"entityType":829,"verifyStatus":25,"verifyTime":4746,"verifyNote":830,"syncStatus":28,"languages":4765,"translateLanguages":26,"viewCount":36,"primaryUrl":4766,"fullTextUrl":26,"authors":4767,"publicationType":918,"publisherRelationship":4973,"citationCount":627,"citationInfo":5004,"publishDate":2770,"publishYear":2771,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":5006,"isForceReanalyzing":1256},"878c028e-2c40-4d93-b023-44c2e601572b","2024-04-20T13:40:05.107+00:00","2025-02-18T08:30:01.624+00:00",[],"-68Ga-DOTATOC-PET-CT-for-meningioma-IMRT-treatment-planning",{"mag":4750,"keywords":4752,"pmc":4753,"openalex":4755,"abstract":4757,"title":4759,"pm":4761,"doi":4763},{"VOID":4751},"2171414123",{},{"VOID":4754},"2785827",{"VOID":4756},"W2171414123",{"EN":4758},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\n          \u003Cjats:sec>\n            \u003Cjats:title>Purpose\u003C\u002Fjats:title>\n            \u003Cjats:p>The observation that human meningioma cells strongly express somatostatin receptor (SSTR 2) was the rationale to analyze retrospectively in how far DOTATOC PET\u002FCT is helpful to improve target volume delineation for intensity modulated radiotherapy (IMRT).\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>\n          \u003Cjats:sec>\n            \u003Cjats:title>Patients and Methods\u003C\u002Fjats:title>\n            \u003Cjats:p>In 26 consecutive patients with preferentially skull base meningioma, diagnostic magnetic resonance imaging (MRI) and planning-computed tomography (CT) was complemented with data from [\u003Cjats:sup>68\u003C\u002Fjats:sup>Ga]-DOTA-D Phe\u003Cjats:sup>1\u003C\u002Fjats:sup>-Tyr\u003Cjats:sup>3\u003C\u002Fjats:sup>-Octreotide (DOTATOC)-PET\u002FCT. Image fusion of PET\u002FCT, diagnostic computed tomography, MRI and radiotherapy planning CT as well as target volume delineation was performed with OTP-Masterplan\u003Cjats:sup>®\u003C\u002Fjats:sup>. Initial gross tumor volume (GTV) definition was based on MRI data only and was secondarily complemented with DOTATOC-PET information. Irradiation was performed as EUD based IMRT, using the Hyperion Software package.\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>\n          \u003Cjats:sec>\n            \u003Cjats:title>Results\u003C\u002Fjats:title>\n            \u003Cjats:p>The integration of the DOTATOC data led to additional information concerning tumor extension in 17 of 26 patients (65%). There were major changes of the clinical target volume (CTV) which modify the PTV in 14 patients, minor changes were realized in 3 patients. Overall the GTV-MRI\u002FCT was larger than the GTV-PET in 10 patients (38%), smaller in 13 patients (50%) and almost the same in 3 patients (12%). Most of the adaptations were performed in close vicinity to bony skull base structures or after complex surgery. Median GTV based on MRI was 18.1 cc, based on PET 25.3 cc and subsequently the CTV was 37.4 cc. Radiation planning and treatment of the DOTATOC-adapted volumes was feasible.\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>\n          \u003Cjats:sec>\n            \u003Cjats:title>Conclusion\u003C\u002Fjats:title>\n            \u003Cjats:p>DOTATOC-PET\u002FCT information may strongly complement patho-anatomical data from MRI and CT in cases with complex meningioma and is thus helpful for improved target volume delineation especially for skull base manifestations and recurrent disease after surgery.\u003C\u002Fjats:p>\n          \u003C\u002Fjats:sec>",{"EN":4760},"[68Ga]-DOTATOC-PET\u002FCT for meningioma IMRT treatment planning",{"VOID":4762},"19922642",{"VOID":4764},"10.1186\u002F1748-717x-4-56",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-4-56",[4768,4790,4809,4830,4852,4871,4893,4908,4925,4939,4954],{"id":4769,"sortIndex":116,"researcher":26,"roles":4770,"affiliations":4771,"properties":4783},"1bc012bb-7b55-44d2-bcf3-a498de4ffc9b",[],[4772],{"id":4773,"sortIndex":36,"affiliation":4774,"properties":26},"ffa5ba1e-45ad-4e39-b62d-042a42e55341",{"id":4775,"createTime":4776,"updateTime":4777,"relativeEntities":4778,"slug":4779,"properties":4780,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"49a7aa8c-0f85-40e3-b93a-f8677419962b","2024-04-20T13:40:05.255+00:00","2024-08-31T12:35:00.725+00:00",[],"Department-of-Radiation-Oncology-LMU-M%C3%BCnchen-M%C3%BCnchen-81377-Germany",{"title":4781},{"EN":4782},"Department of Radiation Oncology, LMU München, München, 81377, Germany",{"openalex":4784,"orcid":4786,"title":4788},{"VOID":4785},"A5052937691",{"VOID":4787},"https:\u002F\u002Forcid.org\u002F0000-0003-4492-614X",{"EN":4789},"Ute Ganswindt",{"id":4791,"sortIndex":162,"researcher":26,"roles":4792,"affiliations":4793,"properties":4804},"9f079d72-589d-4f07-9c51-503a8e02eeef",[],[4794],{"id":4795,"sortIndex":36,"affiliation":4796,"properties":26},"750e4734-d81e-4c85-b3da-98810fc849b6",{"id":4797,"createTime":4798,"updateTime":4798,"relativeEntities":4799,"slug":4800,"properties":4801,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"25b6a665-be7a-4710-bab6-5e77e842efdd","2024-04-20T13:40:05.121+00:00",[],"Department-of-Nuclear-Medicine-University-of-T%C3%BCbingen-T%C3%BCbingen-72076-Germany",{"title":4802},{"EN":4803},"Department of Nuclear Medicine, University of Tübingen, Tübingen, 72076, Germany",{"openalex":4805,"title":4807},{"VOID":4806},"A5069332516",{"EN":4808},"Roland Bares",{"id":4810,"sortIndex":115,"researcher":26,"roles":4811,"affiliations":4812,"properties":4823},"6f4dae95-1ddc-4f44-b6df-f32dfb5bebd2",[],[4813],{"id":4814,"sortIndex":36,"affiliation":4815,"properties":26},"1b1f127f-67e8-4428-ba82-fdf7d7bf036e",{"id":4816,"createTime":4817,"updateTime":4817,"relativeEntities":4818,"slug":4819,"properties":4820,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"38f333a5-526b-4da1-8184-9c700db064db","2024-04-20T13:40:05.135+00:00",[],"Department-of-Radiation-Oncology-University-of-T%C3%BCbingen-T%C3%BCbingen-72076-Germany",{"title":4821},{"EN":4822},"Department of Radiation Oncology, University of Tübingen, Tübingen, 72076, Germany",{"openalex":4824,"orcid":4826,"title":4828},{"VOID":4825},"A5065356310",{"VOID":4827},"https:\u002F\u002Forcid.org\u002F0000-0001-8836-528X",{"EN":4829},"Frank Paulsen",{"id":4831,"sortIndex":50,"researcher":26,"roles":4832,"affiliations":4833,"properties":4845},"7b5ac8ac-0bdd-41ff-8661-5f0a442d763e",[],[4834],{"id":4835,"sortIndex":36,"affiliation":4836,"properties":26},"74d2a9dc-5ade-4779-a30f-dff93ba82fb5",{"id":4837,"createTime":4838,"updateTime":4839,"relativeEntities":4840,"slug":4841,"properties":4842,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"90fca6ad-d439-4f85-bd9c-77170d97a96e","2024-04-20T13:40:05.226+00:00","2024-10-17T15:10:43.319+00:00",[],"Department-of-Nuclear-Medicine-LMU-M%C3%BCnchen-M%C3%BCnchen-81377-Germany",{"title":4843},{"EN":4844},"Department of Nuclear Medicine, LMU München, München, 81377, Germany",{"openalex":4846,"orcid":4848,"title":4850},{"VOID":4847},"A5037412930",{"VOID":4849},"https:\u002F\u002Forcid.org\u002F0009-0005-0734-4994",{"EN":4851},"Peter Bartenstein",{"id":4853,"sortIndex":111,"researcher":26,"roles":4854,"affiliations":4855,"properties":4866},"a7147851-30d1-4e27-82ff-fb43bd1bfb4f",[],[4856],{"id":4857,"sortIndex":36,"affiliation":4858,"properties":26},"4c890b59-2d56-4353-a257-bf6acc2fefeb",{"id":4859,"createTime":4860,"updateTime":4860,"relativeEntities":4861,"slug":4862,"properties":4863,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"32e68ef6-b069-4986-9a61-0ae222d6e503","2024-04-20T13:40:05.175+00:00",[],"Medizinisches-Versorgungszentrum-Nuklearmedizin-Stuttgart-70199-Germany",{"title":4864},{"EN":4865},"Medizinisches Versorgungszentrum Nuklearmedizin, Stuttgart, 70199, Germany",{"openalex":4867,"title":4869},{"VOID":4868},"A5073500378",{"EN":4870},"Susanne Martina Eschmann",{"id":4872,"sortIndex":59,"researcher":26,"roles":4873,"affiliations":4874,"properties":4886},"665c4662-43a9-4130-9e72-30838a2766a7",[],[4875],{"id":4876,"sortIndex":36,"affiliation":4877,"properties":26},"1f3ec882-c903-46b8-91fe-e9eee4a30b88",{"id":4878,"createTime":4879,"updateTime":4880,"relativeEntities":4881,"slug":4882,"properties":4883,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"baf0e0bf-119f-4fa0-9fda-17f3f91452df","2024-04-20T13:40:05.160+00:00","2024-10-20T10:24:25.510+00:00",[],"Department-of-Neuroradiology-University-of-T%C3%BCbingen-T%C3%BCbingen-72076-Germany",{"title":4884},{"EN":4885},"Department of Neuroradiology, University of Tübingen, Tübingen, 72076, Germany",{"openalex":4887,"orcid":4889,"title":4891},{"VOID":4888},"A5041879855",{"VOID":4890},"https:\u002F\u002Forcid.org\u002F0000-0001-7604-3419",{"EN":4892},"Till‐Karsten Hauser",{"id":4894,"sortIndex":114,"researcher":26,"roles":4895,"affiliations":4896,"properties":4903},"8c1c25ba-bc12-482e-b980-76060e100959",[],[4897],{"id":4898,"sortIndex":36,"affiliation":4899,"properties":26},"a9b1068b-14a0-436c-ae1a-f7b509d26bdf",{"id":4797,"createTime":4798,"updateTime":4798,"relativeEntities":4900,"slug":4800,"properties":4901,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4902},{"EN":4803},{"openalex":4904,"title":4906},{"VOID":4905},"A5081610991",{"EN":4907},"Mehmet Ö. Öksüz",{"id":4909,"sortIndex":36,"researcher":26,"roles":4910,"affiliations":4911,"properties":4918},"48820919-bb99-4b76-90c3-144b9556a040",[],[4912],{"id":4913,"sortIndex":36,"affiliation":4914,"properties":26},"9be3d0dc-5eec-4c82-8a24-58c3b6b9c339",{"id":4816,"createTime":4817,"updateTime":4817,"relativeEntities":4915,"slug":4819,"properties":4916,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4917},{"EN":4822},{"openalex":4919,"orcid":4921,"title":4923},{"VOID":4920},"A5085881659",{"VOID":4922},"https:\u002F\u002Forcid.org\u002F0000-0002-0295-9392",{"EN":4924},"Barbara Gehler",{"id":4926,"sortIndex":52,"researcher":26,"roles":4927,"affiliations":4928,"properties":4935},"7e68b8c2-2b5f-465a-8b54-6d88bd962d33",[],[4929],{"id":4930,"sortIndex":36,"affiliation":4931,"properties":26},"03c9c0d6-8a05-46bd-a912-cd13786d2b60",{"id":4775,"createTime":4776,"updateTime":4777,"relativeEntities":4932,"slug":4779,"properties":4933,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4934},{"EN":4782},{"openalex":4936,"orcid":4937,"title":4938},{"VOID":1392},{"VOID":1394},{"EN":1396},{"id":4940,"sortIndex":158,"researcher":26,"roles":4941,"affiliations":4942,"properties":4949},"9a07a93c-ed19-4388-b60d-92d8ef554a25",[],[4943],{"id":4944,"sortIndex":36,"affiliation":4945,"properties":26},"b64d2b4a-54c3-423b-b5ae-9342a9a78f7a",{"id":4816,"createTime":4817,"updateTime":4817,"relativeEntities":4946,"slug":4819,"properties":4947,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4948},{"EN":4822},{"openalex":4950,"title":4952},{"VOID":4951},"A5029197290",{"EN":4953},"M. Bamberg",{"id":4955,"sortIndex":135,"researcher":26,"roles":4956,"affiliations":4957,"properties":4968},"93f58351-e335-4c51-9644-bd4cb1ffb596",[],[4958],{"id":4959,"sortIndex":36,"affiliation":4960,"properties":26},"bc8da396-a3ac-467b-900d-c53003847f85",{"id":4961,"createTime":4962,"updateTime":4962,"relativeEntities":4963,"slug":4964,"properties":4965,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ccd0153b-f1ae-4f7e-a4f7-341236607a2b","2024-04-20T13:40:05.200+00:00",[],"Department-of-Radiology-University-of-T%C3%BCbingen-T%C3%BCbingen-72076-Germany",{"title":4966},{"EN":4967},"Department of Radiology, University of Tübingen, Tübingen, 72076, Germany",{"openalex":4969,"title":4971},{"VOID":4970},"A5082886545",{"EN":4972},"Christina Pfannenberg",{"url":26,"publisher":4974,"properties":5001},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4975,"slug":663,"properties":4976,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4979,"manageAffiliations":4980,"indexDatabases":4981,"url":747,"thumbnailPath":26,"statistic":4996,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":4977,"title":4978},{"VOID":666},{"EN":668},[],[],[4982,4989],{"id":708,"indexDatabase":4983,"url":723,"indexYears":26,"academicFieldIds":4988,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":4984,"label":4985,"description":4986,"key":719,"publicationTags":4987,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":4990,"url":741,"indexYears":742,"academicFieldIds":4995,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":4991,"label":4992,"description":4993,"key":738,"publicationTags":4994,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":4997,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":4998,"totalCitation":768,"totalCitationByYear":4999,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":5000,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},{"volume":5002,"issue":5003},{"VOID":2765},{"VOID":951},{"total":627,"publishYear":26,"statisticByYear":5005},{"2012":356,"2013":52,"2014":356,"2015":59,"2016":158,"2017":50,"2018":52,"2019":298,"2020":135,"2021":51,"2022":356,"2023":50},[5007,5011,5015,5019,5023,5027,5031,5035,5039,5043,5047,5051,5055,5059,5063,5067,5071,5075,5079,5083,5087,5091,5095,5099,5103,5107,5111,5115,5118,5121,5125,5129,5133,5137,5141,5144,5148,5152,5156,5160],{"id":26,"text":5008,"url":26,"identifiers":5009},"Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985,62(1):18-24. 10.3171\u002Fjns.1985.62.1.0018",{"doi":5010},"10.3171\u002Fjns.1985.62.1.0018",{"id":26,"text":5012,"url":26,"identifiers":5013},"McCutcheon IE: The biology of meningiomas. J Neurooncol 1996,29(3):207-216. 10.1007\u002FBF00165650",{"doi":5014},"10.1007\u002FBF00165650",{"id":26,"text":5016,"url":26,"identifiers":5017},"Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG: Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1998,73(10):936-942. 10.4065\u002F73.10.936",{"doi":5018},"10.4065\u002F73.10.936",{"id":26,"text":5020,"url":26,"identifiers":5021},"Mathiesen T, Lindquist C, Kihlstrom L, Karlsson B: Recurrence of cranial base meningiomas. Neurosurgery 1996,39(1):2-7. discussion8–9 10.1097\u002F00006123-199607000-00002",{"doi":5022},"10.1097\u002F00006123-199607000-00002",{"id":26,"text":5024,"url":26,"identifiers":5025},"Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM: Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 1987,20(4):525-528. 10.1097\u002F00006123-198704000-00003",{"doi":5026},"10.1227\u002F00006123-198704000-00003",{"id":26,"text":5028,"url":26,"identifiers":5029},"Goldsmith BJ, Wara WM, Wilson CB, Larson DA: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994,80(2):195-201. 10.3171\u002Fjns.1994.80.2.0195",{"doi":5030},"10.3171\u002Fjns.1994.80.2.0195",{"id":26,"text":5032,"url":26,"identifiers":5033},"Mesic JB, Hanks GE, Doggett RL: The value of radiation therapy as an adjuvant to surgery in intracranial meningiomas. Am J Clin Oncol 1986,9(4):337-340. 10.1097\u002F00000421-198608000-00013",{"doi":5034},"10.1097\u002F00000421-198608000-00013",{"id":26,"text":5036,"url":26,"identifiers":5037},"Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR: The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988,15(2):299-304. 10.1016\u002FS0360-3016(98)90008-6",{"doi":5038},"10.1016\u002FS0360-3016(98)90008-6",{"id":26,"text":5040,"url":26,"identifiers":5041},"Debus J, Wuendrich M, Pirzkall A, Hoess A, Schlegel W, Zuna I, Engenhart-Cabillic R, Wannenmacher M: High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 2001,19(15):3547-3553.",{"doi":5042},"10.1200\u002FJCO.2001.19.15.3547",{"id":26,"text":5044,"url":26,"identifiers":5045},"Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J: Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005,61(3):809-816.",{"doi":5046},"10.1016\u002Fj.ijrobp.2004.07.669",{"id":26,"text":5048,"url":26,"identifiers":5049},"van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJ, Rasch CR: Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol 2008, 3: 41. 10.1186\u002F1748-717X-3-41",{"doi":5050},"10.1186\u002F1748-717X-3-41",{"id":26,"text":5052,"url":26,"identifiers":5053},"Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, Heide UA, van Vulpen M: High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008, 3: 15. 10.1186\u002F1748-717X-3-15",{"doi":5054},"10.1186\u002F1748-717X-3-15",{"id":26,"text":5056,"url":26,"identifiers":5057},"Menkarios C, Azria D, Laliberte B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Ailleres N, Fenoglietto P: Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2: 41. 10.1186\u002F1748-717X-2-41",{"doi":5058},"10.1186\u002F1748-717X-2-41",{"id":26,"text":5060,"url":26,"identifiers":5061},"Baumert BG, Norton IA, Davis JB: Intensity-modulated stereotactic radiotherapy vs. stereotactic conformal radiotherapy for the treatment of meningioma located predominantly in the skull base. Int J Radiat Oncol Biol Phys 2003,57(2):580-592. 10.1016\u002FS0360-3016(03)00587-X",{"doi":5062},"10.1016\u002FS0360-3016(03)00587-X",{"id":26,"text":5064,"url":26,"identifiers":5065},"Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J: Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 2007,68(3):858-863.",{"doi":5066},"10.1016\u002Fj.ijrobp.2006.12.073",{"id":26,"text":5068,"url":26,"identifiers":5069},"Uy NW, Woo SY, Teh BS, Mai WY, Carpenter LS, Chiu JK, Lu HH, Gildenberg P, Trask T, Grant WH, et al.: Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys 2002,53(5):1265-1270. 10.1016\u002FS0360-3016(02)02823-7",{"doi":5070},"10.1016\u002FS0360-3016(02)02823-7",{"id":26,"text":5072,"url":26,"identifiers":5073},"Pirzkall A, Debus J, Haering P, Rhein B, Grosser KH, Hoss A, Wannenmacher M: Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 2003,55(2):362-372.",{"doi":5074},"10.1016\u002FS0360-3016(02)03809-9",{"id":26,"text":5076,"url":26,"identifiers":5077},"Clark BG, Candish C, Vollans E, Gete E, Lee R, Martin M, Ma R, McKenzie M: Optimization of stereotactic radiotherapy treatment delivery technique for base-of-skull meningiomas. Med Dosim 2008,33(3):239-247. 10.1016\u002Fj.meddos.2008.03.003",{"doi":5078},"10.1016\u002Fj.meddos.2008.03.003",{"id":26,"text":5080,"url":26,"identifiers":5081},"Sajja R, Barnett GH, Lee SY, Harnisch G, Stevens GH, Lee J, Suh JH: Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results. Technol Cancer Res Treat 2005,4(6):675-682.",{"doi":5082},"10.1177\u002F153303460500400612",{"id":26,"text":5084,"url":26,"identifiers":5085},"Ganswindt U, Paulsen F, Corvin S, Eichhorn K, Glocker S, Hundt I, Birkner M, Alber M, Anastasiadis A, Stenzl A, et al.: Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 2005, 5: 91. 10.1186\u002F1471-2407-5-91",{"doi":5086},"10.1186\u002F1471-2407-5-91",{"id":26,"text":5088,"url":26,"identifiers":5089},"Ganswindt U, Paulsen F, Corvin S, Hundt I, Alber M, Frey B, Stenzl A, Bares R, Bamberg M, Belka C: Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 2007,67(2):347-355.",{"doi":5090},"10.1016\u002Fj.ijrobp.2006.08.082",{"id":26,"text":5092,"url":26,"identifiers":5093},"Deantonio L, Beldi D, Gambaro G, Loi G, Brambilla M, Inglese E, Krengli M: FDG-PET\u002FCT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008, 3: 29. 10.1186\u002F1748-717X-3-29",{"doi":5094},"10.1186\u002F1748-717X-3-29",{"id":26,"text":5096,"url":26,"identifiers":5097},"Rothschild S, Studer G, Seifert B, Huguenin P, Glanzmann C, Davis JB, Lutolf UM, Hany TF, Ciernik IF: PET\u002FCT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol 2007, 2: 22. 10.1186\u002F1748-717X-2-22",{"doi":5098},"10.1186\u002F1748-717X-2-22",{"id":26,"text":5100,"url":26,"identifiers":5101},"Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M, Nouet P, Dipasquale G, Ratib O, Zaidi H, et al.: [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008, 3: 44. 10.1186\u002F1748-717X-3-44",{"doi":5102},"10.1186\u002F1748-717X-3-44",{"id":26,"text":5104,"url":26,"identifiers":5105},"Singh AK, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert PS, Fichtinger G, Choyke PL, Xu S, Kruecker J, et al.: Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007, 2: 36. 10.1186\u002F1748-717X-2-36",{"doi":5106},"10.1186\u002F1748-717X-2-36",{"id":26,"text":5108,"url":26,"identifiers":5109},"Sharma N, Neumann D, Macklis R: The impact of functional imaging on radiation medicine. Radiat Oncol 2008, 3: 25. 10.1186\u002F1748-717X-3-25",{"doi":5110},"10.1186\u002F1748-717X-3-25",{"id":26,"text":5112,"url":26,"identifiers":5113},"Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC: Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 1998,76(5):620-627. 10.1002\u002F(SICI)1097-0215(19980529)76:5\u003C620::AID-IJC2>3.0.CO;2-S",{"doi":5114},"10.1002\u002F(SICI)1097-0215(19980529)76:5\u003C620::AID-IJC2>3.0.CO;2-S",{"id":26,"text":5116,"url":26,"identifiers":5117},"Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U: PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001,42(7):1053-1056.",{},{"id":26,"text":5119,"url":26,"identifiers":5120},"Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Macke HR, Eisenhut M, Debus J, Haberkorn U: Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005,46(5):763-769.",{},{"id":26,"text":5122,"url":26,"identifiers":5123},"Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, Molls M, Weber WA, Grosu AL: Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 2008,72(4):1161-1167.",{"doi":5124},"10.1016\u002Fj.ijrobp.2008.02.058",{"id":26,"text":5126,"url":26,"identifiers":5127},"Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, Molls M, Nieder C: 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006,66(2):339-344.",{"doi":5128},"10.1016\u002Fj.ijrobp.2006.02.047",{"id":26,"text":5130,"url":26,"identifiers":5131},"Rutten I, Cabay JE, Withofs N, Lemaire C, Aerts J, Baart V, Hustinx R: PET\u002FCT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J Nucl Med 2007,48(5):720-725. 10.2967\u002Fjnumed.106.038216",{"doi":5132},"10.2967\u002Fjnumed.106.038216",{"id":26,"text":5134,"url":26,"identifiers":5135},"Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J: Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006,65(1):222-227.",{"doi":5136},"10.1016\u002Fj.ijrobp.2005.12.006",{"id":26,"text":5138,"url":26,"identifiers":5139},"Astner ST, Bundschuh RA, Beer AJ, Ziegler SI, Krause BJ, Schwaiger M, Molls M, Grosu AL, Essler M: Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography. Int J Radiat Oncol Biol Phys 2009,73(4):1135-1140.",{"doi":5140},"10.1016\u002Fj.ijrobp.2008.05.037",{"id":26,"text":5142,"url":26,"identifiers":5143},"Schulz S, Pauli SU, Handel M, Dietzmann K, Firsching R, Hollt V: Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 2000,6(5):1865-1874.",{},{"id":26,"text":5145,"url":26,"identifiers":5146},"Hildebrandt G, Scheidhauer K, Luyken C, Schicha H, Klug N, Dahms P, Krisch B: High sensitivity of the in vivo detection of somatostatin receptors by 111 indium (DTPA-octreotide)-scintigraphy in meningioma patients. Acta Neurochir (Wien) 1994,126(2-4):63-71. 10.1007\u002FBF01476412",{"doi":5147},"10.1007\u002FBF01476412",{"id":26,"text":5149,"url":26,"identifiers":5150},"Barth A, Haldemann AR, Reubi JC, Godoy N, Rosler H, Kinser JA, Seiler RW: Noninvasive differentiation of meningiomas from other brain tumours using combined 111 Indium-octreotide\u002F99 mtechnetium-DTPA brain scintigraphy. Acta Neurochir (Wien) 1996,138(10):1179-1185. 10.1007\u002FBF01809748",{"doi":5151},"10.1007\u002FBF01809748",{"id":26,"text":5153,"url":26,"identifiers":5154},"Nyberg G, Bergstrom M, Enblad P, Lilja A, Muhr C, Langstrom B: PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol 1997,117(4):482-489. 10.3109\u002F00016489709113425",{"doi":5155},"10.3109\u002F00016489709113425",{"id":26,"text":5157,"url":26,"identifiers":5158},"Ericson K, Lilja A, Bergstrom M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langsrom BB, Mosskin M: Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr 1985,9(4):683-689. 10.1097\u002F00004728-198507010-00005",{"doi":5159},"10.1097\u002F00004728-198507010-00005",{"id":26,"text":5161,"url":26,"identifiers":5162},"Iuchi T, Iwadate Y, Namba H, Osato K, Saeki N, Yamaura A, Uchida Y: Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res 1999,21(7):640-644.",{"doi":5163},"10.1080\u002F01616412.1999.11740989",{"id":5165,"createTime":5166,"updateTime":5167,"relativeEntities":5168,"slug":5169,"properties":5170,"entityType":829,"verifyStatus":25,"verifyTime":5167,"verifyNote":830,"syncStatus":28,"languages":5186,"translateLanguages":26,"viewCount":36,"primaryUrl":5187,"fullTextUrl":26,"authors":5188,"publicationType":918,"publisherRelationship":5240,"citationCount":5268,"citationInfo":5269,"publishDate":5271,"publishYear":5272,"citationAnalyzeStatus":3465,"lastCitationAnalyze":5273,"indexDatabases":26,"openAccess":26,"references":5274,"isForceReanalyzing":1256},"e7c7c52f-a67c-49dc-901c-19ab49e79fe3","2024-04-14T09:21:02.048+00:00","2024-12-26T22:12:48.772+00:00",[],"Counting-colonies-of-clonogenic-assays-by-using-densitometric-software",{"mag":5171,"keywords":5173,"pmc":5174,"openalex":5176,"abstract":5178,"title":5180,"pm":5182,"doi":5184},{"VOID":5172},"2131654458",{},{"VOID":5175},"1770926",{"VOID":5177},"W2131654458",{"EN":5179},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\u003Cjats:p>Clonogenic assays are a useful tool to test whether a given cancer therapy can reduce the clonogenic survival of tumour cells. A colony is defined as a cluster of at least 50 cells which can often only be determined microscopically. The process of counting colonies is very extensive work and so we developed software that is able to count the colonies automatically from scanned flasks. This software is made freely available by us with a detailed description how to use and install the necessary features.\u003C\u002Fjats:p>",{"EN":5181},"Counting colonies of clonogenic assays by using densitometric software",{"VOID":5183},"17212832",{"VOID":5185},"10.1186\u002F1748-717x-2-4",[102],"https:\u002F\u002Fro-journal.biomedcentral.com\u002Farticles\u002F10.1186\u002F1748-717X-2-4",[5189,5206,5222],{"id":5190,"sortIndex":114,"researcher":26,"roles":5191,"affiliations":5192,"properties":5202},"d4878f07-71f0-43cb-b549-55697f6d0feb",[],[5193],{"id":26,"sortIndex":36,"affiliation":5194,"properties":26},{"id":5195,"createTime":5196,"updateTime":5196,"relativeEntities":5197,"slug":5198,"properties":5199,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d943a8fe-89e4-41c8-af2a-729490438fba","2024-04-14T09:21:02.084+00:00",[],"Department-of-Radiation-Oncology-CCC-T%C3%BCbingen-Hoppe-Seyler-Str-3-T%C3%BCbingen-72076-Germany",{"title":5200},{"EN":5201},"Department of Radiation Oncology, CCC Tübingen, Hoppe-Seyler-Str. 3, Tübingen, 72076, Germany",{"openalex":5203,"orcid":5204,"title":5205},{"VOID":1392},{"VOID":1394},{"EN":1396},{"id":5207,"sortIndex":36,"researcher":26,"roles":5208,"affiliations":5209,"properties":5215},"58dc96f9-f943-4610-98dc-c9a870ac6893",[],[5210],{"id":26,"sortIndex":36,"affiliation":5211,"properties":26},{"id":5195,"createTime":5196,"updateTime":5196,"relativeEntities":5212,"slug":5198,"properties":5213,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":5214},{"EN":5201},{"openalex":5216,"orcid":5218,"title":5220},{"VOID":5217},"A5065547065",{"VOID":5219},"https:\u002F\u002Forcid.org\u002F0000-0002-7711-9486",{"EN":5221},"Maximilian Niyazi",{"id":5223,"sortIndex":115,"researcher":26,"roles":5224,"affiliations":5225,"properties":5235},"dda4d3fc-99de-44a0-96f5-7acfc9c5c321",[],[5226],{"id":26,"sortIndex":36,"affiliation":5227,"properties":26},{"id":5228,"createTime":5229,"updateTime":5229,"relativeEntities":5230,"slug":5231,"properties":5232,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a5336949-167e-4ed3-8549-727e4e971a48","2024-04-14T09:21:02.070+00:00",[],"Bureau-for-Technique-and-Documentation-Paracelsusstr-21-Stuttgart-70599-Germany",{"title":5233},{"EN":5234},"Bureau for Technique and Documentation, Paracelsusstr. 21, Stuttgart, 70599, Germany",{"openalex":5236,"title":5238},{"VOID":5237},"A5044885370",{"EN":5239},"Ismat Niyazi",{"url":26,"publisher":5241,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":5242,"slug":663,"properties":5243,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":5246,"manageAffiliations":5247,"indexDatabases":5248,"url":747,"thumbnailPath":26,"statistic":5263,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":5244,"title":5245},{"VOID":666},{"EN":668},[],[],[5249,5256],{"id":708,"indexDatabase":5250,"url":723,"indexYears":26,"academicFieldIds":5255,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":5251,"label":5252,"description":5253,"key":719,"publicationTags":5254,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725,726],{"id":728,"indexDatabase":5257,"url":741,"indexYears":742,"academicFieldIds":5262,"indexDatabaseRanking":746},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":5258,"label":5259,"description":5260,"key":738,"publicationTags":5261,"standard":26},[],{"EN":735,"VI":735},{"EN":735,"VI":737},[740],[744,745],{"impactFactor":36,"impactFactorByYear":5264,"i10Index":754,"i10IndexLast5Year":284,"totalPublication":755,"totalPublicationByYear":5265,"totalCitation":768,"totalCitationByYear":5266,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":5267,"hindexLast5Year":29,"hindex":29},{"2012":750,"2013":634,"2014":645,"2015":751,"2016":132,"2017":752,"2018":386,"2019":642,"2020":753,"2021":169,"2022":169,"2023":634},{"2006":287,"2007":397,"2008":79,"2009":259,"2010":757,"2011":366,"2012":758,"2013":759,"2014":760,"2015":617,"2016":761,"2017":762,"2018":763,"2019":764,"2020":765,"2021":630,"2022":766,"2023":767,"2024":173},{"2006":770,"2007":771,"2008":772,"2009":773,"2010":774,"2011":775,"2012":776,"2013":777,"2014":778,"2015":779,"2016":780,"2017":781,"2018":782,"2019":774,"2020":783,"2021":784,"2022":623},{"2006":787,"2007":788,"2008":789,"2009":790,"2010":791,"2011":792,"2012":793,"2013":794,"2014":795,"2015":796,"2016":797,"2017":798,"2018":799,"2019":800,"2020":801,"2021":802,"2022":803},118,{"total":5268,"publishYear":26,"statisticByYear":5270},{"2012":162,"2013":158,"2014":111,"2015":52,"2016":51,"2017":52,"2018":135,"2019":162,"2020":53,"2021":116,"2022":158,"2023":59},"2007-12-01",2007,"2024-04-14T21:43:53.130+00:00",[5275,5279,5283,5287,5291,5295,5298,5302],{"id":26,"text":5276,"url":26,"identifiers":5277},"Barber PR, Vojnovic B, Kelly J, Mayes CR, Boulton P, Woodcock M, Joiner MC: Automated counting of mammalian cell colonies. Phys Med Biol 2001, 46: 63-76. 10.1088\u002F0031-9155\u002F46\u002F1\u002F305",{"doi":5278},"10.1088\u002F0031-9155\u002F46\u002F1\u002F305",{"id":26,"text":5280,"url":26,"identifiers":5281},"Biston MC, Corde S, Camus E, Marti-Battle R, Esteve F, Balosso J: An objective method to measure cell survival by computer-assisted image processing of numeric images of Petri dishes. Phys Med Biol 2003, 48: 1551-63. 10.1088\u002F0031-9155\u002F48\u002F11\u002F305",{"doi":5282},"10.1088\u002F0031-9155\u002F48\u002F11\u002F305",{"id":26,"text":5284,"url":26,"identifiers":5285},"Dahle J, Kakar M, Steen HB, Kaalhus O: Automated counting of mammalian cell colonies by means of a flat bed scanner and image processing. Cytometry A 2004, 60: 182-8. 10.1002\u002Fcyto.a.20038",{"doi":5286},"10.1002\u002Fcyto.a.20038",{"id":26,"text":5288,"url":26,"identifiers":5289},"Herman CJ, Pelgrim OE, Kirkels WJ, Verheijen R, Debruyne FM, Kenemans P, Vooijs GP: In-use evaluation of the Omnicon automated tumor colony counter. Cytometry 1983, 3: 439-42. 10.1002\u002Fcyto.990030609",{"doi":5290},"10.1002\u002Fcyto.990030609",{"id":26,"text":5292,"url":26,"identifiers":5293},"Mukherjee DP, Pal A, Sarma SE, Majumder DD: Bacterial colony counting using distance transform. Int J Biomed Comput 1995, 38: 131-40. 10.1016\u002F0020-7101(94)01043-Z",{"doi":5294},"10.1016\u002F0020-7101(94)01043-Z",{"id":26,"text":5296,"url":26,"identifiers":5297},"Parry RL, Chin TW, Donahoe PK: Computer-aided cell colony counting. Biotechniques 1991, 10: 772-4.",{},{"id":26,"text":5299,"url":26,"identifiers":5300},"Salmon SE, Young L, Lebowitz J, Thomson S, Einsphar J, Tong T, Moon TE: Evaluation of an automated image analysis system for counting human tumor colonies. Int J Cell Cloning 1984, 2: 142-60.",{"doi":5301},"10.1002\u002Fstem.5530020301",{"id":26,"text":5303,"url":26,"identifiers":5304},"Wilson IG: Use of the IUL Countermat Automatic Colony Counter for Spiral Plated Total Viable Counts. Appl Environ Microbiol 1995, 61: 3158-3160.",{"doi":5305},"10.1128\u002Faem.61.8.3158-3160.1995"]